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The nonsense mediated mRNA decay (NMD) pathway degrades transcripts with 
premature termination codons (PTCs) to prevent the production of C-terminally truncated 
proteins that might have dominant negative properties. Loss of function mutations and 
copy number variation in genes required for NMD have also been implicated in 
neurodevelopmental disorders (NDDs) such as autism spectrum disorders (ASD), 
intellectual disability (ID), childhood onset schizophrenia and attention deficit 
hyperactivity disorder (ADHD). One such gene, UPF3B, located on the X-chromosome, 
is the only NMD factor that has a gene paralog UPF3A, located on chromosome 13. Both 
are implicated in NDDs. Loss of function mutations in UPF3B lead to UPF3A protein 
stabilisation, a phenomena proposed to compensate for loss of UPF3B in order to 
maintain residual NMD activity and during critical periods of development. The impact 
of loss of UPF3B function in neurodevelopment has been investigated in UPF3B patient 
lymphoblastoid cell lines and mice and leads to a deregulation of mRNA important for 
brain function and development. The role of UPF3A has not yet been elucidated. UPF3A 
was initially shown to act as a weak NMD activator until recently when it was shown to 
primarily act to inhibit NMD of a majority, but not all, NMD-targeted mRNAs. In mouse 
loss of UPF3A has been shown to be embryonic lethal. Thus far, the role of NMD and 
UPF3A and UPF3B in particular, have yet to be determined in human cells of the 
developing brain. To elucidate the roles of UPF3A and UPF3B in human cells in a 
neurodevelopmental model, UPF3A and UPF3B knockout (KO) human Embryonic Stem 
Cells (hESCs) were generated using the CRISPR/Cas9 genome editing technology. 
Whole genome sequencing (WGS) of the gene-edited clones revealed that none of the 
small nucleotide variants (SNVs) detected in each gene-edited clone overlapped with the 
predicted off-target sites, however, notable genetic variation in each clone was attributed 
to extended cell culture as part of the CRISPR/Cas9 editing process, presence of 
x 
 
mosaicism in the parental cell line and normal passaging. Larger deletions and 
duplications (structural variants (SVs)) were detected in each gene-edited clones that 
overlapped with the predicted off-target sites. The hESCs were subsequently 
differentiated into neural stem cells (NSCs) and transcriptome wide mRNA sequencing 
analysis was performed both on the UPF3A and UPF3B KO hESCs and NSCs. Loss of 
UPF3A in hESCs did not have any significant effect on the transcriptome of hESCs but 
lead to deregulation of 3.03% of transcripts in NSCs, the majority of which (2.96%) were 
downregulated. Genes deregulated in UPF3A KO NSCs were involved in intracellular 
signalling pathways regulated by the TGF-β superfamily pathway such as extracellular 
matrix remodelling, blood vessel development and morphogenesis and regulation of cell 
adhesion. Mutations in genes that encode components of the extracellular matrix and the 
vascular system lead to embryonic lethality in mice. Loss of UPF3B had an impact at 
both the hESC and NSC stage. Loss of UPF3B in hESCs lead to a deregulation of 0.62% 
(of which 0.21% were upregulated and 0.41% were downregulated) while loss in NSCs 
resulted in a 0.29% deregulation (0.07% upregulated and 0.22% downregulated). Loss of 
UPF3B in hESCs lead to a deregulation in genes that are important in cell-cell adhesion, 
calcium ion binding, synapse assembly and regulation of signalling receptor activity and 
post synaptic membrane potential. In NSCs, loss of UPF3B lead to deregulation of genes 
important for neurodevelopment such as of ARX, an ID gene and neural function such as 
ROBO2 which is important for axonal guidance. Our results suggest that UPF3A could 
act as an NMD inhibitor and is important in regulating the TGF-β superfamily pathway, 
while UPF3B is important for normal neurodevelopment and function. The deregulated 
genes in UPF3A and UPF3B KO NSCs only had two genes that overlapped suggesting 
that these paralogs have separate roles in NMD. In conclusion the CRISPR/Cas9 genome 
editing tool and hESCs were efficient and faithful tools to model NDDs caused by 
mutations in UPF3A and UPF3B. They provided resources to investigate the loss of 
xi 
UPF3A and UPF3B in a suitable cell type that would otherwise be impossible to acquire 
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1.0  Introduction 
Neurodevelopmental disorders (NDDs) are a large group of heterogeneous disorders 
caused by genetic, environmental or epigenetic factors that lead to aberrations in nervous 
system development. The clinical presentations seen in NDDs are postulated to be caused 
by alterations in neurodevelopmental processes such as neurogenesis, cell migration and 
neural connectivity (Ehninger et al. 2008). NDDs include a broad range of disorders such 
as attention deficit hyperactivity disorder (ADHD), epilepsy, autism spectrum disorders 
(ASDs), cerebral palsy and intellectual disability (ID) (Szpir 2006). These disorders result 
in abnormalities that affect an individual’s behaviour, memory and learning (Szpir 2006) 
and the common feature relating them is that the disease onset occurs during periods of 
development (Ehninger et al. 2008). 
 
Genetic factors are the main drivers of these disorders (Ehninger et al. 2008) with 
approximately 12% of genetically inherited disorders caused by premature termination 
codons (PTCs) (Mort, M. et al. 2008). PTCs in mRNAs can arise due to germline or 
somatic mutations in DNA and inaccurate pre-mRNA splicing (Keeling, Du & Bedwell 
2013). PTCs normally cause a significant reduction in mRNA levels due to mRNA 
degradation via the nonsense-mediated mRNA decay (NMD) pathway, and lead to 









1.1 Nonsense mediated mRNA decay pathway (NMD) 
The NMD pathway exists and is conserved within all eukaryotes (Schweingruber et al. 
2013). It was discovered in 1979 in β° thalassemia patients that had nonsense mutations 
in their  β-globin gene and had reduced β-globin mRNA (Chang & Kan 1979). Proteins 
including the upframe-shift factors (UPFs), suppressor with morphogenetic effect on 
genitalia (SMG) proteins and components of the exon junction complex (EJC) form a 
complex that is crucial in initiating the identification and decay of mRNA with PTCs 
(Buchwald et al. 2010). Whilst the degradation of transcripts with PTCs protects against 
the production of truncated proteins with deleterious dominant negative or gain of 
function effects, in some instances the truncated protein might retain some residual 
activity which would lessen the clinical severity incurred by the resulting 
haploinsufficiency. Thus NMD is recognised as a major modifier of clinical outcomes of 
genetic diseases caused by PTC type mutations (Khajavi, Inoue & Lupski 2006). 
 
 
1.2 Classical NMD Mechanism(s) 
The relay of genetic information from DNA to protein requires accurate transmission. 
There are several checkpoints or pathways that are responsible for eliminating any 
transcripts that may lack functionality or fidelity (Smith & Baker 2015). Before genetic 
information in DNA is relayed into protein, DNA is first transcribed into RNA. The RNA 
is processed and non-coding regions (introns) removed before it is translated into 
polypeptides. The NMD pathway is responsible at this stage to ensure that transcripts 
with PTCs in their open reading frames (ORFs) are degraded to prevent such transcripts 





When introns are removed from RNA (splicing), EJCs are deposited between 20-24 
nucleotides (nts) upstream of the exon-exon boundary (Le Hir et al. 2000). The EJC has 
an inner core complex that contains the EJC factors, MAGOH/Y14 (RBM8A), BTZ and 
eIF4AIII. The inner core complex is tightly bound to the mRNA by the eIF4AIII protein 
(Ballut et al. 2005). The EJC also associates with peripheral proteins in its outer shell 
which contains splicing factors such as ACINUS, PININ, RNPS1, SAP18 and the mRNA 
export factor REF/Aly (Tange et al. 2005; Wang et al. 2018).   
 
In the classical NMD mechanism, the EJC aids discrimination of physiological stop 
codons from PTCs. As the vast majority of physiological stop codons are encoded in the 
last exon, mRNA with PTCs have a unique mRNA landscape in which an EJC is located 
further downstream of a stop codon. A stop codon needs to be located  >50-55 nts 
upstream of an EJC to be recognised by the NMD machinery (Figure 1.1) (Nagy & 
Maquat 1998). Thus the EJC aids the NMD mechanism to identify and subsequently 
degrade transcripts that contain a stop codon followed by an EJC (Nagy & Maquat 1998).  
 
NMD occurs during mRNA translation. While it has been reported that NMD only occurs 
during the pioneering round of translation (Ishigaki et al. 2001) some studies reveal that 
mRNAs have the ability to be degraded during each round of translation (Durand & 
Lykke-Andersen 2013; Hoek et al. 2019; Rufener & Muhlemann 2013). After the 
assembly of the EJC on the mRNA, the NMD factor UPF3B binds to the EJC using its 
C-terminal domain (Kadlec, Izaurralde & Cusack 2004) to interact with the EJC 
component Y14 (Le Hir et al. 2001). When the mRNA is exported from the nucleus into 
the cytoplasm for translation, a second NMD factor UPF2 binds to the EJC through 







Figure 1.1: The 55 nucleotide NMD rule.                                                             
After pre-mRNA is transcribed it is processed to produce mRNA. These processing steps 
include splicing, capping and polyadenylation. During splicing after introns are removed 
exons are ligated together creating exon-exon boundaries. If a transcript contains a PTC 
located more than 55 nts upstream from an exon-exon boundary it is targeted and 
degraded by the NMD machinery, while PTCs located 55 nts or less normally escape 
NMD with exceptions to this rule. PTCs less than 55 nts from the exon-exon boundary 
do not elicit NMD as the ribosomes would have already displaced the EJCs by the time 
the scanning ribosomes recognise the PTC as EJCs are located 24 nts upstream of the 
exon-exon boundary and the ribosome footprint is approximately 20 nts on either side 











During translation, when the ribosome encounters an authentic stop codon, the ribosome-
bound eukaryotic release factor 1 (eRF1) and eRF3 bind poly(A) binding protein 
cytoplasmic 1 (PABPC1) and terminate translation (Zahdeh & Carmel 2016). In the 
instance when ribosomes encounters a PTC, termination is inefficient and the ribosome 
stalls due to the absence of the termination stimulating factors between PABPC1 and the 
eRFs (Amrani, Sachs & Jacobson 2006). Instead of binding to PABPC1, eRF3 recruits 
UPF1 and SMG1 to the EJC complex and triggers the formation of a downstream 
complex called SURF (SMG1, UPF1, eRF1 and eRF3), together with SMG8 and SMG9 
which collectively activates the first step in the NMD pathway (Kashima et al. 2006; 
Longman et al. 2013; Yamashita 2013).  
 
The SURF complex allows formation of the decay inducing complex (DECID), which 
results from the association of SURF, ribosomes, UPF2 and the EJC. In this DECID 
complex UPF2 binds with the C-terminal of SMG1 inducing the dissociation of SMG8-
SMG9, activating the kinase activity of SMG1. SMG1 then phosphorylates the C-
terminal serine-glutamine motifs of UPF1, which is a key event in activating mRNA 
decay machinery (Arias-Palomo et al. 2011). The phosphorylation of UPF1 leads to the 
recruitment of SMG6 and SMG5-7 (Okada-Katsuhata et al. 2012). The PilT N-terminus 
domain of SMG6, initiates mRNA decay through its endonuclease activity (Franks, Singh 
& Lykke-Andersen 2010) which creates unprotected free 5’ and 3’ mRNA ends (Popp & 
Maquat 2014). SMG5-SMG7 complexes recruit decapping and deadenylases enzymes 
that remove the terminal 5’ and 3’ mRNA modifications, allowing access to 5’-3’ end 





UPF2 also binds to the regulatory cysteine-histidine rich domain of UPF1, causing a 
conformational change that promotes UPF1 helicase activity (Chakrabarti et al. 2011). 
This conformational change switches the helicase domain of UPF1 from a RNA-
clamping function to a RNA-unwinding function (Chamieh et al. 2008). This is needed 
for the presentation of the 3’-cleavage product generated by SMG6 to the 5’- to -3’ 
exonuclease XRN1 (Franks, Singh & Lykke-Andersen 2010) and to recycle essential 













Figure 1.2: NMD mechanism  
In the nucleus during mRNA splicing, introns are removed and exons are ligated. 
20-24 nt upstream from the exon-exon boundary EJCs are loaded on the transcript. 
UPF3B, an NMD factor also binds the EJC. In the cytoplasm UPF2 attaches to the 
EJC through binding to UPF3B. During translation, EJCs are removed by 
ribosomes. However if there is a PTC, the ribosomes stall, leading to the 
recruitment of the NMD factors and the eRFs which form the SURF complex. 
Association of the SURF complex, ribosomes, UPF2, and the EJC form the decay 
inducing complex and leads to degradation of the mutated transcript. Figure from 
(da Costa, Menezes & Romao 2017).  
 
 
1.2.1 Alternative NMD pathway(s) 
The classical NMD pathway model suggests that the NMD pathway occurs in a linear 
manner with respect to the involvement of the core NMD factors UPF1, UPF2 and 
UPF3B: UPF3B first binds to the EJC in the nucleus and after the transcript is exported 
into the cytoplasm, UPF2 binds UPF3B and finally UPF1 to form a bridge between the 
EJC and UPF1, resulting in NMD pathway activation (Chakrabarti et al. 2011; Gehring 
et al. 2003). However alternative NMD pathways exists that act independently of some 
of these core NMD factors (Chan et al. 2007; Gehring et al. 2005).  
 
A prime example of this stems from observations in patients with UPF3B mutations, in 
which the PTC containing mutant mRNA of UPF3B is itself NMD degraded despite the 
absence of the UPF3B protein (Nguyen et al. 2012; Tarpey et al. 2007). There is also a 
UPF3A/B independent branch of NMD that does not require these gene paralogs that is 
shown to occur in T-cell receptors (TCR). The TCR locus undergoes programmed 
rearrangements that generate PTCs which are degraded by the UPF3A/B independent 





Gehring et al., 2005 identified two different branches of the NMD pathway that require 
different EJC factors. The UPF2 independent pathway that requires eIF4A3, Y14/Magoh 
and BTZ (Figure 1.3a). In support of the UPF2 independent pathway, there is prevailing 
evidence that UPF3B can bind directly to UPF1 independent of UPF2 (Gehring et al. 
2005; Kunz et al. 2006; Neu‐Yilik et al. 2017; Shum et al. 2016). The UPF2 dependent 
pathway requires the EJC factor RNPS1 (Figure 1.3b). These two pathways converge at 
a point where they both require UPF1 and UPF3B to activate NMD (Gehring et al. 2005). 
 
The reason why different branches of the same pathway exist is unknown however it may 
be due to the availability of the NMD/EJC factors in that specific cell type (Huang & 
Wilkinson 2012). The exact mechanisms and complexity of the different NMD pathways 
and how these function in specific cell types across different developmental stages is still 




Figure 1.3: Alternative NMD pathway.  
The two different branches of NMD that require different EJC factors. a) The UPF2 
independent branch does not require the EJC factor RNPS1. b) The UPF2 dependent 
pathway requires the EJC factor RNPS1. These two pathways converge at a point where 
they both require UPF1 and UPF3B to activate NMD. White coloured shapes indicate 





1.2.2 The UPF3A dependent NMD pathway                                                                   
In vertebrates, UPF3B is the only NMD factor that has an autosomal paralog gene, 
UPF3A (Jones & Wilkinson 2017). UPF3B is well established as a known strong NMD 
activator, whilst only limited studies on UPF3A have been conducted, which suggest 
UPF3A is a weak NMD activator (Kunz et al. 2006). UPF3A and UPF3B are expressed 
in the same tissue, although UPF3B expression is usually much higher than that of 
UPF3A except in the testis (Shum et al. 2016; Tarpey et al. 2007). Both UPF3A and 
UPF3B have a UPF2 and Y14 binding domain (Lykke-Andersen, Shu & Steitz 2000). 
The peptide sequence at the UPF2 binding domain is highly similar, but more divergent 
in the EJC binding domain (88% and 56% respectively) (Shum et al. 2016). The Y14 
binding domain of these proteins is important in NMD activation and specifically, an 
arginine residue (R419) in UPF3B’s Y14 binding domain is responsible for UPF3B’s 
strong NMD activity. In UPF3A, this residue is replaced by alanine (A432) which 
weakens its interaction with Y14, and substitution of this alanine with arginine converts 
UPF3A into a strong NMD activator like UPF3B (Kunz et al. 2006; Shum et al. 2016). 
 
When both UPF3A and UPF3B are present, UPF3B binds to UPF2. This is because 
UPF3B has a higher binding affinity for UPF2 compared to UPF3A. Consequently only 
a small amount of UPF3A is bond to UPF2 while most is degraded (Figure 1.4a). When 
UPF3B is absent, as in the case of patients with loss of function mutations in UPF3B, or 
in cells manipulated to deplete or delete UPF3B, there is stabilisation of the UPF3A 
protein (Figure 1.4b) (Chan et al. 2009; Jolly et al. 2013; Nguyen et al. 2012). The 
stabilisation of UPF3A in the absence of UPF3B has been postulated to be due to binding 
of UPF3A to UPF2, preventing its degradation. Aligned with evidence that UPF3A is a 
weak NMD activator, (Kunz et al. 2006), its stabilisation is proposed to partially rescue 




determinant in the severity of clinical neurological phenotypes in patients with loss of 
function UPF3B mutations as patients with more UPF3A protein have a milder clinical 
phenotype and vice versa (Nguyen et al. 2012).  
 
 UPF3A came into existence during a UPF3B gene duplication event which occurred 
approximately 400 million years ago (Shum et al. 2016). As mentioned above, UPF3B is 
a strong NMD activator while UPF3A is a weak NMD activator (Kunz et al. 2006) and 
compensates for UPF3B when it is unavailable. However, the persistence of these gene 
paralogs suggests that they may have different functions (Innan & Kondrashov 2010). In 
support of this, recently UPF3A has been shown to act as an NMD inhibitor (Shum et al. 
2016).  
 
   
 
Figure 1.4: UPF3A dependent NMD pathway.  
a) When UPF3B protein is present in the cell it binds to UPF2 and free UPF3A 
protein is degraded. b) When UPF3B protein is absent, the UPF3A protein is 
stabilised through bind to UPF2. The red cross indicates the absence of the protein. 














1.2.3 NMD substrates                                                                                                         
In addition to aberrant transcripts that contain PTCs, normal transcripts can be targeted 
for degradation by NMD due to the presence of ‘NMD inducing features’. NMD targets 
normal mRNA transcripts that have an upstream open reading frame (uORF) (Karam et 
al. 2013) or alternative spliced mRNA, as alternative spliced exons may have stop codons 
in their uORFs (Rebbapragada & Lykke-Andersen 2009). Other NMD inducing features 
include leaky translation due to differential usage of an internal ribosomal entry site 
(Welch & Jacobson 1999), the presence of one or more introns in the 3’-untranslated 
region (UTR), a long 3’-UTR(>1.5 Kbp) (Schweingruber et al. 2013) and poly (A) site 
mutations or alternative polyadenylation sites (Martins et al. 2012). In all these different 
classes of NMD substrates, translation termination occurs at an unusual position which 
is distant from the poly(A) tail or with an EJC located between the stop codon and the 
poly(A) tail (Schweingruber et al. 2013).  
 
1.2.4 Auto regulation of NMD 
NMD regulates 3-10% of the transcriptome across the phylogenic tree, and therefore a 
defective NMD pathway can significantly alter the transcript profiles in cells and as such 
biological functions (He et al. 2003; Lelivelt & Culbertson 1999; Nguyen et al. 2012; 
Rehwinkel et al. 2005; Rodriguez-Gabriel et al. 2006; Wittmann, Hol & Jack 2006). The 
NMD mechanism therefore has a buffering mechanism that confers robustness of the 
NMD pathway, as such that when NMD is inhibited there is an upregulation of NMD 
factors triggered by a feedback regulatory loop (Chan et al. 2007; Huang, L et al. 2011; 
Mendell et al. 2004; Singh, Rebbapragada & Lykke-Andersen 2008). The mRNA species 
encoding the NMD factors that are upregulated during the feedback mechanism all 






NMD factors 3'-UTR length (nt) uORF (amino acids) 3'-UTR intron 
UPF1 1712 No Noa 
UPF2 1275 Yes: 32, 35, 36 aa No 
UPF3A 889 No No 
UPF3B 852 No No 
SMG1 4715 Yes: 6 aa No 
SMG5 1361 Yes: 30 aa No 
SMG6 1653 No No 
SMG7 2259 Yes: 18 aa No  
aIntron located 3 nt downstream from stop codon. 
Table 1-1: NMD factors involved in the NMD feedback regulatory network. 




1.3 Role of NMD in human embryonic stem cells 
NMD factors are highly expressed in human pluripotent stem cells (hESCs) and their 
levels decrease upon loss of pluripotency (Alrahbeni et al. 2015; Bruno et al. 2011; Cho 
et al. 2012; Gong et al. 2009; Lou et al. 2016). NMD is important during early 
embryogenesis as loss of function mutations in Upf1, Upf2, Upf3a, Smg1 and Smg6 result 
in early embryonic lethality in mice (Li et al. 2015; McIlwain et al. 2010; Medghalchi et 
al. 2001; Shum et al. 2016; Weischenfeldt et al. 2008). Perturbation of the NMD pathway 
through knock down of UPF1 and UPF3B in H9 hESCs and P19 cells leads to a reduction 
in the stem cell markers, NANOG and OCT3/4 and triggers the initial stages of 
endodermal differentiation (Lou et al. 2016; Lou et al. 2014).  
 
 
In addition to having a role in maintaining stem cell pluripotency, NMD also has a role 




UPF3B leads to an enrichment of cells in the G1 phase of different cell types including 
hESCs (Lou et al. 2016; Lou et al. 2014). In Drosophila deletion of NMD factors 
impaired cell proliferation and led to cell cycle arrest at the G2/M phase (Rehwinkel et 
al. 2005) while in HeLa cells it led to an early S phase arrest (Azzalin & Lingner 2006). 
 
 
1.4 Role of NMD in neural development and function in animal models  
The discovery that mutations in NMD and EJC factor genes are strongly associated with 
NDDs suggests that NMD is critical for neural development and function (Jaffrey & 
Wilkinson 2018; Nguyen et al. 2013). UPF3B null mice present with fear-conditioned 
learning and defects in neurogenesis such as failure of dendritic spine maturation and 
neural differentiation defects (Huang et al. 2018; Jolly et al. 2013). Expression of 
missense mutant UPF3B in rat neurons and mice neurons depleted of UPF3B have 
reduced branching of neurites (Alrahbeni et al. 2015; Jolly et al. 2013). Mice NSCs 
depleted of UPF3B are also hyper-proliferative and have a higher capacity for self-
renewal (Huang et al. 2018; Jolly et al. 2013).  
 
Mutations in other NMD and EJC factors in other species also have effects on 
neurogenesis and behaviour. For example haploinsufficiency of the EJC component 
Magoh in mice causes microcephaly due to intermediate neural progenitor depletion 
(Silver et al. 2010). Overexpression of Y14, another EJC component has been implicated 
in anxiety and abnormal social interaction in mice (Alachkar et al. 2013). In zebrafish, 
upf1 morphants had brain patterning defects, predominantly at the midbrain-hindbrain 
boundary (Wittkopp et al. 2009).  Heterozygous mutations in upf2, smg1 and smg6 in 




structure, delayed neurotransmission responses and impaired synaptic vesicle cycling 
(Long et al. 2010). Commissural neurons from Upf2 conditional knockout mice exhibited 
aberrant axonal trajectories (Colak et al. 2013).  
 
Polypyrimidine tract binding proteins 1 (PTBP1) and PTBP2 are regulators of the neuron-
specific alternative splicing program that are regulated by NMD (Boutz et al. 2007). They 
are important in the development of the nervous system. Mice deficient of PTBP2 show 
neuronal progenitor defects and premature neurogenesis and die after birth (Licatalosi et 
al. 2012). PTBPs bind to regulatory sequences within or adjacent to alternative exons to 
repress or activate splicing or cause intron retention (Kafasla et al. 2012). PTBP1 is 
known to regulate nervous system-specific genes (Yap & Makeyev 2013) such as Gabbr1 
which encodes the GABAB1 receptor mostly expressed at post synaptic terminals of 
inhibitory synapses (Pinard, Seddik & Bettler 2010) and Dlg4 which encodes for the 
PSD-95 protein which is abundant in post synaptic neurons and regulates structure and 
function of excitatory synapses (Sheng & Hoogenraad 2007). Mice without the PSD-95 
proteins show spatial learning defects, enhanced glutamate receptor-dependent long-term 
potentiation and reduced long term depression (Migaud et al. 1998). These function of 
NMD on regulating such important neuronal genes demonstrates the importance a well-
functioning NMD pathway is for normal neurodevelopment and function and may 
explain some of the NDDs that present with a defective NMD. 
   
1.5 Mutations in NMD factors cause genetic disease                                                                      
Copy number variants and mutations in NMD and EJC genes have been reported to be 
associated with NDDs (Alachkar et al. 2013; Brunetti-Pierri, N. et al. 2008; Favaro et al. 




factor whose loss of function causes NDDs is expressed in neurons and dendritic spines, 
which are essential structures, needed for proper neurotransmission, learning and 
memory processes (Laumonnier et al. 2010). Loss of function mutations in UPF3B cause 
a broad spectrum of NDDs that include autism, ADHD, childhood onset schizophrenia 
and ID (Addington et al. 2011; Lynch et al. 2012; Szyszka et al. 2012; Tarpey et al. 2007; 
Xu et al. 2013). Transcriptome profiling lymphoblastoid cell lines (LCLs) of patients with 
UPF3B mutations detected deregulated genes that have important neural functions such 
as neurogenesis and synaptic plasticity (Nguyen et al. 2012). Approximately 23% of 
transcripts are co-expressed between LCLs and brain tissue (Rollins et al. 2010). 
Heterozygous copy number losses of UPF3A has been associated with neural tube defects 
(Luo et al. 2000).  
 
A heterozygous deletion of UPF2 is associated with NDDs (Nguyen et al. 2013) and de 
novo missense UPF2 mutations have been identified in patients with schizophrenia 
(Gulsuner et al. 2013). Transcriptome profiling of patients LCLs with heterozygous 
deletions of UPF2 had thirty eight percent of deregulated genes overlapping with patients 
with hemizygous UPF3B mutations. Ninety five percent of these genes shared the same 
trend of deregulation, suggesting that the NDDs stemming from alteration of different 
genes encoding NMD factors may arise from deregulation of a common underlying set 
of transcripts. These genes also have important functions in neurodevelopment (Nguyen 
et al. 2013).  
 
Thrombocytopenia absent radius (TAR) syndrome is caused by a heterozygous deletion 
and a non-coding single nucleotide polymorphism on the unaffected allele of RBM8A 




binds to UPF3B. About 7% of patients with a defective RBM8A present with ID 
(Alachkar et al. 2013). Micro deletions and duplication near the1q21.1 region which 
contains the RBM8A gene has been associated with ID, brain defects and congenital 
alterations without TAR syndrome (Rosenfeld et al. 2012). Some of these patients with 
abnormal RBM8A dosage have schizophrenia while others have schizophrenia with 
microcephaly and facial dysmorphic features (Brunetti-Pierri, Nicola et al. 2008).  
 
A noncoding expansion in the EJC factor, eIF4AIII is also known to cause a craniofacial 
disorder associated with limb defects (Favaro et al. 2014) such as a midline cleft 
mandible, laryngeal defects and radial and tibial deficiencies associated with clubfeet 
called Richieri-Costa-Pereira syndrome (Favaro et al. 2011). The abnormal development 
of the pharyngeal arches are due to the reduction of eIF4AIII transcript levels (Favaro et 
al. 2014). Approximately 50% of affected individuals have learning and language 
disabilities (Favaro et al. 2011).  
 
A homozygous amino acid substitution mutation in the NBAS gene located in a highly 
conserved position amongst species is known to cause a hereditary short stature (SOPH) 
syndrome. This syndrome also presents with optic nerve atrophy, postnatal growth 
retardation, facial dysmorphism and Pelger-Huet anomaly. Even though the mutation 
does not seem to affect the expression it affects its activity and it is assumed that this may 






Patients with NDDs have also shown to have both copy number losses and duplication in 
NMD and EJC factors. Compared to a control cohort, a significant enrichment of copy 
number gains in UPF2, SMG6, RMB8A, eIF4AIII and RNPS1 and copy number losses in 
UPF3A and RBM8A (Nguyen et al. 2013) were found in patients with NDDs.  
 
1.6 Disease modelling tools  
 
NDDs affect a considerable number of the world’s population and creates a significant 
social, behavioural and economic burden to the patients, their families and the society 
overall. Currently available medications, such as anti-epileptic drugs (AEDs) are partially 
effective and have major side effects on nervous system function or development (Al-
Harbi 2012). The search for better therapeutics for these disorders has been challenging, 
and only a few novel treatments have been developed in the last few decades. It appears 
the major obstacle along this drug development pipeline is the lack of suitable preclinical 
models that can be used for studying disease mechanisms, identifying therapeutic targets 
and effectively testing a larger number of potential drugs (Wen 2017).  
 
It is desirable to study the molecular basis of a disease using the best available and 
appropriate models which provides the context of the affected cellular and tissue 
pathology as molecular pathways are shaped by cell type specific gene expression 
(Handley et al. 2015).  Relevant human tissue or cell samples are however difficult to 
obtain and typically require surgery or are only available post-mortem. Isolated cells also 
cannot be maintained or expanded with conventional culture conditions and generally 
require immortalisation for long-term use (Kumar, Blangero & Curran 2018). In the 
absence of primary tissue or cells of interest, animal models (typical mice and rats) have 




1.6.1 The limitations of mice in disease modelling 
 
While rodents continue to be tremendously valuable models for biomedical research, 
rodents do not always accurately model human disease or biological responses (Seok et 
al. 2013). The evolutionary distance between rodents and humans (diverged 
approximately 87 million years ago) (Springer et al. 2003) may in part explain the 
significant differences in biological function between these species which can prevent the 
recapitulation of human disease in mice (Avior, Sagi & Benvenisty 2016).  
 
Mice and humans differ in many aspects such as embryonic development, genetic, 
physiological background and neocortical development including cortical expansion and 
the duration of human brain development. In addition to having a large brain size, the 
human cortex also has diverse types of interneurons compared to other mammals (Clancy, 
Darlington & Finlay 2001; Hamlin & Altschuld 2011; Hansen et al. 2013; Molnar & 
Clowry 2012; Strachan, Lindsay & Wilson 1997; Zhao & Bhattacharyya 2018). These 
differences may account for variable impacts that a particular mutation may have between 
mice and humans. For example monosomy X is viable in mice but lethal in humans 
(Saenger 1996), while mutations in BLM in humans cause Bloom syndrome but is fatal 
in mice (Chester et al. 1998). Lesch-Nyhan syndrome (Eiges et al. 2007; Urbach, 
Schuldiner & Benvenisty 2004) and Turner syndrome (Urbach & Benvenisty 2009) are 








1.6.2 iPSCs in disease modelling 
 
The need for suitable model systems to recapitulate diseases caused by variants of 
unknown function has led to an advance in human disease research over the last decade. 
One critical development was that of ‘somatic cell pluripotent reprogramming (cellular 
reprogramming)’ technologies, where human somatic cells such as skin fibroblasts or 
blood cells are reprogramed into induced pluripotent stem cells (iPSCs) (Figure 1.5) 
(Kunisato et al. 2010; Takahashi et al. 2007; Takahashi & Yamanaka 2006; Yu et al. 
2007). The directed differentiation of iPSCs into disease relevant cell types enables 
experiments to be performed on cell types otherwise difficult or impractical to obtain 
from patients. iPSCs are a genetically faithful model as they are derived from the patient 
and carry the patient’s genetic identity. They therefore provide the opportunity to study 
cellular and molecular mechanisms in the same genetic environment for a given disease 
(Bellin et al. 2012; Wen et al. 2016).  iPSCs provide a new platform for disease modelling 
and drug development (Wen 2017). For example in disease modelling patient’s iPSCs 
were generated and differentiated into neurons to study PCDH19 Girls Clustering 
Epilepsy. In drug development, RG7800 was tested on motor neurons derived from iPSCs 
from patients with spinal Muscular Atrophy. RG7800 increased the survival of motor 
neurons and has been through clinical trials (Homan et al. 2018; Kletzl et al. 2019; Ratni 
et al. 2018).  
 
There are several issues to however consider when using iPSCs based models. First and 
foremost, it requires access to patient derived cell lines, which is not always available. 
For instance, in mutations that lead to very early embryonic lethality such as KHDC3L 
and TLE6 (Alazami et al. 2015; Zhang et al. 2019). Second, iPSCs can acquire new 
genetic alterations during reprogramming and subsequent culture (Puri & Nagy 2012). 
22 
Third the current practice in the field of iPSC disease modelling requires gene editing to 
correct the disease-causing mutations to provide the study of isogenic control cell lines. 
It is imperative to generate isogenic control cell lines as they have the same genetic 
background as the iPSCs. This involves further manipulation and selection, potentially 
affecting cellular phenotypes. Altogether, iPSCs reprogramming and gene editing is 
specialised and laborious technique that requires handling of large number of clonal lines 
to ensure selection of clonally pluripotent cells, precise gene-editing and preservation of 
karyotype. Even though hESCs and iPSCs have been shown to be very similar, there are 
important differences to note between the two cell types such as the persistence of 
transcriptional and epigenetic memory from the somatic cells tissue of origin (Bar-Nur et 
al. 2011; Chin et al. 2009; Doi et al. 2009; Kim, K et al. 2011; Ohi et al. 2011), differential 
DNA methylation signatures (Lister et al. 2011; Ruiz et al. 2012) and a higher degree of 
genetic aberrations acquisition in iPSCs (Gore et al. 2011; Yung et al. 2013). However, 
extended culture of iPSCs in culture conditions defined to support pluripotency has been 
shown to erase somatic cell memory at the transcriptional, epigenetic and genome 
topology levels (Krijger et al. 2016). 
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Figure 1.5: The use of iPSCs for regenerative medicine, disease modelling and 
drug screening.
Patient-derived somatic cells are reprogrammed to generate iPSCs carrying a disease 
specific genetic mutation. These cells have the ability to self-renew and are pluripotent 
and can be differentiated into the disease affected cell type for studying mechanisms of 
disease pathology. The generated iPSCs can be used for high-throughput screening of 
drugs. Figure was taken from (Ebert, Liang & Wu 2012). 
This figure has been removed due to Copyright restrictions
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1.6.3 The application of hESCs and gene editing technologies to model diseases 
The field of genome engineering is rapidly evolving due to new technological 
developments. The ability to combine human embryonic stem cells (hESC)-based 
technology with advanced gene editing technology is an attractive approach to generate 
new in vitro disease models and resources for basic and applied biology research into 
genetic disease (Hendriks, Warren & Cowan 2016). It enables systematic interrogation 
of causative genetic variation across multiple diverse cell types and tissues of disease 
relevance (Ding, Qiurong et al. 2013).   
1.6.3.1 Human embryonic stem cells (hESCs) 
hESCs were first isolated in 1998 and are derived from the inner cell mass of the 
blastocyst (Thomson et al. 1998). hESC lines attracted attention as they have the ability 
to proliferate indefinitely in-vitro and maintain the potential to differentiate into any cell 
type of the body (Löser et al. 2010). The use of hESCs is important in the absence of 
patient-derived somatic cells for example in cases of genetic aberrations and aneuploidies 
that lead to very early embryonic lethality (As mentioned in section 1.6.2) (Urbach & 
Benvenisty 2009).  
1.6.3.2 Gene editing technologies 
Gene editing technologies employ the same concept. They use a specific sequence 
complementary to the targeted region, tethered to an endonuclease. The complementary 
sequence homes the endonuclease to the target gDNA where it cuts the genome 
generating double stranded breaks (DSBs). Gene editing technologies also exploit the 
endogenous DNA repair pathway that introduces mutations by deleting or inserting 
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nucleotides during the repair. They differ in the DNA recognition mechanism and the 
specific endonuclease involved. The first custom-engineered, site specific endonucleases 
used for genome editing in hESCs were the Zinc-Finger Nucleases (ZFNs) (Hockemeyer 
et al. 2009). These are fusion proteins composed of several tandem Zinc-finger DNA 
binding domains coupled to the FokI endonuclease catalytic domain. The DNA binding 
domain of ZFNs consists of three to six zinc finger DNA-binding domains (ZFDBD) 
assembled in an array. This array construction of the ZFN allows for specific targeting of 
genetic loci, as each ZFDBD binds to a specific nucleotide triplet. FokI endonuclease is 
only active when dimerised (Figure 1.6a) (Bibikova et al. 2003; Urnov et al. 2005). ZFNs 
are difficult to engineer and their design and construction remains technically challenging 
(Hendriks, Warren & Cowan 2016).  
Another different custom-engineered endonuclease is the Transcription Activation-Like 
Effector Nuclease (TALEN) (Figure 1.6b). Like ZFNs, TALENs consist of a customised 
TALE DNA binding domain fused to a non-specific FokI nuclease domain. The TALE 
DNA binding domain comprises arrays of 33-35 amino acids (Joung & Sander 2013) 
where the amino acids in position 12 and 13 of each array determine nucleotide binding 
specificity (Bogdanove, Schornack & Lahaye 2010). As with the design of ZFNs, each 
DNA target sequence requires re-engineering of the TALE DNA binding domain 
(Hendriks, Warren & Cowan 2016).  
Similar to the ZFNs and TALENs, the CRISPR/Cas9 technology stimulates DSBs at the 
target genomic site (Hsu & Zhang 2012). However, unlike the ZFNs and TALENs which 
use a method of tethering the FokI endonuclease catalytic domains to modular DNA 




CRISPR/Cas9 technology utilises the Cas9 endonuclease homed by a 20 nt guide RNA 
(gRNA) through Watson-Crick base pairing to a target DNA (Figure 1.6c) (Mali, Esvelt 
& Church 2013). Unlike the ZFNs and TALENs, the CRISPR/Cas9 genome editing 











Figure 1.6: Gene editing technologies.  
a,b) ZNFs and TALENs require a pair of fusion proteins with DNA binding domains 
fused to the FokI endonuclease on opposite DNA strands. These two fusion proteins are 
separated by a small fragment called a spacer sequence. In the nucleus, the FokI domains 
located at the C-termini of the chimeric protein dimerise to cause a double stranded break 
in the spacer sequence. c) The CRISPR/Cas9 technology generates DSBs by utilising the 
Cas9 endonuclease under the guidance of the gRNA to a complementary sequence in the 










1.7 Hypothesis and aims 
A defective NMD mechanism due to knockout/knockdown of NMD factors is known to 
cause a deregulation in approximately 3-10% of the whole transcriptome across multiple 
species (He et al. 2003; Lelivelt & Culbertson 1999; Nguyen et al. 2012; Rehwinkel et 
al. 2005; Rodriguez-Gabriel et al. 2006; Wittmann, Hol & Jack 2006). Genes that are 
deregulated as a consequence of malfunctioning NMD can explain the NDD phenotypes 
of patients but have not yet been systematically identified in a human brain context. Most 
of the research work on the NMD pathway has so far been performed using transformed 
cell lines, mouse/rat neural progenitor cells and mouse/rat stem cells derived neurons and 
other species such as the Drosophila melanogaster (Alrahbeni et al. 2015; Jolly et al. 
2013; Lou et al. 2014; Nguyen et al. 2012; Rehwinkel et al. 2005).  
 
Given that NMD regulates approximately 3-10% of the transcriptome and that at least a 
proportion of NMD targets can be species specific (Jolly et al. 2013; Rehwinkel et al. 
2005) it is important to study the role of NMD in neurodevelopment in a relevant human 
brain disease model. There is paucity of suitable human cell-based disease models to 
investigate how a defective NMD pathway leads to NDDs, and in particular NDDs 
stemming from mutations in UPF3B, and its gene paralog UPF3A. Whilst the role of 
UPF3B in promoting NMD is well established, the role of UPF3A is enigmatic, with both 
NMD-promoting and NMD-inhibiting activity being reported in different experimental 
contexts (Shum et al. 2016). The main goal of this research is to generate UPF3A and 
UPF3B KO hESCs and differentiate them into neural stem cells (NSCS) and identify 
NMD targeted or regulated transcripts in UPF3A and UPF3B KO hESCs and hESCs 
derived neural stem cells. The significance of identifying these transcripts is that we will 
identify genes associated with phenotypes in UPF3B patients. It will also help in 




UPF3A and the role of UPF3A in NMD (activator vs inhibitor). Having an understanding 
of the role of UPF3A and UPF3B in a brain cell model will help better understand the 






















UPF3A and UPF3B KO hESCs would be viable and not drastically affect pluripotency. 
   
Aim 1 
To use CRISPR/Cas9 genome editing technology to generate UPF3A and UPF3B KO 
hESCs clones.  
 
Aim 2 
Assess pluripotency in CRISPR/Cas9 edited hESCs.   
 
Hypothesis 2  
Transcriptome profiling of UPF3A and UPF3B KO hESCs and NSCs would elucidate 
the role of UPF3A and UPF3B in neurodevelopment and the role of UPF3A in NMD. 
 
Aim 1 
To differentiate UPF3A and UPF3B KO hESCs clones into NSCs. 
 
Aim 2 
To perform RNASeq on hESCs and hESC-derived neural stem cells in UPF3A and 






































2.1 Cell Culture Methods 
2.1.1 List of equipment, reagents and medium  
 
2.1.1.1 Cell culture equipment 
 
• 37°C water bath 
• Cell culture centrifuge with swing arm bucket rotor 
• Cell culture humidified incubator, 5% CO2, 37°C 
• Biological safety cabinet class II (VWR, PA, USA) 
• Dissecting microscope (Olympus SZX16 stereo microscope, Tokyo, Japan) 
• Inverted microscope 
• CoolCell®LX, freezing container (Bioscision Cat# BCS-405, CA, USA) 
• Cell counter (Countess II FL, Life Technologies, CA, USA) 
• Liquid nitrogen cell storage tank 
 
2.1.1.2 Cell culture materials 
 
• Six well plates (Corning® Costar® Cat# CLS3516, NJ, USA) 
• 96 well plates (NUNC Cat# 167008, RKE, Denmark) 
• Six well plate (NUNC Cat# 140675) 
• 35 mm dishes (NUNC Cat# 150318) 
• Cryovials (NUNC Cat# 377224) 
• 10 ml Polypropylene tube graduated screw capped sterile (Technoplas Cat# P10316SU) 
• Cell scrappers (TTP Cat# 99003) 
• 1 mL disposable syringe (BD Cat# 302100) 




• Fetal Bovine Serum, ESC-qualified US origin (hESC FBS) (Gibco, Thermo Fisher Scientific 
Cat# 10439024, MA, USA). 
• Fetal Bovine Serum, qualified, Australia (FBS) (Gibco, Thermo Fisher Scientific Cat# 
10099141). 
• Dulbecco’s Modified Eagle Medium (DMEM, high glucose) (Gibco, Thermo Fisher Scientific 
Cat# 11995081). 
• Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12/GlutaMAXTM supplement 
(DMEM/F12 GlutaMAX) (Gibco, Thermo Fisher Scientific Cat# 10565042). 




• Knockout Serum replacement (KSR) (Gibco, Thermo Fisher Scientific Cat# 10828028). 
• β-Mercaptoethanol (55 mM) (Life Technologies Cat# 21985-023). 
• Gelatin from bovine skin (Sigma-Aldrich Cat# G9391, NSW, Australia). 
• Basic Fibroblast Growth Factor (AA 10-1055: bFGF) Human recombinant protein (Invitrogen, 
Thermo Fisher Scientific Cat# PHG0023). 
• Human recombinant Epidermal Growth Factor (EGF) (StemCell Technologies, Cat# 78006.1, 
VIC, Australia). 
• Y-27632 dihydrochloride (ROCK-Inhibitor) (Tocris Bioscience Cat# 1254, Bristol, UK). 
• Neurobasal® medium (Gibco, Thermo Fisher Scientific Cat# 21103049). 
• N-2 supplement (100X) (Gibco, Thermo Fisher Scientific Cat# 17502048). 
• B-27 supplement, serum free (50X) (Gibco, Thermo Fisher Scientific Cat# 17504044). 
• Trypan blue stain (0.4%) (Gibco, Thermo Fisher Scientific Cat# 15250016) 
• Extra cellular matrix (ECM) from Engelbreth-Holm-Swarm murine sarcoma (Sigma-Aldrich 
Cat# E1270). 
• Accutase (StemCell Technologies Cat# 07920). 
• Insulin solution human (Sigma-Aldrich Cat# I9278). 
• Dispase II (Gibco, Thermo Fisher Scientific Cat# 17105041). 
• L-Glutamine (200 mM) (Gibco, Thermo Fisher Scientific Cat# 25030081). 
• MEM Non-essential amino acids solution (NEAA) (Gibco, Thermo Fisher Scientific Cat# 
11140050). 
• Penicillin-Streptomycin (10,000 units) (P/S) (Gibco, Thermo Fisher Scientific Cat# 15140122). 
• SB431542 (Tocris Bioscience Cat# 1614). 
• Dorsomorphin (Sigma-Aldrich Cat# P5499). 
• Poly-L-Ornithine solution (Sigma-Aldrich Cat# P4957). 
• Laminin (Sigma-Aldrich Cat# L2020). 
• Vitronectin XFTM (StemCell Technologies Cat# 07180). 
• TeSRTM –E8TM (StemCell Technologies Cat# 05940). 
• mTeSR-1 medium without phenol red (StemCell Technologies Cat# 85850). 
• Gentle cell dissociation reagent (StemCell Technologies Cat# 07174). 
• CellAdhereTM dilution buffer (StemCell Technologies Cat# 07183). 
• Dimethylsulfoxide (DMSO) (Sigma-Aldrich Cat# D2438) 










2.1.1.4 Medium/solutions for cell culture 
 
Medium/solution  Reagents 
iMEF medium 10% hESC FBS, 100U/mL P/S, 1X NEAA, DMEM (high glucose). 
Store at 4°C for 1 month. 
Incomplete hESC medium DMEM/F12 GlutaMAX, 20% KSR, 1X NEAA, 50 U/mL P/S. Store 
at 4°C for up to 1 months. 
Complete hESC medium Incomplete hESC medium, 0.1 mM β-Mercaptoethanol, 8ng/mL 
bFGF. Use immediately. 
Complete hESC conditioned 
medium 
Incomplete hESC medium conditioned with MEFs for 24hrs, 0.1 
mM β-Mercaptoethanol, 8 ng/mL bFGF. Use immediately. 
B-27 medium Neurobasal medium, 1X B-27 supplement, 1 mM L-Glutamine, 100 
U/mM P/S. Store at 4°C for up to 2 weeks. 
N-2 DMEM/F12 GlutaMAX, 1X N-2 supplement, 5 μg/mL Insulin, 1 
mM L-Glutamine, 1X NEAA, 0.1 mM β-Mercaptoethanol, 100 
U/mL P/S. Store for up to 2 weeks. 
Neural maintenance medium 1:1 N-2: B-27 medium. Store at 4°C for up to 2 weeks. 
Neural induction medium #1 Neural maintenance medium, 10 μM SB431542, 1 μM 
Dorsomorphin. Store at 4°C and use within 5 days. 
Neural induction medium #2 Neural maintenance medium, 1 μM Dorsomorphin. Store at 4°C and 
use within 5 days. 
Dispase solution Make 10 mg/mL stock by resuspending powder in DPBS without 
magnesium and calcium. Filter sterile through a 0.22 μM filter. 
Store at 4°C. Stable for 24 months. 
Gelatin solution Make 0.1% W/V gelatin solution in MilliQ water. Autoclave and 
store at 4°C. Filter through a 0.22 μM filter prior to use.  
ECM 1:2 dilution of ECM and cold DMEM/F12 GlutaMax medium 
Neural progenitor freezing 
medium 
Neural maintenance medium with 10% DMSO and 20 ng/μL FGF 
and 20 ng/μL EGF.  















2.1.2 Culturing hESCs  
hESCs were cultured as either feeder depended or feeder free cultures. They were 
routinely cultured in feeder depended conditions and transferred onto feeder free 
conditions before experiments.  
 
2.1.2.1 Standard hESCs culture on irradiated Mouse Embryonic Fibroblast (iMEF) 
feeder layer. 
 
2.1.2.1.1 Preparation of iMEF Feeder cultures 
 
Six-well plates were coated with 1 mL/well of 0.1% gelatin for a minimum of 2 hrs to 
overnight at 37°C before plating iMEFs (Stemcore, Ltd, Queensland, Australia). Gelatin 
was aspirated and left in the biological safety hood for 1 hr to dry before plating iMEFs. 
Cryopreserved iMEFs were thawed quickly by the addition of pre-warmed iMEF 
medium, to the cryovial of cells and transferring to a 10 mL warmed iMEF medium tube 
using a transfer pipette. The cells were centrifuged at 120 g for 5 mins. The supernatant 
was aspirated and the cells resuspended in iMEF medium. A 20 μL aliquot was removed 
and diluted 1:1 with trypan blue to perform a viable cell count using a haemocytometer. 
The cell suspension was diluted with iMEF medium to give 1.9x105 cells/mL. The cells 
were mixed well by inversion and 1 mL of cell suspension added to each well of a gelatin 
coated 6-well plate, giving a density of 20, 000 MEFs/cm2. An additional 1 mL of iMEF 
medium was added to each well of the plate. The cells were mixed to allow even 






2.1.2.1.2 Culturing hESCs on iMEF feeder cultures 
The H1 hESC line obtained from WiCell (Madison, WI, USA) were cultured on an iMEF 
feeder layer (Section 2.1.2.1.1) as described previously (Briggs et al. 2013) with an bFGF 
concentration of 8 ng/mL (Rosler et al. 2004) . The day after plating iMEFs, the medium 
was aspirated and the wells washed with Dulbecco’s Phosphate Buffered Saline (DPBS) 
to remove any remaining FBS. 2 mL (section 2.1.2.3.1) or 1 mL (section 2.1.2.3.2.1) of 
complete hESC medium was added to each well and equilibrated for 1 hr in the incubator 
(37°C, 5% CO2). hESCs were then seeded into each well (Section 2.1.2.3.1, 2.1.2.3.2.1). 
Cells were incubated at 37°C in 5% CO2. Complete hESC medium was changed daily 
(and made fresh daily) with the morphology of hESCs colonies monitored closely by 
bright field analysis on an inverted microscope (Olympus CKX31, Tokyo, Japan) to 
determine when the cells required passaging. This was determined by the size of colonies 
and the presence of differentiation in the culture.  
 
2.1.2.2 Standard hESC feeder-free culture conditions 
 
2.1.2.2.1 iMEF conditioned medium 
iMEF conditioned medium (CM) was prepared to harvest growth factors secreted by 
iMEFs and supply them to hESCs grown on feeder-free cultures. CM was prepared by 
plating 1x107 iMEFs in a T125 flask with iMEF medium. A day after plating, the cells 
were washed once in DPBS. Incomplete hESCs medium (90 mL) was added and 
collected 24 hrs later. Medium was repeatedly replenished and collected every 24 hrs 
over a period of 6 days. The daily collected aliquots were filtered every second day as a 






2.1.2.2.2 Feeder-free hESCs culture using extracellular matrix (ECM) 
The H1 clonal hESC line were cultured as described previously by (Xu et al. 2001).  Six-
well culture plates were coated with the ECM gel diluted 1:50 from stock in cold 
DMEM/F12 GlutaMax medium for between 2 hrs to overnight at 37°C. Before use, ECM 
was aspirated and the wells washed once with DPBS. 2 mL (section 2.1.2.3.1) or 1 mL 
(section 2.1.2.3.2.1, 2.1.2.3.2.3) of complete iMEF CM was added in each well and 
placed in the incubator to equilibrate for 1 hour. hESCs were seeded into each well 
(section 2.1.2.3.1 or 2.1.2.3.2.1 or 2.1.2.3.2.3). Cells were incubated at 37°C in 5% CO2. 
Complete iMEF CM was changed daily (and made fresh daily) with the morphology of 
hESCs colonies monitored closely by bright/Phase contrast analysis on an inverted 
microscope to determine when the cells required passaging. This was determined by size 
of colonies and the presence of differentiating cells in culture. 
 
 
2.1.2.2.3 Feeder-free hESCs culture using chemically defined TeSRTM –E8TM 
medium 
H1 hESCs were cultured as described in the ‘Maintenance of Human pluripotent stem 
cells in TeSRTM –E8TM technical manual’ (StemCell Technologies). Six-well plates were 
coated with 1 mL/well of 10 μg/mL Vitronectin XFTM diluted with the cellAdhereTM 
dilution buffer for between 1 hr minimum to overnight at 37°C. Vitronectin XFTM was 
aspirated before use and the wells rinsed once with DPBS. 1 mL of TeSRTM –E8TM was 
added into each well and left in the incubator to equilibrate for 1 hr. hESCs were seeded 
into each well (section 2.1.2.3.2.2). Cells were incubated at 37°C in 5% CO2. TeSRTM –
E8TM medium was changed daily with the morphology of hESC colonies monitored 
closely by bright/Phase contrast analysis on an inverted microscope to determine when 
the cells required passaging. This was determined by size of colonies and the presence of 





2.1.2.3 Passaging hESCs 
hESCs were passaged every 5-7 days as required. Prior to passaging, plates were prepared 
as described (Section 2.1.2.1.1, 2.1.2.2.2 or 2.1.2.2.3) and returned to the incubator to 
equilibrate for approximately 1 hr with appropriate growth medium added. 
 
2.1.2.3.1 Mechanical passaging of hESCs 
Mechanical passaging was performed in a biological safety cabinet class II (VWR) using 
a dissecting microscope (Olympus SZX16 stereo microscope, Tokyo, Japan). hESC 
colonies were selected based on morphology at 40X magnification. Those that appeared 
pluripotent were dissected into smaller square shaped pieces using a 21-guage needle. 
Using a 200 μL pipette and barrier tip, dissected colonies were carefully lifted off the 
plate and transferred to the newly prepared plate. Care was taken to avoid cutting and 
transferring differentiating regions of hESC colonies. Pieces of the same hESC colony 
were transferred to different wells/plates to avoid subculture of colonies. Approximately 
50-60 dissected squares were transferred to each well of a 6-well plate. Cells were 
incubated at 37°C in 5% CO2 with daily medium changes.  
 
2.1.2.3.2 Enzymatic passaging of hESCs 
 
Prior to enzymatic passaging of hESCs any differentiating cells/colonies were removed 
from the culture by mechanically removing selected differentiating regions of colonies 
under the dissecting microscope. These regions were lifted off the plate using a 200 μL 
pipette and a barrier tip. Medium containing the differentiating cells was aspirated and 1 
mL of PBS was added and aspirated to ensure removal of all differentiating cells from 




2.1.2.3.2.1 Dispase passaging of hESCs 
 
800 μL of 10 mg/mL Dispase pre-warmed to 37°C was added to each well of a 6-well 
plate. The plates were returned to the incubator for 2 mins or after the edges of colonies 
started to curl upwards. Dispase was removed by aspiration and 1 mL of incomplete 
hESC medium was added to the well to wash off any remaining Dispase. The medium 
was again aspirated and an additional 1 mL of incomplete hESC medium added. Using a 
cell scrapper hESC colonies were lifted off the surface of the plate and transferred to a 
10 mL tube containing 6 mL of 37°C pre-warmed incomplete hESC medium using a 5 
mL serological pipette. An additional 1 mL of medium was added to the well and any 
remaining hESC colonies collected and transferred to the tube. hESC colonies were 
centrifuged at 80 g for 3 mins with low break. The supernatant was removed by aspiration 
and 1 mL of complete hESC medium (or complete iMEF CM) added to the cell pellet. 
Using a 1000 μL pipette, the hESC colonies were gently resuspend and triturated by 
pipetting up and down 2-3 times until the colonies were mechanically dissociated into 
smaller pieces. Additional hESC medium was then added to ensure an adequate split ratio 
(approximately 1:4 to 1:5 split) and 1 mL of cell suspension transferred to pre-prepared 
hESC plates using a 5 mL serological pipette to avoid complete dissociation to single 
cells. The volume of medium was adjusted to 2 mL/well of a 6-well plate. Cells were 
incubated at 37°C in 5% CO2 with daily medium changes.   
 
2.1.2.3.2.2 Passaging cells grown using TeSRTM-ETM medium 
 
1 mL of gentle cell dissociation reagent was added for 10 mins at RT. The reagent was 
aspirated and 1 mL of DMEM/F12 GlutaMAX medium was added. The cells were gently 
detached using a cell scrapper. The colonies were transferred into a 10 mL tube 




once with 1 mL DMEM/F12 GlutaMAX medium and collected in the 10 mL tube. The 
cells were centrifuged at 300 g for 5 mins with low break. Medium was aspirated off and 
1 mL of TeSRTM –E8TM medium was added to the cells and pipetted up and down with a 
P1000 pipette twice to triturate the colonies. A 1:6 – 1:10 dilution ratio (depending on 
the cell density prior to passaging) was performed and the cells re-plated. The cells were 
then transferred into the incubator at 37°C with 5% CO2 in a humidified environment, re-
feed daily and passaged every 6-7 days. 
 
2.1.2.3.2.3 Accutase single cell passaging of hESCs 
 
Fresh complete iMEF CM containing 10 μM of ROCK inhibitor (Y-27632 
dihydrochloride) was added to cells for 2 hrs before single cell passaging. After 2 hrs, the 
medium was aspirated and cells rinsed once in DPBS and 800 μL of AccutaseTM cell 
detachment solution pre-warmed at 37°C was added to each well of a 6-well plate. The 
plate was returned to the incubator for 10 mins until hESC colonies could be seen to 
dissociate into single cells under the inverted microscope. 1 mL of incomplete hESC 
medium was added to the well and hESC removed from the well and transferred into a 
10 mL tube with 6 mL of pre-warmed at 37°C incomplete hESC medium. An additional 
1 mL of incomplete hESC medium was added to the well and any remaining hESCs 
removed from well and into the 10 mL tube. Cells were then collected by centrifugation 
at 120 g for 3 mins with low break. The supernatant was aspirated and the hESCs 
resuspended in 1 mL of complete iMEF CM containing 10 μM ROCK inhibitor using 
trituration with a P1000 μL pipette to generate a single cell suspension. Complete iMEF 
CM supplemented with 10 μM ROCK inhibitor was added to dilute cells appropriately 
and a 20 μL aliquot was removed and diluted 1:1 with trypan blue to perform a viable 
cell count using a haemocytometer. hESCs were plated at a high density by plating 




to 2 mL/well of a 6-well plate. Cells were incubated at 37°C in 5% CO2 with medium 
changed the following day to complete iMEF CM without ROCK inhibitor and 
subsequent daily medium changes.   
 
2.1.2.4 Cryopreservation of hESCs 
hESCs were expanded into a T25 cm2 tissue culture flasks (ECM/iMEF) or 6-well plates 
(Vitronectin). hESC were passaged using Dispase (ECM/iMEFs) or Gentle cell 
dissociation reagent (Vitronectin) as described above. Cells harvested from T25 sized 
flask were frozen into a single cryogenic vial, while cells harvested from one well of a 6-
well plate were frozen into a single cryogenic vial. After centrifugation cells were 
resuspended in 1 mL of hESC freezing medium ensuring minimum disruption to hESCs 
colony size. Resuspended cells were transferred into a cryogenic vial and placed into an 
isopropanol filled freezing containers and stored at -80°C. After 24 hrs the vials were 
transferred to liquid nitrogen for long term storage.  
 
2.1.2.5 Thawing hESCs 
To thaw hESCs, plates with iMEF feeder layers, ECM or Vitronectin were prepared 1 
day in advance. The plates were rinsed once with DPBS and 1 mL of complete hESC 
medium, iMEF CM or TeSR-E8 medium with 10 μM ROCK inhibitor was added and 
placed in the incubator to equilibrate for 1 hr. 9 mL of incomplete hESCs medium 
(iMEFs, ECM based cultures) or DMEM/F12 GlutaMAX (Vitronectin based cultures) 
was warmed at 37°C in a water bath in a 10 mL tube. A cryogenic vial of the cells were 
quickly thawed by adding the warmed medium in the 10 mL tube to cells in a dropwise 
manner and collecting them in the same 10 mL tube with warmed medium. This was 




80 g for 3 mins (iMEFs, ECM) or 300 g for 5 mins (Vitronectin) with low break. The 
supernatant was removed and cells resuspended in complete hESC medium, iMEF CM 
or TeSR-E8 with 10 μM ROCK inhibitor, mildly triturated by pipetting once or twice, 
and transferred to the plates with the equilibrated medium. Cells thawed from the harvest 
of T25 flask (i.e. ECM/iMEF based cultures) were distributed across two wells of a 6-
well plates, while cells harvested from one well of the 6-well plate (i.e. Vitronectin based 
cultures) were distributed across six wells of a 6-well plate. Cells were then incubated at 
37°C at 5% CO2 in a humidified atmosphere. After 24 hrs the medium was changed to 
medium with no ROCK inhibitor. Medium changes were performed daily until cells were 
ready to be passaged.  
 
2.1.3 CRISPR/Cas9 Genome Editing 
The CRISPR/Cas9 gRNAs were designed to introduce gene disrupting deletions via 
exploitation of the NHEJ pathway in target genes UPF1, UPF2, UPF3A and UPF3B (see 
section 2.2). Validation of gRNA gene targeting was performed initially in HEK293T 
cells before use in hESCs. The validation protocol was based on Ran et al., 2013. The 
CRISPR/Cas9-gRNA delivery method employs the PX459 V2 plasmid (Addgene 
plasmid #62988, USA) that expresses the Cas9 protein, gRNA and the PAC gene 
encoding puromycin-N-acetyltransferase that confers resistance to the antibiotic 
puromycin. 
 
2.1.3.1 Human Embryonic Kidney 293T cell line (HEK293T) culture   
HEK293T cells were cultured in DMEM supplemented with 10% FBS and 100U 
Penicillin/Streptomycin (PenStrep). Cells were incubated in 5% CO2 at 37°C in a 




with Trypsin as follows; medium was aspirated and cells rinsed once with DPBS. The 
cells were incubated in pre-warmed 37°C 0.25% Trypsin for 5 mins at 37°C. Complete 
DMEM was then added to neutralise the Trypsin, the dissociated cells were harvested by 
centrifugation at 120 g for 5 mins. The supernatant was aspirated and cells resuspended 
in the appropriate amount of complete DMEM. A cell count was performed and cells 
were replated at 1x106 cell/well in a 6-well plate for transfection in 2 mL of medium. 
 
2.1.3.2 Transfecting CRISPR/Cas9 plasmids in HEK293T cells 
A day prior to transfections, HEK293T cells were seeded at a density of 1x106 in a 6-well 
plate. After 24 hrs post seeding, transfections were performed using Lipofectamine 2000 
(Cat# 11668019, Invitrogen, Thermo Fisher Scientific) as per manufacturer’s 
instructions. Briefly 2 μg of plasmid DNA (PX459 V2 plasmid control or with inserted 
gRNAs) was added to 150 μL of Opti-MEM (Cat# 3198062, Gibco, Thermo Fisher 
Scientific) at RT. In a second tube, 8 μL of Lipofectamine 2000 was added to 150 μL of 
Opti-MEM at RT. The DNA: Opti-MEM solution was then added to the Opti-MEM: - 
Lipofectamine solution and incubated for 5 mins at RT. This mixture was added dropwise 
to cells while swirling the plate. After 24 hrs, puromycin selection was performed by 
adding 2 μg/mL of puromycin to cells for 48 hrs. Cells were expanded and cell pellets 
collected for RNA, gDNA and protein analysis.  
 
2.1.3.3 Nucleofecting gRNA CRISPR/Cas9 plasmids in hESCs 
Nucleofection was performed using the Amaxa P3 Primary Cell 4D nucleofectorTM X kit 
L (Cat# V4XP-3024, Lonza, Mount Waverley, VIC). 2 hrs before nucleofection, 
complete iMEF CM was replaced with fresh iMEF CM containing 10 μM ROCK 
inhibitor. Complete hESC medium containing 10 μM ROCK inhibitor was also added to 




incubator. Single cell suspensions were collected by detaching cells with Accutase. A cell 
count was performed and the required cells (1x106 cells/nucleofection) were centrifuged 
at 115 g for 3 mins with low break. Medium was aspirated and cells were resuspended 
carefully in 100 μL of nucleofector solution (82 μL of nucleofector solution and 18 μL 
of supplement) at RT as per manufactures instruction. The cell solution was then added 
to 2 μg of plasmid DNA. The following plasmids were nucleofected: 1. p.GFPmax 
(negative control); 2. PX459 V2 (positive control); 3. PX459 V2 -G1-3 (where G1-3 
represents one of the three gRNAs used to target each gene (UPF3A and UPF3B). 
Nucleofection was performed using program CB-150 with the Lonza 4D NucleofectorTM 
unit. Nucleofected cells were resuspended in 500 μL of equilibrated complete hESC 
medium supplemented with the ROCK inhibitor, pipetted up and down three times gently 
and placed in 100 mm dishes containing iMEFs. The cells were evenly distributed and 
placed in the incubator.  
 
2.1.3.4 Selection and expansion of CRISPR/Cas9 edited clones. 
See optimised protocol in Appendix 1. 
 
2.1.4 Neural differentiation 
 
2.1.4.1 Neural induction of hESCs 
Neural differentiation was performed on hESC colonies (Lukovic et al. 2017) using the 
dual SMAD inhibition method in a 2D adhesion culture system (Shi, Kirwan & Livesey 
2012). High quality pluripotent hESC cultures (≥ 90% pluripotent, <10% differentiated) 
were passaged onto a 6-well Nunc plate coated with 10 μg/mL of Vitronectin. After 5 




was added to cells. This event was called Day 0 of neural differentiation. Medium was 
changed every second day.  
 
2.1.4.2 Passaging of Neuroepithelial sheet  
At day 6 of neural differentiation, formation of a ‘neuroepithelial sheet’ was observed in 
which cells displayed a uniform characteristic compact morphology with a small 
prominent nuclei. At day 7 of neural differentiation, medium was changed to Neural 
Induction Medium 2 (NIM2). Medium was changed every second day until day 10 where 
the neuroepithelial sheet was denser and thickened at which point it was passaged (Neural 
Differentiation Passage 1). Prior to passaging, Nunc dishes (35 mm) were coated with 
Poly-L-ornithine (PLO) for 4 hrs then aspirated and coated with 20 μg/mL of Laminin 
(diluted in cold DPBS) overnight. The dishes were rinsed once with DPBS before use 
and 1 mL medium added and equilibrated for 1 hr.  
 
The neuroepithelial sheet was passaged by adding 800 μL/well of pre-warmed 37°C 
Dispase and incubating at 37°C for 5 mins. The medium and Dispase were aspirated and 
cells rinsed with 1 mL Neural Maintenance (NM) medium.  The medium was aspirated 
and 1 mL of NM medium was added. A cell scraper was used to carefully detach the 
neuroepithelial sheet from the plate. The cells were transferred to a 10 mL tube containing 
6 mL of pre-warmed NM medium with a 5 mL serological pipette. Remaining cells in 
the wells were collected. The harvested cells were centrifuged at 80 g for 3 mins with 
low break. The medium was aspirated and cells were resuspended in NIM2 supplemented 
with 10 μM ROCK inhibitor and 20 ng/mL bFGF. The tube was inverted to mix cells and 
distributed across 2 Nunc dishes (i.e. equivalent to a 1:2 split). The next day medium was 




2.1.4.3 Passaging of Neural Rosettes  
By day 13 of neural differentiation, the presence of ‘neural rosettes’ started appearing in 
the cultures. Neural rosettes represent neural stem cells (NSCs) adopting an elongation 
morphology and arranged in a ‘pin-wheel’ architecture dictated by an overt acquisition 
of apical-basal polarisation (Wilson & Stice 2006). At day 15 neural rosettes structures 
were manually passaged (Neural Differentiation Passage 2); Neural rosettes were 
manually dissected (as per manual passaging of hESCs), avoiding the edges (as they 
contain contaminating neural crest cells) and transferred into a 35 mm dish pre-coated 
with PLO/laminin and pre-equilibrated with NM medium supplemented with 20 ng/mL 
of bFGF. 
 
Rosettes from two 35 mm dishes were transferred into one 35 mm dish to generate a high 
density culture. The next day medium was changed to neural maintenance medium 
without bFGF. Medium was changed every second day. Five days after manual selection 
of neural rosettes (i.e. day 20 of neural differentiation) , cells were passaged again (Neural 
differentiation Passage 3) by adding 800 μL of pre-warmed 37°C Dispase directly into 
the medium and incubated for 5 mins at 37°C. Cells were collected and centrifuged at 80 
g for 3 mins with low break. The medium was aspirated and 1 mL NM medium added to 
cells and using a P1000 pipette, pipetted once to break large neural rosettes and plated 
into a 35 mm PLO/laminin coated dish containing equilibrated NM medium. NM medium 
and changed every second day.  
 
2.1.4.4 Dissociating Neural Rosettes to Isolate Neural Stem cells  
At 5 days after Dispase passaging the neural rosettes (i.e. day 25 of neural differentiation), 
neurons were observed at the periphery of the rosettes. At this stage the cultures were 




aspirated from the cells, and the cells washed once with DPBS. Pre-warmed 37°C 
Accutase (700 μL) was added to the cells and incubated at 37°C for 10 mins. One mL of 
NM medium was added to the dish and the cells pipetted up and down twice using a 
P1000 pipette. Cells were collected and centrifuged at 120 g for 3 mins with low break. 
The medium was aspirated and 1 mL of NM medium supplemented with 20 ng/mL of 
bFGF and 20 ng/mL of EGF was added to cells and pipetted up and down four times to 
generate a single cell suspension. Cells were plated at a density of 1x106 cells/well of a 
6-well Nunc coated plate with ECM. Medium was changed every two days and cells 
passaged when they reached 90% confluency. From this point the cells in these cultures 
were referred to as NSCs. 
 
 
2.1.4.5 Maintaining neural stem cells    
 
NSCs cultures were passaged by Accutase dissociation upon reaching 80-90% 
confluency (NSC Passage). Six-well plates were pre-coated with ECM and subsequently 
rinsed with DPBS. 1 mL NM medium supplemented with 20 ng/mL of bFGF and 20 
ng/mL EGF was added to the wells and equilibrated in the incubator for 1 hr. NSCs were 
rinsed once with DPBS and 800 μL of pre-warmed 37°C Accutase added and incubated 
until the NSCs started to lift off the surface. 1 mL of NM medium was added to each well 
and NSCs removed from the well and transferred into a 10 mL tube with 5 mL of NM 
medium pre-warmed at 37°C. An additional 1 mL of NM medium was added to the well 
and any remaining NSCs collected and added to the 10 mL tube. Cells were centrifuged 
at 120 g for 5 mins with low break. The supernatant was aspirated and the NSCs 
resuspended in 1 mL of NM medium supplemented with 20 ng/μL of bFGF and 20 ng/μL 
of EGF and using a P1000 pipette to generate a single cell suspension. A viable cell count 




cells/well of a 6-well plate.  Medium was changed every second day with freshly added 
20 ng/mL of bFGF and 20 ng/mL of EGF. NSCs were re-passaged once 80-90% 
confluent.   
 
2.1.4.6 Cryopreservation of NSCs 
 
At Passage 4 NSCs were cryopreserved. After Accutase dissociation, 2x106 cells were 
resuspended into NSC freezing medium and transferred to a cryovial. The cryovial was 
placed in a coolCell®LX freezing container and stored at -80°C overnight and then 
transferred into liquid nitrogen for long term storage. 
 
2.1.5 Cell proliferation assay 
Cell proliferation assays were performed using the CellTiter 96® AQueous non-radioactive 
cell proliferation assay (Cat# G5421, Promega) according to manufacturer’s instructions. 
3x104 hESCs were plated in quadruplicate on a Vitronectin coated 96-well plate with 100 
μL of mTeSR-1 medium without phenol red (Cat# 85850, StemCell Technologies). 20 
μL of MTS/PMS was added to the medium and incubated for 1 hr before reading. Plate 
readings were taken at day 0, day 2, day 4 and day 6. Absorbance was measured at 490 
nm using a FLUOstar Omega photospectromic plate reader (BMG LabTech, VIC, 
Australia). 
 
2.1.6 Cell Cycle analysis by DNA content 
Single cell passaging was performed on hESCs. A cell count was performed and 2x106 
cells were collected from each clonal hESC line and centrifuged at 120 g for 5 mins with 




cells were then resuspended in 1 mL ice cold DPBS. The cells were added dropwise while 
vortexing gently into 9 mL of cold 70% ethanol in a 15 mL polypropylene centrifuge 
tube. Cells were stored at 4°C until they were ready for analysis. For analysis cells were 
centrifuged at 200 g for 10 mins at 4°C and resuspend in 3 mL cold DPBS. The cells were 
again centrifuged at 200 g for 10 mins at 4°C and resuspended in 500 μL of PI/Triton X-
100 staining solution containing 50 μg/mL of Propidium iodide (Cat# P4864, Sigma-
Aldrich) and 100 μg/mL of RNase A (Cat# 1007885, Qiagen) in 0.1% Triton X-100 (v/v) 
(Cat# 8787, Sigma-Aldrich) in 1X PBS (137 mM NaCl, 2.7 mM KCI, 10 mM Na2HPO4, 
and 2 mM KH2PO4, pH 7.4). The cells were incubated at 37°C for 15 mins and analysed 
by flow cytometry using the BD FACS Canto1 (NJ, USA) and analysis performed using 
the BD FACS Diva software. Live cells were plotted using the FSC/SSC (representing 
the distribution of cells in the light scatter based on size and intracellular composition). 
 
2.1.7 Microscopy 
Fluorescence was observed using the Zeiss AxioImager M2 fluorescence microscope 
(Carl Zeiss, Germany). Fluorescent images were acquired with the AxioCam MRm high 
resolution camera and the Axio Vision software Vs4.9.1.0 (Car Zeiss, Germany). Phase 
contrast images were observed on Zeiss Vert.A1 inverted microscope and images 
captured using the AxioCam MRm high resolution camera and the Axio Vision software 
Vs4.9.1.0 Carl Zeiss, Germany). 
 
2.1.8 Karyotype analysis 
G-band chromosome analysis of hESCs clones was performed by SA Pathology (SA, 





2.2 CRISPR/Cas9 Cloning Methods 
 
2.2.1 gRNA design 
gRNAs for UPF1, UPF2, UPF3A and UPF3B were designed using an online gRNA 
CRISPR design tool (http://tools.genome-engineering.org). Sequences at the beginning 
of the genes ORFs were used as input sequences. Three guides with the highest output 
score were selected (Table 2-1). The score is based on 100 as the percentage of the guide 
binding the specific DNA sequence minus the off-target score (possibility of it binding 
to off-target regions in the genome with high sequence similarity). To facilitate ligation 
of a dsDNA fragment encoding the gRNA into the Bsb1 restriction site of PX459 V2, 
nucleotide (nt) overhang sequences were added: 5’-CACC-3’ at the 5’ end of the gRNA 
and 3’-CAAA-5’ added at the 5’end of the complementary strand (Figure 2.1). A G nt 
was also added at the beginning of the gRNA sequence if not already present to ensure 





Figure 2.1: The nucleotide overhangs in the gRNA are important for ligation into 
the CRISPR plasmid.  
After designing gRNAs the nt overhangs in red were added to the gRNA 
sequence. These overhangs are needed to ligate the gRNA into the Bbs1 site in 
the CRISPR plasmid. The highlighted G (green) is important for U6 
transcription and should be added if absent from the gRNA. Figure taken from 








NMD Factors Guide Guide sequence Scores 
UPF1 G1 AAAGTCGGTGAACTCGAACT 94 
 G2 GGGGAGGTCCTTCGTGTAAT 94 
 G3 AGAAGACACCTATTACACGA 90 
UPF2 G1 GCTGGCTTTTTACGCTCAGC 89 
 G2 GTGAGCTTGATATCGTCTTT 88 
 G3 GCGTAAAAAGCCAGCAAGTA 74 
UPF3A G1 AACTTCGTCCTCCGGTTGCG 97 
 G2 ACTTCGTCCTCCGGTTGCGG 96 
 G3 CCGCAACCGGAGGACGAAGT 93 
UPF3B G1 GTAACCCTGTTAACCCCCGC 96 
 G2 AACCCTGTTAACCCCCGCCG 95 
 G3 TAACCCTGTTAACCCCCGCC 94 
Table 2-1: gRNA sequences from the online CRISPR design tool.   
 
 
2.2.2 Oligonucleotide annealing and phosphorylation 
The oligonucleotides encoding the top and bottom strands of each gRNA were 
synthesized by Geneworks (Adelaide, Australia). Complementary fragments were 
phosphorylated and annealed by adding 1 μL (100 μM) of each DNA fragment, 1 μL 10X 
T4 ligation buffer (Cat# B0202S, New England BioLabs, MA, USA), 6.5 μL H2O and 
0.5 μL T4 PNK ligase (Cat# M0201S, New England BioLabs). The cycling conditions 
were; 37°C for 30 mins, 95°C for 5 mins and the temperature ramped down to 25°C at 







2.2.3 Plasmid digestion  
Five μg of PX459 V2, 5 μL of FastDigest Bpil (Cat# FD1014, Thermo Fisher Scientific), 
5 μL of FastAP (Cat# EF0654, Thermo Fisher Scientific) and 5 μL of 10X FastDigest 
buffer (Cat# FD1014, Thermo Fisher Scientific) were added together and made up to a 
total reaction mixture of 50 μL using H2O and incubated overnight at 37°C with shaking. 
The digested DNA was visualised via DNA Agarose Gel Electrophoresis: (1% Agarose 
gel (Cat# HE121-0500, ProSciTech) and buffer consisting of 1X Tris Borate EDTA 
buffer (TBE):- 89 mM Tris Base, 89 mM Boric acid, 2 mM EDTA).   
 
 
2.2.4 Gel Extraction 
After running the digested plasmid on a 1% Agarose gel for 30 mins the DNA was excised 
from the gel and purified using the QIAquick gel extraction kit (Cat# 28704, Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. 
 
2.2.5 Plasmid ligation  
A ligation reaction was set up by adding 50 ng of the Bbsl digested PX459 V2 plasmid, 
1 μL of the diluted phosphorylated and annealed oligo duplexes, 2 μL of 10X T4 DNA 
ligase buffer (Cat# B0202S, New England BioLabs), 1 μL of T4 DNA ligase (Cat# 
M0202S, New England BioLabs) and made to a total reaction mixture of 10 μL with H2O. 
The ligation reaction mixture was incubated at 16°C overnight in a thermocycler.  
 
2.2.6 Transformation  
Two μL of the ligated plasmid was added to 20 μL of ice cold chemically competent 
DHα5 cells (F-; φ80lacZΔM15; Δ(lacZYA-argF)U169; deoR; recA1; endA1; hsdR17(rk-
mk+); phoA; supE44; thi-1; gyrA96; relA1; γ-) (Cat # 18265017, Invitrogen) and 




immediately put on ice for 2 mins. 100 μL of SOC medium (Cat # 15544034, Invitrogen) 
was added to the cells and plated on a Luria Broth (LB) agar plate containing 100 μg/mL 
ampicillin. The plates were incubated overnight at 37°C. Three colonies were selected 
per ligation and inoculated into a 3 mL of LB broth with 100 μg/mL ampicillin (Cat # 
A9518, Sigma). The culture was incubated while shaking at 37°C overnight. After 24 hrs, 
plasmid DNA was isolated using a QIAprep spin minikit (Cat# 27106, Qiagen) according 
to the manufacturer’s instructions. Restriction DNA digest and Sanger sequencing 
reactions were performed on the extracted DNA to confirm correct ligation (See below).  
 
2.2.7 DNA restriction digest 
To confirm ligation, restriction digest reactions were performed as follows: 500 ng of 
plasmid, 2 μL of NEB buffer 2 (Cat# 7002S, New England BioLabs), 2 μL of BSA (10X) 
(Cat# 9001S, New England BioLabs), 0.5 μL of Kpnl (Cat# R0142s, New England 
BioLabs), 0.5 μL of EcoRV (Cat# R0195S, New England BioLabs) were combined and 
H2O added to a final volume made up to 20 μL. Reactions were incubated overnight at 
37°C with shaking and products separated by agarose gel electrophoresis as described 
above. Digested plasmids exhibiting the expected band sizes were subsequently subjected 
to Sanger sequencing to verify the fidelity of the inserted gRNA sequence using the 
primer: 5’- GAGGGCCTATTTCCCATGATTCC-3’ 
 
2.2.8 Plasmid DNA extraction for transfections and nucleofections 
 
For preparation of transfection/ nucleofection competent plasmids, cultures of bacterial 
clones harbouring plasmids of interest were prepared and processed using the QIAfilter 
Plasmid Midi Kit (Cat# 12243, Qiagen) for transfections and Endofree Plasmid Maxi kit 





2.2.9 Glycerol stocks 
Glycerol stocks of bacterial clones were prepared from the LB broth cultures by adding 
an equal volume of 80% glycerol (Cat# G5516, Sigma-Aldrich) to the bacterial culture. 
Glycerol stocks were immediately stored at -80°C. 
 
2.2.10 pGEM-T Easy vector cloning 
PCR amplified products were ligated using a 1:3 ratio with the pGEM-T Easy vector 
overnight at 4°C following manufactures instructions (Cat# A1360, Promega, Madison, 
























2.3 Biochemical Methods 
 
2.3.1 RNA extraction with RNeasy isolation kit 
RNA isolation was performed using Trizol (Cat# 15596018, Ambion) and the RNeasy 
mini kit (Cat# 74104, Qiagen) as per manufactures instructions. Briefly, Trizol (0.5 mL) 
was added to thawed cell pellets and incubated at RT for 5 mins. Chloroform (Cat# 
1024451000, AmsureR) (100 μL) was added to Trizol-cell solution, mixed vigorously by 
shaking for 1 min and left at RT for 3 mins. Samples were centrifuged at 200 g for 15 
mins at 4°C. The upper aqueous phases containing RNA were transferred to a tube. 1 
volume of 70% ethanol (Cat# 437433T, VWR) was added to the homogenised lysate and 
mixed well by pipetting and added to RNeasy mini-spin columns and processed as per 
manufacturer’s instructions. RNA was separated using Gel Electrophoresis (1% Agarose 
gel) to check integrity. RNA yield was quantitated using the Nanodrop 1000 photo-
spectrometer (Thermo Fischer Scientific).  
 
 
2.3.2 RNA extraction using the Maxwell® RSC Instrument 
RNA extractions were performed according to the Maxwell’s RSC simple RNA 
extraction kit (Cat# AS1390, Promega) following manufacturer’s instructions. 200 μL of 
chilled 1:50 1-Thioglycerol: Homogenization solution was added into each thawed cell 
pellet. The samples were vortexed to create an even cell suspension. 200 μL of lysis buffer 
was added to cells and vortexed vigorously for 15 secs. The samples were then processed 
on the Maxwell RSC instrument. RNA was quantitated using the Nanodrop and ran on a 






2.3.3 cDNA synthesis 
Two μg of RNA was added to 1 μL of random heximers (100 ng) (RP-6-AMINO, 
Geneworks) and diluted with H2O to a final volume of 12 μL. This was heated to 65°C 
for 5 mins and incubated on ice for 1 min. Subsequently, 4 μL of 5X first strand buffer 
(Cat# P/N y02321, Invitrogen), 2 μL of 0.1M DTT (Cat# P/N y00147, Invitrogen), 1 μL 
of dNTPs (Cat# P/N 55082-P/N 55085, Invitrogen) and 1 μL of superscript III RT (Cat# 
56575, Invitrogen) were added and subjected to the following thermocycler protocol: 
25°C for 5 min, 50°C for 50 min and inactivated by heating at 70°C for 15 mins. cDNA 
was diluted 1:3 and stored at -20°C. 
 
 
2.3.4 Isolation of genomic DNA from cell 
Genomic DNA (gDNA) was extracted from cells pellets using High Pure PCR template 
preparation kit (Cat# 11796828001, Roche) according to the manufacturer’s instructions. 
 
 
2.3.5   Isolation of gDNA from hESCs small colonies 
hESC clones generated after CRISPR/Cas9 genome editing were genotyped without 
extensive clonal expansion. A small section of cells dissected from each clone at the time 
of clonal isolation was harvested and gDNA extracted using the QuickExtract DNA 









2.3.6 Preparation of gDNA for whole genome sequencing 
DNA was extracted from cells pellets using the DNAeasy blood and Tissue Kit (Cat# 
69504, Qiagen) according to manufacturer’s instructions. The DNA quality was analysed 
by running on a 1% Agarose gel with 1X TBE buffer. For DNA quantification, DNA 
were prepared using the Qubit dsDNA BR assay kit (Q32853, Invitrogen) according to 
the manufacturer’s instructing and analysed using the Qubit 3 Fluorometry.  
 
2.3.7 Polymerase Chain Reaction (PCR) using Taq DNA polymerase 
 
PCR reactions that used the Taq DNA polymerase (Cat# 11146173001, Roche, Basel, 
Switzerland) were performed according to the manufactures instruction. PCR reactions 
that used the MasterAmpTM 2X PCR PreMix Buffer was prepared by adding 10 μL of the 
MasterAmpTM 2X PCR PreMix Buffer, 1 μL of forward primer, 1 μL of reverse primer, 
1 μL of DNA (100 ng/mL)/ 1 μL cDNA , 0.4 μL of Taq DNA polymerase and made up 
to 20 μL with water. The cycling conditions were the same as using Taq DNA 
polymerase, following manufactures instructions. Forward and reverse primers and the 
annealing temperatures are listed in Table 2-2. 
 
 
2.3.8 Bacterial Colony PCR 
Bacterial colony PCRs were performed on bacterial colonies selected after the 
transformation of the ligated cDNA PCR product into the pGEM-T Easy vector (section 
2.2.10). This was performed by adding 10 μL of MasterAmpTM 2X PCR PreMix Buffer 
J, 1 μL of cDNA Forward primer, 1 μL of cDNA Reverse primer, 0.4 μL of Taq DNA 
polymerase and made up to 20 μL with water. A pipette tip was then used to scrape off a 




PCR reaction was conducted as per the Taq DNA polymerase manufacturer’s instructions 
with an annealing temperature of 58°C. 
 
2.3.9 PCR using KAPA HiFi DNA polymerase 
 
DNA amplified using KAPA HiFi DNA polymerase (Cat# KP-KK2101, KAPA 
Biosystems) was performed according to the manufacturer’s instructions. Forward and 
reverse primers and the annealing temperatures are listed in Table 2-2. 
 
 
2.3.10 PCR using Herculase DNA polymerase 
DNA amplified using Herculase II Fusion DNA polymerase (Cat# 600677, Agilent 
Technologies) was performed according to the manufacturer’s instruction. Forward and 
reverse primers and the annealing temperatures are listed in Table 2-2. 
 
 
2.3.11 PCR purification 
PCR products were purified using the QIAQuick PCR purification kit (Cat# 28106, 
Qiagen) according to the manufacturer’s instructions.  
 
 
2.3.12 Sanger Sequencing 
Purified DNA was sequenced using BigDye™ Terminator sequencing kit (Applied 
Biosystem™ BigDye Terminator v3.1 Cycle sequencing kit, Cat# 4337455, Thermo 
Fisher Scientific). Purified PCR DNA (10-40 ng), 1.5 μL of 5X buffer, 1 μL of Big dye, 




H2O. The cycling conditions for the reaction were as follows: 96°C for 5 min and 30 
cycles of 96°C for 10 secs and 50°C for 5 secs with a final step at 60°C for 4 mins. 
 
 
2.3.12.1  Sanger Sequencing reaction clean up 
After sequencing, 80 μL of 75% isopropanol was added to each reaction. The tubes were 
vortexed gently and DNA precipitated by incubating in the dark for 10 mins. The tubes 
was centrifuged at 160 g for 20 mins. The supernatant was discarded, and the DNA pellet 
washed with 250 μL of 75% isopropanol with a gentle vortex. The tubes were centrifuged 
for 10 mins at 160 g and supernatant removed. The tubes were centrifuged for another 5 
mins and the remaining isopropanol removed. The pellet was dried by heating at 95°C 




































640 Herculase 60 
UPF2 
 
Heteroduplex F: TGAATCTGAGTGATGGGTACG 
R: CTGCCTTACTTCATCTGAGCA 































Heteroduplex F: CTAGTGAGGCAAAATTTGGACG 
R: AACCTGAGAAAGAAAGGGGGC 










Β-Actin PCR  F-ATGGGTCAGAAGGATTCCTATGTG 
R- TGTTGAAGGTCTCAAACATGATCTGG 








































573 Taq 60 












































































































2.3.13 Quantitative Real Time PCR 
Quantitative real time PCR (qPCR) was used to determine the expression of mRNA. 10 
μL reactions were set up that contained 2 μL of cDNA, 1X Fast SYBR Green Real-Time 
PCR master mix (Cat# 4385612, Applied Biosystems), 0.5 μM of Forward primer, 0.5 
μM of Reverse primer and made up to 10 μL with water. Βeta Actin (ACTB) was used as 
a house keeping gene to normalise data. RT-qPCR primers are listed on Table 2-3. Each 
reaction was performed in triplicate. The plate was centrifuged for 30 secs at 234 g and 
ran on the CFX 384 real time system (Bio-Rad, CA, USA). The cycling conditions were 
a hot start at 95°C for 20 secs, and then 40 cycles of denaturation at 95°C for 3 secs and 
annealing at 60°C for 30 secs. This was followed by a melt curve set as follows: 95°C for 
15 secs, 60°C for 1 min followed by a 0.3% continuous ramp from 60°C to 95°C. All 
primers used were validated by the ability to generate a single product by the analysis of 
a single melting temperature, and by validating the efficiency of the amplification. 
Efficiency of the amplification was determined by comparing the Cross Threshold (Ct) 
values acquired through serial dilutions of a control template. The Bio-Rad CFX manager 
software was used to calculate range percentage efficiency. Using this method all primers 
sets used were found to have an efficiency of 100 ± 10%.  Results and normalised gene 
expression level were analysed using the Bio-Rad CFX manager software which uses the 

























UPF3B F- CTTCAGGGCAAAGAATAGAGAGA 
R- TTGACACAAGACTTACTCCTCTG 
77 (Nguyen et al. 2012) 
GADD45B F-CAGCTACTGCGAAGAAAGC 
R-GTTTGTGGCAGCAACTCAAC 









124 (Tarpey et al. 2007) 
PANK2 F-GGATTATTGGTCCAAGGG 
R-GTAATGATCACGGGATCTTC 


















247 (Tarpey et al. 2007) 
NAT9 F: CGGGCATGCTTTCTAAACACA 
R: TGGGAGGCCTTAGGCAAGT 
100 (Huang, L et al. 
2011) 
ATF3 F: GATGTCCTCTGCGCTGGAAT 
R: CTTCTTGTTTCGGCACTTTGC 
151 (Huang, L et al. 
2011) 
SMG7 F: GCCCTCTTCGAGAGAAATTG 
R: CTGCTCGGTTTCATTGCTAA 
143 (Huang, L et al. 
2011) 
HNMT NMD 1 F:  GCTTGTTTTCTGACCACGGG 










Table 2-3: Primers used for RT-qPCR analysis. 
 
 
2.3.14 Taqman RT-qPCR 
Pre-designed Taqman expression assays (Primer-probes) for RT-qPCR were purchased 
from Thermo Fisher Scientific (Table 2-4). At the 5’end they were conjugated to the 
FAMTM label and on the 3’end a miner groove binder (MGB) and a non-fluorescence 
quencher (NFQ). Taqman amplifications were all performed as triplicate reactions using 
the housekeeper gene ACTB with a VIC® dye label. All 20 μL reactions contained: 2 μL 
cDNA, 1X Taqman gene expression master mix, 1X Taqman gene expression assay, 1X 
Taqman endogenous control and made up with water. PCR reactions were run on the 
CFX real time system (Bio-Rad) and data collected and analysed using the Bio-Rad CFX 
manager. All reactions were ran using the following parameters: 50°C for 2 mins, 95°C 









HIST1H2AC F:  TTAGGCCGCTGGTTTTGGTG 
R:  GCGTAGTTGCCTTTACGGAG 
159 Wilkinson, 
unpublished 
AUTS2 F:  GCATTTCAGCCGAAGTTGACA 



















ROBO2 Hs00326067_m1  
ARX Hs00417686_m1 
NETO1 Hs00371151_m1 














2.3.15  Heteroduplex analysis of CRISPR/Cas9 Genome Edited cells 
Heteroduplex analysis was performed by purifying PCR products derived from the 
amplification of genomic regions flanking gRNAs targeted sites in a pool of 
heterogeneous CRISPR edited cells. Reactions contained 18 μL of purified PCR product 
(20 ng/μL) and 2 μL of 10X Taq PCR buffer. Reaction products were denatured and 
slowly annealed with the cycling conditions in Table 2-5. The heteroduplex products 
were separated by polyacrylamide electrophoresis using either an 8% (Cat# EC6215, 
Invitrogen), 10% (Cat# EC62752, Invitrogen) or 10% (home-made) polyacrylamide gel 





1 95°C for 3 mins 
2 95-85°C, -2°C s-1 
3 85°C for 1 min 
4 85-75°C, -0.3°C s-1 
5 75°C for 1 min 
6 75-65°C, -0.3°C s-1 
7 65°C for 1 min 
8 65-55°C, -0.3°C s-1 
9 55°C for 1 min 
10 55-45°C, -0.3°C s-1 
11 45°C for 1 min 
12 45-35°C, -0.3°C s-1 
13 35°C for 1 min 
14 35-25°C, -0.3°C s-1 
15 25°C for 1 min 
16 25-4°C, -0.3°C s-1 
17 4°C hold 
 




2.3.16 10% polyacrylamide gel 
6 mL of 5X TBE buffer and 3.75 mL of 40% acrylamide/bisacrylamide (Cat# A9926, 
Sigma-Aldrich) were mixed and made up to 15 mL with water. 10 μL of TEMED (Cat# 
17919, Thermo Fisher Scientific) was added to the above reaction and mixed. 37.5 μL of 
20% APS (Cat# A3678-259, Sigma-Aldrich) was immediately added and mixed by 
inverting the tube. The acrylamide solution was poured into gel plates and allowed to 
polymerise for 30 mins before use. 
 
2.3.17 Western Blot 
 
2.3.17.1 Protein extraction 
100 μL of RIPA buffer (65.3mM Tris, 150 mM NaCI, 1% (v/v) Nonidet P-40) was 
supplemented with 4% 25X Protease inhibitor cocktail (Cat # P8340, Sigma), 0.5% of 
Na3VO4 (200 mM), 0.5% of NaF (200 mM) and 0.5% of phenylmethylsulfonyl (PMSF) 
(200 mM)). The supplemented RIPA buffer was added to cells and pipetted to create 
uniformly resuspend cells. Cells were passed through a 21 G needle 10 times to lyse the 
cells. The lysate was centrifuged at 160 g for 30 mins at 4°C to clear debris. The 
supernatant was stored at -80°C.  
 
2.3.17.2 Protein quantification 
Aliquots of protein lysate samples were diluted 1:10 or 1:20 prior to Bradford 
quantification. 10 μL of the diluted samples were added to a 96 clear flat bottom well in 
triplicates along with standard samples of bovine serum albumin (BSA) standards (0, 0.2, 
0.4, 0.6, 0.8 and 1.0 mg/mL) (Cat# A7030, Sigma-Aldrich). 200μL of 1X Bradford 
reagent (Cat# 500-0006, Biorad) was added to each sample and light absorbance at 620 
nm was analysed by a photospectroscopic plate reader (FLUOstar Omega, LabTech). The 




2.3.17.3 Separation of protein on an SDS-PAGE gel 
40 μg of protein was prepared by adding, 1X loading buffer (Cat# NP0007, Invitrogen), 
10% (v/v) DTT and made up to a total volume of 40 μL with water. Samples were 
denatured at 95°C for 5 mins and returned to ice. The XCell SureLock Mini-Cell system 
(Invitrogen, Thermo Fisher Scientific) was used to perform SDS-PAGE as per 
manufacturer’s instructions. NuPAGETM 4-12% Bis-Tris gels (Cat # NP0322, Invitrogen) 
were used, and running buffer (Cat# NP0001, Invitrogen) prepared by adding 500 μL of 
anti-oxidant (Cat# NP0005, Invitrogen) to the inner chamber. The outer chamber was 
half filled with running buffer only. The denatured protein samples were separated by 
adding 10 μL of the sample into the gel wells and electrophoresis conducted at 150V for 
150 mins.  
 
 
2.3.17.4 Western transfer of protein to cellulose membrane  
Western transfer was conducted using Xcell Blot II Module apparatus (Invitrogen, 
Thermo Fisher Scientific) as per manufacturer’s instructions. Spongers, filter papers and 
the cellulose membrane were soaked in cold transfer buffer (1X Towbin (0.025 M Tris 
and 0.192 M Glycine), supplemented with 20% methanol (v/v)). Gels were soaked in 
transfer buffer for 10 mins. The transfer chamber was loaded with pre-soaked sponges, 
filter papers, gel, cellulose membrane, filter paper and spongers. The chamber was 
inserted into the tank and clamped. The inner chamber was filled with cold transfer buffer. 






2.3.17.5 Immunoblotting  
After protein transfer onto the cellulose membrane, ponceau staining was performed by 
incubating the cellulose membrane with the ponceau stain for 5 mins, and then rinsed 
with water for 5 mins, to determine successful transfer. The cellulose membrane was then 
washed with PBST (PBS with 0.2% Tween 20 (Cat# 9416, Sigma)) to remove the 
ponceau stain. The cellulose membrane was blocked with 5% skim milk (w/v), 5% BSA 
(w/v) and 5% Goat serum (GS) (Cat# 16210064, Gibco, Thermo Fisher Scientific) / 
Horse serum (HS) (Cat# 16050130, Gibco, Thermo Fisher Scientific) (v/v) depending on 
the secondary antibody used for 1 hr or overnight. The blocking solution was removed 
and replaced with a primary antibody solution in 1% blocking solution. Primary antibody 
concentration are listed in Table 2-6. Primary antibodies were incubated overnight in a 
humidified atmosphere at 4°C.  The membrane was washed with PBS-T three times to 
remove the primary antibody and incubated with the secondary antibody (1:4000) in 1% 
blocking solution (Table 2-6). The membrane was washed with PBS-T three times to 
remove the secondary antibody. Bound secondary antibodies were detected by incubating 
the membrane with the Clarify™ western ECL substrate (Cat# 170-5061, Bio-Rad) as 
per manufacture’s instruction. After 5 mins incubation, chemiluminescence was captured 












Protein  Primary antibody and 
dilution 
Secondary antibody Protein size 









UPF2 RENT2 (C-18), Goat 
polyclonal 




































Y14 Y14, Mouse monoclonal 








MAGOH MAGOH, Mouse 
monoclonal 

















2.3.18 Immunofluorescence analysis 
Cells were fixed in 4% paraformaldehyde (PFA) (w/v) (Cat# P6148, Sigma-Aldrich) at 
RT for 15 mins. The fixed cells were washed three times with PBS and permeabilised in 
0.5% Triton X-1000 in PBST for 2 mins for hESCs and 5 mins for neural rosettes. The 
cells were washed once with PBST and blocked in 5% HS in PBST for 1 hr at RT. The 
permeabilised cells were incubated with the primary antibody diluted (Table 2-7) in 0.5% 
HS-PBST overnight at 4°C. After the overnight incubation, cells were rinsed three times 
with PBST for 5 mins and incubated with a secondary antibody in 0.5% HS-PBST 
(1:1000 dilution) (Table 2-7) for 1 hr at RT. The secondary antibody was removed and 
cells washed three times with PBST and lastly rinsed with 1X PBS. Cells were mounted 
using ProLongTM Diamond Antifade mountant with DAPI (Cat# P36962, Invitrogen, 
















Protein Primary antibody and 
dilutions 
Secondary antibody 




Alexa Fluor Donkey anti-goat 
Invitrogen 
A21432 
OCT3/4 OCT3/4 Monoclonal mouse  
Santa Cruz Biotechnology 
SC-5279 
1:200 
Alexa Fluor Donkey anti-mouse 
Invitrogen 
A21202 




Alexa Fluor Donkey anti-rabbit  
Invitrogen 
A31573 




Alexa Fluor Donkey anti-rabbit  
Invitrogen 
A31573 
N-CADHERIN N-CADHERIN Polyclonal Mouse 
BD Transduction Laboratories 
610921 
1:300 
Alexa Fluor Donkey anti-mouse 
Invitrogen 
A21202 



















2.4 Whole genome analysis of gene-edited clones 
 
Whole genome sequence (WGS) analysis was performed by Dr Mark Corbett and Dr 
Atma Ivancevic (Neurogenetics Laboratory, University of Adelaide). DNA Samples were 
sequenced with 150 bp paired reads by Illumina HiSq X-10 at the Kinghorn Centre for 
Clinical Genomics (NSW, Australia). Published H1 WGS data were downloaded from 
the European Nucleotide Archive (H1 Published: SRR2070629) (Yazdi, P. G. et al. 
2015). For SNV analysis Fastq formatted sequence files were mapped to the University 
of California Santa Cruz (UCSC) hg19 build of the human genome using Burrow-
Wheeler Aligner (BWA) (Li & Durbin 2009). Duplicate reads were marked with 
Sambamba (Tarasov et al. 2015) and single nucleotide variants (SNVs) and indels were 
called using the genome analysis toolkit (GATK) V3.8 haplotype caller (Li & Durbin 
2009; Van der Auwera et al. 2013). Samples were jointly genotyped with 16 additional 
unrelated WGS of DNA extracted from human blood using GATK to generate variant 
call format (VCF) files with non-reference calls for each samples. Bcftools were used to 
apply the following variant exclusion filters, where at least all variants had at least 10 
reads per total (DP<10), a quarter of reads had alternate alleles (QD<20, FS>60.0, 
MQ<30.0, MQRankSum<-12.5, ReadPosRanlSum<-8.0), and reach the minimum 
qualities recommended by GATK (MIN(AD[1]/FMT/DP)<0.25) (Van der Auwera 2012) 
and the GATK variant quality score recalibration (VQSR) metrics to retain PASS and 
VQSRTrancehlINDEL99.00to99.90 variants. Comparisons between different samples 
were made with the vcf-compare command from the bcftools package. Variants loaded at 
potential off target sites were identified using bfctools view filtered with a custom bed 
file that had a 20 bp window flanking each predicted off target site. A list of off-targets 
was generated using the Cas-OFFinder program (www.rgenome.net/cas-offinder) (Bae, 
Park & Kim 2014) and the CRISPR design program (crispr.mit.edu). Relatedness 




were annotated with ANNOVAR (Van der Auwera et al. 2013) and alignments at variants 
were viewed using the Integrative Genomics Viewer (IGV). 
 
DELLY was used to call and genotype structural variants in all samples. Output vcf files 
were merged and re-genotyped using multi-sample cohort containing 160 samples as 
reference. Bcftools was used to merge the final vcfs into a multi-sample vcf file 
containing the eight samples of interest. BedTools was used to overlap each sample with 
the corresponding off-target regions, allowing for a 200 bp window around the predicted 
off-target regions. Resulting structural variants were de-duplicated (since the provided 
off-target regions have overlapping records) and filtered to remove low quality variants 
(set FILTER=PASS). Variant candidates were then extracted from the original vcf and 
run through SVScore to predict possible pathogenicity and look for gene overlaps. 
 
2.5 RNA-Sequencing   
RNA-Sequencing analysis was performed by Dr Stephen Pederson (Bioinformatics Hub, 
University of Adelaide) and Urwah Nawaz (Neurogenetics Laboratory, University of 
Adelaide). RNA-Seq samples were sequenced with 75 bp paired-end reads by Illumina 
TruSeq (SAHMRI Genomics Facility, SA, Australia). The raw fastq reads were checked 
for quality using FASTQC (Andrews 2010). Adapters and low quality bases were 
trimmed using TrimGalore 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Salmon v0.8.2 
(Patro, Duggal & Kingsford 2015) was used for transcript quantification and the resulting 
transcript abundance were imported to R using tximport (Love, Soneson & Robinson 
2017), converting transcript counts to gene counts. Gene level quantification was 




genes, if 3 or less samples had a counts per million (CPM) < 1 for a particular gene, that 
gene was removed from the counts matrix. Differential expression analysis was carried 
out using DESeq2 (Love, Huber & Anders 2014). Genes were considered differentially 
expressed if they had an adjusted p-value of <0.05 and a log 2 fold change. The effects 
of loss of UPF3A and UPF3B were detected in hESCs and NSCs using the Wald test in 
a model with condition and collection or condition only respectively. Pairwise 
comparisons using DESeq2 was performed to compare gene expression between hESCs 
and NSCs in the main 3 genotypes, controls, UPF3A KO and UPF3B KO. Genes with an 
adjusted p-value of <0.05 and a log 2 fold change were used for gene ontology analysis 
using ClusterProfiler (Yu et al. 2012). All volcano plots were made using the 
EnhancedVolcano package for all DE analyses (Blighe, 2018). Heatmaps were generated 
by normalising the raw gene counts to log transformed CPM using the pheatmap package 
(pheatmap: Pretty Heatmaps v.1.0.12, 2019).  
 
2.6 Statistical analysis 
 
Statistical significance was calculated using a two-tailed students T test with significance 







Chapter 3 - Generating UPF3A and UPF3B null 


























Complete loss of function mutations in UPF3B cause a spectrum of NDDs including 
autism, ID, ADHD and childhood onset schizophrenia (Addington et al. 2011; Lynch et 
al. 2012; Szyszka et al. 2012; Tarpey et al. 2007; Xu et al. 2013). UPF3B, is the only 
NMD factor gene that has a paralog UPF3A. UPF3B is located on the X chromosome 
and loss of function mutations of this gene affects males while female carriers are 
unaffected (Laumonnier et al. 2010). UPF3A is autosomal and located on chromosome 
13 (Linder, Fischer & Gehring 2015). Heterozygous copy number losses of UPF3A is 
linked to NDDs (neural tube defects) (Luo et al. 2000). Intriguingly loss of function 
mutations in UPF3B lead to stabilisation of UPF3A protein (Chan et al. 2009; Jolly et al. 
2013; Nguyen et al. 2012).  
 
UPF3B is well established as an NMD activator and its role in neurodevelopment has 
mainly been derived from patient LCLs and other species such as mice.  Initially UPF3A 
was shown to have weak NMD promoting activity when tethered artificially to an NMD 
reporter transgene (Kunz et al. 2006; Lykke-Andersen, Shu & Steitz 2000) but recent 
gain and loss function approaches aligned UPF3A function more as an NMD inhibitor 
upon assessment of changes in expression of endogenous NMD targeted mRNA (Shum 
et al. 2016). However, even this study provided evidence that UPF3A could still act on a 
minority of endogenous NMD transcripts as an NMD promoter. Whilst the role of 
UPF3A as an NMD factor itself is still unclear, its role in neurodevelopment is even less 
well known, having never been formally studied. Therefore there is an unmet need to 
study the role of both UPF3A and UPF3B in models of brain development to better 
understand the involvement of these factors in NMD in general and in human NDDs. The 
other reason for investigating the role of UPF3A parallel to UPF3B is because these two 




of UPF3A and UPF3B in NDDs a cell model system that replicates neurodevelopment in 
patients with loss of function mutations in UPF3A and UPF3B was generated. The 
CRISPR/Cas9 genome editing technology and H1 hESCs (derived from a male embryo) 
were used to generate UPF3A and UPF3B KO hESCs. A male cell line was used, as 
deletions in UPF3B cause X-linked inherited NDDs. Directed differentiation of UPF3A 
and UPF3B KO hESCs into neural stem cells provides a model system of human brain 
development.  
 
3.1.1 CRISPR/Cas9 in bacterial immunity 
CRISPR/Cas9 is an adaptive immune system that protects bacteria and archaea from 
bacteriophages and plasmids (Hryhorowicz et al. 2016). It was first discovered in E.coli 
by Ishino in 1987 (Ishino et al. 1987). The CRISPR/Cas9 system develops ‘immuno-
memory’ by inserting foreign viral DNA derived sequences called ‘spacers’ between 
repeat sequences within the bacterial CRISPR locus during the first viral exposure (Heler 
et al. 2015). The CRISPR locus contains all information about the cells (and its 
predecessor cells) encounters with foreign DNA (i.e. from phage’s or plasmids) in the 
past (Rath et al. 2015). There are three known CRISPR systems (I to III) (Ran et al. 2013). 
The type II CRISPR-Cas system used for genome editing is from the bacteria 
Streptococcus pyogenes (Sternberg et al. 2016). The type II CRISPR locus contains a 
trans-activating CRISPR RNA (tracrRNA), the CRISPR associated (Cas) genes (Cas9, 
Cas1, Cas2 and Csn2) (Cas complex) and a long pre CRISPR RNA (pre-crRNA) 
transcribed from the spacer repeat locus (Mali, Esvelt & Church 2013). A detailed 










Figure 3.1: CRISPR/Cas9 immunity in bacteria.  
a) In the CRISPR/Cas9 system, the Cas complex specifies the spacer sequence in the 
foreign DNA sequence next to a protospacer adjacent motif (PAM) site) cleaves the 
spacer sequence and inserts it between the repeats in the CRISPR locus (Heler et al. 2015). 
At this stage the DNA fingerprint of the infection is stored (Mali, Esvelt & Church 2013). 
b) In subsequent infections the CRISPR locus is transcribed to produce the CRISPR/Cas9 
unit that guides the degradation of homologous sequences on the foreign DNA (Terns & 
a) Acquisition of new spacers   




Terns 2011). The generation of the CRISPR/Cas9 unit occurs by tracrRNA binding to the 
long pre crRNA on the spacer sequence and the Cas9 endonuclease forming a stable 
ribonucleoprotein. RNase III cleaves the tracrRNA: crRNA (dsRNA) and the 5’end of 
each of the spacers is removed generating a CRISPR/Cas9 functional unit. The 
CRISPR/Cas9 unit hybridises with the complementary sequence upstream of the PAM 
sequence on the foreign DNA sequence and Cas9 cuts the DNA creating double stranded 
breaks (DSBs) (Mali, Esvelt & Church 2013) using its RuvC and HNH nuclease domains 




3.1.2 Exploiting CRISPR/Cas9 for genome editing  
 
Genome editing technologies have been developed that both harnesses the CRISPR/Cas9 
system ‘genome-homing DSBs’ mechanism and leverages the cells innate mechanisms 
that repairs DNA DSBs (e.g. that occur during exposure to damaging DNA radiation and 
chemicals, DNA replication and repair (Cannan & Pederson 2016) and meiosis I (de 
Massy 2013)). DNA DSBs threaten genome integrity and failure to detect and repair them 
are detrimental to the cell (Ceccaldi, Rondinelli & D’Andrea 2016). DNA DSB are 
repaired by either the non-homologous end joining (NJEJ) or homology directed (HD) 
repair, the latter using a repair donor DNA template. The HD repair pathway occurs 
during the S and G2 phase of the cell cycle where the two sister chromatids are in close 
proximity- a wildtype chromatid providing a donor template for repair of a homologous 
site in the damaged chromatid (Lieber 2010). In the absence of the donor template the 
NHEJ pathway is responsible for repairing the DSBs. Unlike the HD repair this pathway 
can occur in any phase of the cell cycle (Cannan & Pederson 2016) but is dominant in the 
GO/1 and G2 phase (Karanam et al. 2012; Lieber et al. 2003).  Because the NHEJ 
pathway is error prone and generates insertion or deletions (indels) during the repair 
mechanism this often leads to frameshift mutations and subsequently PTCs when this 




In this chapter, the CRISPR/Cas9 genome editing technology was used to create UPF3A 
and UPF3B KO hESCs. The methodology employed was based on a protocol by Ran et 
al., 2013 and leverages the NHEJ repair pathway. The protocol uses the PX459 V2 
plasmid which contains three expression cassettes in cis that facilitate expression of the 
Cas9 protein, a specific gRNA and the PAC gene encoding puromycin N-
acetyltransferase that confers resistance to the antibiotic puromycin (for antibiotic 
selection). The specific gRNAs cloned into PX459 V2 were first validated for their ability 
to facilitate editing at their targeted genetic loci in HEK293T cells. Next, these validated 
gRNAs were used to generate gene-edited hESC clones. Despite following a published 
method, problems with attaining clonal hESCs were encountered. This chapter outlines 
the validation of CRISPR/Cas9 gRNAs in HEK293T cells and the optimisation steps 
taken to generate hESC clones. The optimised method proved to be robust, reproducible 



















3.2.1 CRISPR/Cas9 design  
 
gRNAs that target the 5’ coding regions (exon one or two) of UPF1, UPF2, UPF3A and 
UPF3B were designed using an online gRNA CRISPR design tool (http://tools.genome-
engineering.org). 5’ coding regions were targeted as frameshift events impacting the 5’ 
end of the gene are most likely to cause a PTC and lead to complete loss of functional 
protein (Pelley 2007). The PX459 V2 plasmid is depicted in Figure 3.2. Three unique 
gRNAs were selected for each gene with the view that clonal lines derived from the use 
of several unique gRNAs targeted to the same gene will cater for any possible off-targets 
generated by any single gRNA. The effectiveness of the gRNAs in generating DSBs 
(indels) at the desired loci was performed in HEK293T cells before use in hESCs.  
 
3.2.2 Validation of CRISPR guides in HEK293T cells 
To determine the targeting efficiency of gRNAs, validation of the gRNAs were 
performed in HEK293T cells as these cells are human and easy to grow and transfect. 
Cells were transiently transfected with an empty PX459 V2 plasmid (PX2, negative 
control) or with PX459 V2 plasmid encoding the gRNAs that target either UPF1, UPF2, 
UPF3A or UPF3B. Non-transfected cells were included as an additional negative control. 
The expected outcome is that control experiments will have wildtype loci, whilst 
experiments that include gene specific gRNA will cause editing events at the respective 
loci. A key feature in this experiment is that transfected cells are analysed as a pool of 
cells (rather than clones) and as such, editing events at a loci will be highly variable (a 
range of indels) between each cell in the pool of cells analysed. This heterogeneity of 
editing events can however be resolved and would strongly support that the gRNA is 




Cas9 endonuclease by the individual gRNAs was determined by three assays; 1. 
heteroduplex formation analysis, 2. Sanger sequencing, and 3. ability to reduce the 








Figure 3.2: CRISPR/Cas9 genome editing PX459 V2 plasmid.  
The PX459 V2 plasmid encodes the Cas9 endonuclease, a puromycin resistance 






3.2.2.1 Heteroduplex analysis 
 
Heterogeneous CRISPR/Cas9 editing events at a gene loci in a pool of cells can be 
identified by heteroduplex assays. A heteroduplex is a dsDNA molecule with partial 
mismatched complementarity. Compared to homoduplex dsDNA molecules, 
heteroduplexes migrate slower during gel electrophoresis because of kinks and loops 
introduced by the mismatched pairs (Hestand et al. 2016). The sequence of PCR products 
derived from wildtype alleles are identical, and as such upon denaturing to ssDNA and 
reannealing, homoduplex products are formed. In contrast, PCR products derived from 
amplification of edited alleles from the transiently transfected pools of CRISPR/Cas9 
edited cells should contain heterogeneous sequences caused by NHEJ-mediated indels 
and as such after denaturing and reannealing will form heteroduplexes. Thus, the 
heteroduplex formation of PCR products is diagnostic of CRISPR/Cas9 editing in the 
analysis of pooled cells (Figure 3.3). 
 
gDNA was extracted from the above described transfection experiment (section 3.2.2) 
and Herculase II or KAPA HiFi, high fidelity PCR enzymes were used to generate PCR 
products across relevant loci. PCRs products from UPF3A loci were markedly smaller in 
size indicative of frequent large deletions within this locus (Figure 3.4a). PCR products 
across UPF1, UPF2 and UPF3B loci generated single products by gel electrophoresis 
and were further analysed by the heteroduplex formation assay. PCR products were 
purified, denatured to produce ssDNA species and slowly annealed. The annealed 
products were separated using polyacrylamide gel electrophoresis which permits high 
resolution size discrimination. Annealed PCR products derived from CRISPR/Cas9 
edited loci had extra bands on the gel compared to controls (Figure 3.4b, c, d). This 




CRISPR-Ca9 editing. The fastest migrating bands are homoduplexes that migrate easily 
and quicker and represent wild type loci products.   
 
 
Figure 3.3: Analysis of heteroduplex formation in CRISPR edited heterogeneous 
cells.  
Heteroduplex analysis on a pool of cells that contain heterogeneous genotypes. After 
denaturation and reannealing, alleles with either the wildtype or mutated genotypes will 
anneal randomly despite the mismatches. This will result in dsDNA that contain either 
the wildtype alleles, mutated alleles (homoduplexes) or either dsDNA strands that have 
mismatched sequences (heteroduplexes). The difference in homoduplexes and 
heteroduplexes is resolved by running the denatured and reannealed DNA on a 
polyacrylamide gel as these travel at different rates during electrophoresis. Figure 






Figure 3.4: Efficient CRISPR/Cas9 targeting by gRNAs revealed by PCR and 
heteroduplex assay.  
gRNAs targeted at (a) UPF3A, (b) UPF3B, (c) UPF1 and (d) UPF2 were tested for their 
ability to introduce indels in HEK293T cells. PX459 V2 empty vector (PX2) or one of 
the three gene specific gRNAs (G1, G2, G3) were transfected into HEK293T and gDNA 
extracted for use in PCR and subsequent heteroduplex assay. PCR and duplex products 
were separated on agarose and polyacrylamide gel respectively. NT: non-transfected. NB. 
Smaller size PCR products in (a) indicative of larger deletions.                                                                                                                                                                                                                                                                                                                     
 
 
UPF3A PCR UPF3B PCR UPF3B heteroduplex 
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3.2.2.2 Sequence traces of gDNA from CRISPR/Cas9 edited cells 
 
A second measure used to determine if the gRNAs were effective at targeting/homing the 
Cas9 to the specific genomic location is use of Sanger sequencing of the PCR product 
generated above from the gDNA of transfected cells. Because each cell has a potentially 
unique array of indels at the targeted loci, effective Cas9 homing is visualised as a loss 
of a single sequence trace downstream of the gRNA sequence. The sequence 
chromatograms of the respective gene loci’s (UPF1, UPF2. UPF3A, UPF3B) were clean 
in cells that were non-transfected (NT) or transfected with an empty PX459 V2 plasmid 
(PX2). In contrast, the sequence chromatograms derived from PCR products in HEK293T 
cell population targeted with PX459 V2 encoding loci specific gRNA had a mixed signal 
downstream of the respective gRNA sites (Figure 3.5) (sequence traces for UPF2, 
UPF3A and UPF3B not shown). This data aligns with effective homing of the Cas9 







Figure 3.5: Aberrant sequence traces of UPF1 edited heterogeneous cells.   
gDNA was extracted from wildtype cells (NT), and cells either treated with an empty 
vector (PX2) or 3 different guides targeting UPF1 loci in HEK293T cells. A PCR was 
performed flanking the targeted region and the PCR product sequenced using Sanger 






       Guide 2 
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3.2.2.3 Protein analysis 
 
The final and ultimate assessment of the gRNA design and functionality is that the 
targeted loci will not be able to produce functional protein due to creation of an early 
frameshift mutation. HEK293T cells were transfected as described above (section 3.2.2). 
Protein was isolated and subjected to western blot analysis. Because a range of indels 
were created including in-frame, a targeted loci would result in reduced rather than absent 
levels of the respective protein compared to controls (non-transfected and PX2). 
CRISPR/Cas9 targeted (G1, G2, G3) cells did indeed show obvious reduction in their 
protein levels in UPF1 and UPF2 and to a lesser extend UPF3B compared to controls 
(Figure 3.6). UPF3A protein is lowly detected in HEK293T cells, therefore no western 
blot was performed on the UPF3A edited cells.  
 
In aggregate the three independent lines of validation including heteroduplex formation, 
Sanger sequencing and analysis of protein levels all aligned with the gRNAs being able 
to correctly target Cas9 to their respective gene loci and create indels of varying degrees 
that resulted in loss of protein expression. 
 
Figure 3.6: Western blot analysis of CRISPR edited HEK293T cells.  
Protein was extracted from wildtype cells (NT), and cells either treated with an empty 
PX459 V2 vector or three different guides targeting (a) UPF1 (b) UPF2 (c) UPF3B loci 
in HEK293T cells. The protein lysates were probed for UPF1, UPF2 and UPF3B protein 
in the respective gene-edited cells. β-Actin (bottom panel) was used as a loading control. 











3.2.3 Optimising CRISPR/Cas9 genome editing technology in hESCs. 
 
Functional validation of the gRNAs in the HEK293T cells proved that the gRNAs were 
effective in homing Cas9 to the genomic loci to introduce DSBs. To cater for possible 
off-target effects three unique gRNAs were selected to generate UPF3A and UPF3B KO 
clones in hESCs. Generating UPF3A and UPF3B KO clones were prioritised due to their 
involvement in NDDs and relationship as paralogs. Due to time constraints, generation 
of UPF1 and UPF2 KO clones was not pursued further.  The method used to generate 
loss of function mutations in UPF3A and UPF3B in hESCs was previously published 
(Ran et al. 2013). Briefly, in this method, clonal hESCs were generated by nucleofecting 
2x105 cells with 1 μg of the PX459 V2 plasmid and plating the cells in a 100 mm ECM 
coated dish. After nucleofection, cell culture medium was supplemented with 10 μM 
ROCK inhibitor for 24 hrs to promote cell survival. 24 hrs post nucleofection, ROCK 
inhibitor was removed and medium containing puromycin (0.5 μg ml-1) was added for 2 
additional days. During this time non-transfected cells die off whilst transfected cells 
survive and can be expanded as single colonies allowing isolation of clones. After 
following this protocol no surviving cells were observed after puromycin selection (data 
not shown). As such a series of optimising strategies were undertaken.  
 
One protocol parameter that was postulated to influence cell survival was the post 
nucleofection cell density. hESCs typically grow best as colonies, and dissociating them 
into single cells and performing nucleofection leads to cell death. To promote healthier 
growth and increase cell survival post nucleofection the rationale was to increase cell 
density to allow cells to re-establish cell to cell contact (Byrne, Mali & Church 2014).  
The initial post-nucleofection plating density as published was considered low (at 2x105 




may have also been a low nucleofection efficiency. Transfection efficiency was ~30% 
based on parallel nucleofection of a plasmid encoding GFP: pGFPmax control (Figure 
3.7a). As such, a relatively low number of cells were likely to be expressing the 
puromycin resistance gene required to tolerate puromycin selection.  
 
A second protocol with alternative plating densities was tested as described by Yang et 
al., (2014). In this method, 1x106 cells and 1 μg of DNA was used and cells were plated 
at a very high density (in 1 well of a 48-well plate) (Figure 3.7b)).  Under these 
conditions, however, some cells in the control (pGFPmax, no puromycin resistance gene) 
survived the puromycin selection process (data not shown). It has been reported that drug 
selection of cells cultured at a very high density can be inefficient (Moore et al. 2010). 









Figure 3.7: Different plating density of cells after nucleofection. 
a) 1x106 cells were nucleofected with 1 μg of p.GFPmax plasmid and plated at low 
density on ECM coated plates. Image taken at day 4 post nucleofection. b) 1x106 cells 
were nucleofected with 1 μg of p.GFPmax and plated at high density on 48 well plates 
coated with ECM. Image taken 2 days post nucleofection. Images acquired at 40X 




The Yang et al., (2014) method was repeated, but plating density reduced (1x106 cells in 
a well of a 6-well plate). In this instance, cells did survive post-selection and grew into 
colonies, however the colonies differentiated in culture over time (Figure 3.8a). The 
method by Yang et al., (2014) used medium supplemented with small molecule cocktail 
of four inhibitors (SMC4) after they performed drug selection. SMC4 contains 
SB431542, PD0325901, CHIR99021 and Thiazovivin which are inhibitors of the TGF-
β, MEK, GSK and ROCK pathways, respectively. Combination of these molecules have 
been shown to increase the viability of hESCs as single cells and help in maintaining their 




include medium supplemented with SMC4 after puromycin selection. Colonies formed 
again, but the cells still differentiated and failed to maintain pluripotency (Figure 3.8b).  
 
 
Figure 3.8: Cells plated on a feeder free culture (ECM) after nucleofection.  
a) Differentiating colonies 10 days post selection. Cells fail to form colonies with well-
defined borders. b) Cells were plated on ECM after nucleofection. After selection cells 
were cultured in media supplemented with SMC4. Imagen taken 4 days post selection. 
Images acquired at 40X magnification. 
 
  
In another protocol by Byrne et al., 2014, SMC4 was used for a period of 8 days post 
selection, which in their hands greatly improved the viability of their cells. In another 
modification, instead of plating cells in a feeder independent culture (as I had done 
previously) they used a feeder dependent culture system. Given that my cultures were 
also feeder dependent prior to nucleofection and with rationale that growth on feeders 
can support hESCs growth even at low density, I assessed if puromycin selection could 




1 μg/mL of puromycin treatment over 24 hrs had no identifiable effect on iMEF viability 
(Taniguchi et al. 1998). In a pilot experiment, it was discovered that this regime was 
sufficient to kill wildtype hESCs with no overt effect on iMEF viability (data not shown).  
 
Based on these findings I performed the following experiment; 1x106 cells were 
nucleofected with 1 μg of PX459 V2 DNA. After nucleofection cells were plated on 100 
mm iMEF prepared dishes in conditioned medium at low density to prevent resultant 
colonies from merging and cross contamination. 24 hrs later, puromycin selection (1 
μg/mL for 24 hrs) was performed and medium changed to medium supplemented with 
SMC4 for 6 days at which point pluripotent colonies were identifiable by phase contrast 
microscopy. Long periods of SMC4 exposure has been reported to cause hESCs to 
differentiate (Yang, L. et al. 2014). In an attempt to further refine the protocol cells were 
treated with either 10 μM of ROCK inhibitor or SMC4 for only 1 day following selection 
(compared to 6 days as per above), however, the use of SMC4 for 6 days post selection 
was optimal in getting the highest numbers of pluripotent colonies (Figure 3.9). This 
strategy had no effect on pluripotency and genome stability of the generated clones 
(Figure 3.10). 
 
 In summary after several rounds of optimisation, including testing different cell 
densities, culture platforms, medium supplementation and puromycin selection criteria, 
an optimised protocol for the isolation of PX459 V2 transfected hESCs was developed. 






Figure 3.9: Cells plated on iMEFs and supplemented with ROCK or SMC4.                    
1x106 cells were nucleofected and plated on iMEF plates. After puromycin selection cells 
were either cultured with media supplemented with a) 10 μM ROCK for 1 day, b) SMC4 
for 1 day or c) SMC4 for 6 days. b) Graph showing the number of clones that grew in 











Figure 3.10: hESCs colonies isolated using optimised protocol maintain 
pluripotency and have a normal karyotype.                                                                                        
a) Representative immunofluorescence image of a hESC clone at day 10 post selection. 
Cells were fixed and stained with antibodies against pluripotent marker proteins; OCT3/4 
(green), NANOG (red) and SOX2 (far red). Nuclei are counterstained with DAPI (blue). 
Images acquired at 40X magnification. b) Representative metaphase spread of 
chromosomes isolated from hESC colonies 10 days post selection and expanded in a T25 















3.2.4 Generating clonal UPF3A and UPF3B KO human embryonic cells 
lines 
UPF3A and UPF3B KO clones were generated using the optimised CRISPR/Cas9 gene-
editing protocol (Appendix 1). Ten days post selection, 6 control colonies (nucleofected 
with an empty PX459 V2 plasmid; PX2) and all colonies nucleofected with the UPF3A 
and UPF3B gRNAs that survived puromycin selection were manually selected. hESC 
clones generated after CRISPR/Cas9 genome editing were genotyped without extensive 
clonal expansion. A small section of the clone was dissected from each clone at the time 
of clonal isolation and gDNA harvested. PCR was performed on the gDNA with primers 
flanking the targeted gene loci. The amplified gDNA was then subjected to Sanger 
sequencing. Figure 3.11 and Figure 3.12 show examples of sequence traces across the 
UPF3A and UPF3B targeted loci from a control and three UPF3A and three UPF3B 






Figure 3.11: Sanger sequencing chromatographs showing UPF3A KO hESCs. 
gDNA was extracted from a control (PX2) and three UPF3A KO clones. PCR 
amplification was performed with primers flanking the targeted UPF3A loci and Sanger 
sequencing performed on the PCR product. Sequence chromatograph of the sequenced 
clones. Guide 1 to 3 sequences on the sequence chromatograph show the location of 
where the gRNA target the UPF3A gene. UPF3A-G3 has no guide aligned with the 






Figure 3.12: Sequence traces for UPF3B KO clones and controls selected for 
analysis.  
gDNA was extracted from a control (PX2) and three UPF3B KO clones. PCR 
amplification was performed with primers flanking the targeted UPF3B loci and Sanger 
sequencing performed on the PCR product. Sequence chromatograph of the sequenced 
clones. Guide 1 to 3 sequences on the sequence chromatograph show the location where 






After Sanger sequencing, clones with wildtype, in-frame and possible frameshift 
mutations were identified by determining the number of indels generated. For UPF3B, 
this was done by looking at the sequence as only one sequence trace is expected as 
UPF3B is located on the X chromosome. However, UPF3A is autosomal and in an event 
where a single or both alleles have been edited, two sequence traces would be visible. To 
deconvolve the sequence and identify the number of indels on each UPF3A allele, a 
software known as TIDE was used. Sanger sequences from Figure 3.11 were put through 
the TIDE software to determine the number of indels on each allele and results are shown 
in Figure 3.13. In addition to identifying the compound heterozygous indels at UPF3A 
loci, this program also detected non-clonal lines such as in UPF3A G3 CF and UPF3A 













Figure 3.13: Detecting the number of indels in UPF3A KO hESCs using TIDE. 
Output information from the TIDE program from three UPF3A clones from Figure 3.11. 
The x-axis shows the size of indels in each sequence trace, while the y-axis shows the 
percentage in abundance of each allele sequence in the sequence chromatography. To 
determine the number of indels on each allele, the Sanger sequencing trace from a control 
(empty PX459 V2 plasmid treated cells; PX2) and gene-edited clones (UPF3A KO 
clones) and the gRNA sequence were upload via the TIDE software. The program aligns 
the control sequence trace and the gRNA to determine the break region. The control and 
the gene-edited clone trace sequences are then aligned together to determine the 
differences in the two sequences. TIDE uses the heights of the peaks in each sequence 








The optimised CRISPR/Cas9 genome editing technology protocol was successfully used 
to generate gene-edited UPF3A and UPF3B KO hESC clones. Table 3-1 shows a 
summary of all the clones selected from each guide and the number of clones that were 
targeted by Cas9 (which either generated a frameshift or an in-frame mutation). From the 
total number of clones that were selected a targeting efficiency (defined as the proportion 
of clones that had a disrupted target allele) of 34.9% was achieved with 16.5% having a 
mutation that generated a frameshift mutation. UPF3A gRNAs generated more clones 
with frameshift mutations (both single and bi-allelic) than UPF3B gRNAs (Table 3-2). 












Guides Clones Mutations Type of mutation 
UPF3A G1    
 UPF3A G1 C1 Normal, 5 bp del, 10 bp del, 
12 bp del (mixed) 
Discarded/mixed colony 
 UPF3A G1 C3 1 bp ins, 4 bp del Compound heterozygous 
 UPF3A G1 C6 Normal, 1 bp ins Heterozygous 
 UPF3A G1 C8 1 bp ins * 
UPF3A G2    
 UPF3A G2 C1 5 bp del, 7 bp del Compound heterozygous 
 UPF3A G2 C4 Normal, 5 bp del Heterozygous 
 UPF3A G2 C5 2 bp del, 14 bp del Compound heterozygous 
 UPF3A G2 C7 Normal, 5 bp del Heterozygous 
UPF3A G3    
 UPF3A G3 C5 Normal, 1 bp del Heterozygous 
 UPF3A G3 C10 12 bp del, 14 bp del Compound heterozygous 
 UPF3A G3 C11 1 bp del, 1 bp insert Compound heterozygous 
 UPF3A G3 C14 7 bp del, 17 bp del Compound heterozygous 
 UPF3A G3 C15 Normal, 25 bp del Heterozygous 
 UPF3A G3 CF Normal, 1 bp del, 14 bp del 
(mixed) 
Discarded/mixed colony 
UPFB G1    
 UPF3B G1 C2 14 bp del  
 UPF3B G1 C13 29 bp del  
 UPF3B G1 C14 4 bp del  
 UPF3B G1 C17 5 bp del, Normal (mixed) Discarded/mixed colony 
UPF3B G2    
 UPF3B G2 C8 1 bp ins  
UPF3B G3    
 UPF3B G3 C12 1 bp ins  
 UPF3B G3 C13 13 bp del  
 
Table 3-2: Indels generated in the selected UPF3A and UPF3B KO clones with 
frameshift mutations. 
* This clone could either have a large deletion on one allele that is not being detected 





3.2.5 Karyotype analysis 
Karyotype analysis was performed on controls and all clones that had a frameshift 
mutation after genome editing. Twenty metaphases were analysed from cultures that did 
not show any abnormalities when screened. However, if an abnormality was detected a 
larger number of metaphases were analysed. From the 24 clones that were karyotyped 
only one clone had an abnormal karyotype showing mosaicism for trisomy 12 (47, XY, 
+12/46, XY) (Table 3-3 and Figure 3.14). For downstream analysis four controls and 
three UPF3A and UPF3B KO clones with a normal karyotypes were randomly selected 
(clones highlighted in bold). These clones are represented in Figure 3.11 and Figure 
3.12. The mutation annotations of these KO clones are presented in Chapter 5 (Table 
5-1). The transcript level, protein expression, and the expected size of proteins from the 



















CONTROLS PX1 3 20 Normal 
 PX2 3 20 Normal 
 PX3 3 20 Normal 
 PX4 3 20 Normal 
 PX5 3 20 Normal 
 PX6 3 20 Normal 
UPF3A G1     
 UPF3A G1 C3 6 20 Normal 
 UPF3A G1 C6 8 20 Normal 
 UPF3A G1 C8 5 20 Normal 
UPF3A G2     
 UPF3A G2 C1 7 20 Normal 
 UPF3A G2 C4 5 20 Normal 
 UPF3A G2 C5 5 20 Normal 
 UPF3A G2 C7 6 20 Normal 
UPF3A G3     
 UPF3A G3 C5 5 20 Normal 
 UPF3A G3 C10 5 20 Normal 
 UPF3A G3 C11 7 22 (47, XY, +12/46, XY) 
 UPF3A G3 C14 6 20 Normal 
 UPF3A G3 C15 7 20 Normal 
UPFB G1     
 UPF3B G1 C2 6 20 Normal 
 UPF3B G1 C13 6 20 Normal 
 UPF3B G1 C14 5 20 Normal 
UPF3B G2     
 UPF3B G2 C8 5 20 Normal 
UPF3B G3     
 UPF3B G3 C12 5 20 Normal 
 UPF3B G3 C13 6 20 Normal 
  





Figure 3.14: Karyotype analysis of selected clones.                   
Representative metaphase spread of chromosomes isolated from a hESCs that had an 




















CRISPR/Cas9 genome editing technology is an easy and efficient method to edit the 
genome. It has a stream-lined workflow requiring a single ligation step of the DNA 
encoding the gRNA when using the plasmid expressing the Cas9 and gRNA. This is 
particularly useful when editing more than one gene.  Furthermore, expression of multiple 
gRNA sequences using a single CRISPR/Cas9 or multiple plasmids can enable 
simultaneous editing of several genomic sites within the mammalian genome (Cong, Le 
et al. 2013). The CRISPR/Cas9 editing technology enables studies to be performed for 
loss of function mutations by creating indels (utilising the NHEJ pathway) which may 
lead to frameshift mutations (Kuscu et al. 2017) or it can be used to generate specific 
knock-in mutations using a single-stranded oligo DNA nucleotide (DNA repair template) 
(HDR pathway) (Cong, L. et al. 2013). When combined with hESCs, these tools provide 
a powerful resource to investigate the effects of genetic variants across a broad range of 
developmental models and tissue types. In this Chapter, CRISPR/Cas9 gene editing 
technology was applied to hESCs to generate frameshift mutations (i.e. knockout 
mutations) in genes involved in the NMD pathway. Loss of function mutations in NMD 
genes result in a range of NDDs in humans.    
 
The optimised method derived from the initial study from Ran et al., 2013 to generate 
clonal hESCs using CRISPR/Cas9 proved to be efficient and robust. It did not have any 
effects on the pluripotency and genome stability of the hESCs as shown by 
immunofluorescence staining of pluripotency markers (OCT3/4, NANOG and SOX2) 
and karyotype analysis (Figure 3.10). A targeting efficiency (defined as the proportion 
of clones that had a disrupted targeted allele) of between 26.5 and 48.8% (UPF3B and 
UPF3A respectively) was achieved (Table 3-1). This targeting efficiency was high 




efficiencies between 2-4% and 1-10% respectively (Byrne, Mali & Church 2014; Mali et 
al. 2013). Our targeting efficiency was however lower compared to a study by Ding et 
al., 2013 that reported a targeting efficiency of between 51-79% (Ding, Q. et al. 2013). 
The method used to introduce the CRISPR/Cas9 components (Cas9 and gRNA) into cells 
has been shown to have an impact on the targeting efficiency. Lower targeting efficiency 
has been reported when the Cas9 protein and the gRNAs were delivered as crRNA and 
tracrRNA fusion transcripts (mRNA) (Byrne, Mali & Church 2014; Mali et al. 2013). In 
studies where a higher targeting efficiency was reported, the CRISPR/Cas9 components 
were delivered as DNA via two separate plasmids that expressed either the Cas9 
endonuclease or gRNA (Ding, Q. et al. 2013). This was however, unexpected as it has 
been reported that Cas9 protein and gRNA mRNA delivery has a higher targeting 
efficiency compared to the CRISPR/Cas9 DNA delivery (Sahel, Mittal & Chitkara 2019). 
Therefore the difference in the targeting efficiencies could be due to the gRNAs used as 
the ability of a gRNA to efficiently create DSB in the target DNA can vary based on the 
guide RNA sequence and position in the targeted gene (Wang, T. et al. 2014). From the 
UPF3A KO hESCs clones that were selected, both heterozygous and compound 
heterozygous clones were obtained (41.7% and 50% respectively (Table 3-2)). No clone 
with homozygous mutations were detected, however Ding et al., 2013 detected 7-25% 
homozygous clones. One UPF3A KO clone had a single bp insertion detected using TIDE 
(a program that deconvolutes sequence traces and detects the number of indels in each 
sequence). This suggests that either this clone has a 1 bp insertion in each allele, or that, 
there is one 1 bp insertion on one allele and a large deletion in the other allele that is not 
being detected by the primers flanking the targeted genomic loci. However this was not 
investigated further.  The CRISPR/Cas9 genome editing technology was able to generate 
a range of indels ranging from 1 bp deletions to as large as 55 bp (data not shown) in 




in some large deletions whereas editing of UPF1, UPF2 and UPF3B only had small 
indels (Figure 3.4). The large deletions that were observed in HEK293T where not 
observed in UPF3A CRISPR/Cas9 edited hESCs, with the largest deletion detected being 
25 bp in hESCs (Table 3-2). The difference in the size of deletions generated by the same 
gRNA in HEK293T cells and hESCs could be due to the different cell types.  
 
Karyotype analysis was performed on control cell lines and all clones with frameshift 
mutations generated at the targeted loci. Karyotyping analysis revealed one abnormal 
clone with mosaicism for trisomy 12 (Figure 3.14). Karyotyping after CRISPR-Cas 9 is 
important as hESCs genomes are unstable (Henry et al. 2018). During the editing process, 
hESCs are passaged as single cells, nucleofected and selected with an antibiotic. These 
unfavourable environments impose a strong selective pressure on viability which may 
favour genetic alterations with positive influence (Peterson & Loring 2014). Gain of 
chromosome 12, 17, 20 and X have been frequently detected in hESCs cultures (Baker et 
al. 2007; Nguyen et al. 2014). These abnormalities may provide a selective advantage by 
promoting self-renewal or proliferation in culture for example through gain of NANOG 
which is located on chromosome 12 (Tosca et al. 2015).  
 
In conclusion CRISPR/Cas9 genome editing technology was successfully used to 
generate a series of UPF3A and UPF3B frameshift mutant hESC lines that would enable 
the study of the impact of UPF3A and UPF3B loss-of-function mutations in disease. The 
use of iMEFs and SMC4 were important in the gene-editing method to attain pluripotent 
colonies. The process of editing also had no discernible effect on the pluripotency and 
genome stability at the level of analysis performed. However it has been shown that 




caused by gRNA binding to mismatched DNA sequences. The experimental design of 
choosing three independent gRNAs to generate unique gene edited lines served to control 
against potential off-target effects. In the next chapter the genome wide interrogation of 























Chapter 4 : Whole genome sequencing of 






















CRISPR/Cas9 gene editing technology is a highly effective gene editing tool used for 
modifying the genome for functional elucidation of genetic variants in cell culture (Wang, 
Tim et al. 2014) and animals models such as mice (Platt et al. 2014; Swiech et al. 2015). 
As described in chapter 3, CRISPR/Cas9 genome editing technology utilises a gRNA that 
binds a complementary sequence of DNA to home the Cas9 endonuclease to specific 
genome sites and generates DSBs (Pattanayak et al. 2013). However, the complementary 
binding of the gRNA to the DNA is not completely specific. It has been shown that the 
gRNAs can bind mismatched sequences of DNA at low frequency and as such Cas9 can 
be homed to undesired locations where it can potentially generate undesired ‘off-target’ 
mutations (Cradick et al. 2013; Fu et al. 2013; Hsu et al. 2013).  
 
Binding of the gRNA to a mismatched DNA sequence has been shown to depend on 
several factors such as the number of nucleotide mismatches and the position of the 
mismatch (Fu et al. 2013). The 8-13 nucleotide 5’ of the PAM sequence in the gRNA is 
known as the ‘seed sequence’ and has been shown to lead to the specificity of the gRNA 
binding to the complementary DNA sequence (Byrne, Mali & Church 2014; Cong, Le et 
al. 2013). The remaining nucleotides of the gRNA sequence have been shown to tolerate 
some degree of mismatch. In addition to binding mismatched DNA sequences, the gRNA 
can bind DNA sequences that contain insertions (DNA bulge) or deletions (RNA bulge) 
within the targeted region, further introducing opportunities for off-target homing of Cas9 
(Lin et al. 2014).  
 
For clinical applications such as gene therapy, off-target mutations are a major concern 
as these genomic changes can affect important genes and create chromosomal 




on results of various functional studies when elucidating genetic variants if coding 
regions within a gene are affected. This indicates that comprehensive off-target analysis 
should be performed on CRISPR gene-edited cells to detect any off-target mutations.  
 
A limited number of studies have employed whole genome sequencing (WGS) of 
CRISPR/Cas9 gene-edited hESCs and iPSCs clones, and have shown little or no off-
target mutations respectively (Smith et al. 2014; Veres et al. 2014) while other human 
cell lines have low levels of off-targets mutations (Anderson et al. 2015). Even though 
no off-target mutations were identified in iPSCs exposed to CRISPR/Cas9 gene-editing 
systems, individual iPSCs clones had unique indels caused by clonal heterogeneity 
(Veres et al. 2014).  
 
This chapter describes in detail the experiment and the analysis performed to detect off-
target mutations in the CRISPR/Cas9 clones generated as part of this study using WGS. 
It includes a brief description of how the gene-edited hESCs were generated, a detailed 
description of the detection of clone specific de novo small nucleotide variants (SNVs) 
and structural variants (SVs) and validation of the variant calls. The results showed that 
none of the unique de novo SNVs detected were likely due to off-target mutations 
generated by CRISPR/Cas9 gene. However, SV analysis detected large deletions (21-578 
bp, with the largest detected being ~13 megabases) and duplications (294-626 bp) that 
overlapped with predicted off-target sites and their validation is still in progress to 
determine if they are real. The analysis revealed that the detected de novo variants were 
more likely due to extended culturing of hESCs, the process of CRISPR/Cas9 editing, 
and presence of mosaicism in the parental cell line. Even though a relatively large number 




clones, parental cell line and an external H1 cell line (published H1 WGS data) revealed 




4.2.1 hESCs generated using the CRISPR/Cas9 gene editing technology  
H1 hESCs were used to generate gene modified stem cells. H1 hESCs were expanded 
and single cell passaging was performed to generate a pool of cells (7x106 cells) to 
execute a series of nucleofection experiments required to generate all clonal lines in 
parallel. After nucleofection, puromycin selection was performed, colonies isolated and 
clonal cell lines expanded (Figure 4.1a). Loci specific genotyping was performed, and 
the clones with indels generating frameshift mutations karyotyped. Four controls 
(nucleofected with the empty PX459 V2 vector (PX2)), and three UPF3A and three 
UPF3B KO clones (each generated with a different gRNA) were selected for further 
analysis. Each clone was expanded for approximately 20 passages before gDNA was 
collected and submitted for WGS. Samples submitted for WGS included the parental cell 
line at passage number 30 (P30) from the initial vial/ stock, one control (PX2) and six of 










Figure 4.1: CRISPR/Cas9 gene-editing process and clones selected for WGS 
analysis.  
a) UPF3A and UPF3B KO clones were generated from a single cell derived from a large 
pool of H1 hESCs that were nucleofected with the designed CRISPR/Cas9 plasmid and 
selected through drug selection and expanded. b) Samples submitted for WGS included 









4.2.2 Identification of unique de novo SNVs and SVs analysis in gene-edited 
hESCs. 
 
DNA samples were sequenced using 150 bp paired reads by Illumina HiSq X-10. Fastq 
formatted sequence files were mapped to the UCSC hg19 build of the reference human 
genome and SNVs were called using GATK (Van der Auwera et al. 2013) and SVs 
called with DELLY (Rausch et al. 2012) (Figure 4.2). To comprehensively investigate 
off-target mutations generated by CRISPR/Cas9 technology, clonal specific de novo 
mutations were identified from the WGS data. 
 
 
Figure 4.2: Analysis of SNVs and SVs in UPF3A and UPF3B KO hESCs clones.  
WGS was performed with 150 bp paired reads using Illumina Hisq X-10 on the parental 
cell line, a control and three UPF3A and UPF3B KO clones. The sequencing results were 
analysed using GATK to detect SNVs and DELLY for SVs in the CRISPR edited clones.   
 
 
SNV analysis detected approximately 4.4x106 variants in the parental H1 and each of 
the analysed control and KO clones when compared to the human genome reference 
sequence (Table 4-1a).The identification of de-novo SNVs due to off-target 
mutagenesis was achieved by removing germ line and acquired variants present in the 
parental H1 line from the PX2 control and KO clones. Removal of the H1 variants 
revealed variants ranging between 16.7x104 and 23.2x104 per clonal cell line. The 
detection of approximately 20x104 variants across clones after removal of germ line and 




acquired variants in the parental was mainly due to the lower passage number of the 
parental cell line, ~56 passages lower than the control and KO clones (see section 4.2.1). 
This is because the parental clone had fewer variants due to a lower passage number. 
The longer the cells are passaged and stay in culture, the more variants they acquire. 
Therefore a higher passage number cells with have a higher number of variants 
compared to lower passage cells. The detected variants in the KO clones (each using 1 
of 6 different gRNAs) were further filtered to remove all variants present in the control. 
After filtering, the number of SNVs in the KO clones was reduced to between 6.1x103 
to 8.4x103 SNVs per cell line. The reason for this reduction is that the control clone is 
approximately the same passage number as the KO clones, and also went through the 
same experimental process leading to clonal cell isolation. Further filtering of the 
variants was performed to identify unique de novo variants by removing all variants that 
were detected in at least two clone. This further reduced the variants detected in each 
clone to approximately ~3083 variants. These unique de novo variants where then 
categorised into single nucleotide polymorphisms (SNPs) and insertions/deletions 
(indels). As these variants can affect results of functional studies when elucidating the 
role of UPF3A and UPF3B if coding regions within a gene are affected, variants located 
in exons or those with a role in splicing were analysed. From these variants, 
nonsynonymous, frameshift or variants with unknown function were selected. Genes 
that contained these variants were then identified (Table 4-1a). To explore if any of 
these unique de novo SNVs are due to likely off-targets mutations, a list of predicted 
off-targets was generated and overlapped with the SNVs for each clone (See section 
4.2.3).  
 
Cas9-induced DNA DSBs are predominantly repaired by NHEJ to produce small indels 




up to 600 bp in mouse zygotes (Shin, Ha Youn et al. 2017). Large deletions and complex 
genomic rearrangements at CRISPR/Cas9 targeted loci in mouse ESCs and human 
differentiated cell line have also been reported (Kosicki, Tomberg & Bradley 2018). To 
determine if Cas9-induced DNA DSBs lead to SVs such as deletions, insertions, 
inversions or duplications, unique de-novo SVs were identified using DELLY. The SVs 
identified in this section are additional larger variants not detected using GAKT 
(independent of SNVs). The filtering criteria of the data to detect unique de novo SVs 
was performed stepwise as above (SNVs), where the Fastq formatted sequence files were 
first mapped to the reference human genome and the H1, control and any shared variants 
between two or more clones were removed from the KO clones systematically.  The 
number of unique de novo variants were between 1524 and 2135. These variants were 
then categorised based on the type of SV in each clonal line. This revealed that from the 
SVs detected, deletions represented the largest proportion and inversions being the least 
frequent across all clones (Table 4-1b). To explore if any of these unique de novo SVs 
are due to likely off-target mutations, a list of predicted off-targets was generated and 
overlapped with the SVs for each clone (See section 4.2.3). 
 
 
4.2.3  Off-target mutation analysis in gene-edited clones 
To determine if any of the unique de novo SNVs and SVs in each KO clone were due to 
off-target mutations, a list of predicted gRNA off-targets sites were generated using the 
Cas-OFFinder program (www.rgenome.net/cas-offinder) (Bae, Park & Kim 2014) (Off-
targets-a) and the CRISPR design program (crispr.mit.edu) (Off-target-b) (Table 4-2). 
SNVs located at the potential off-target sites were identified using bfctools viewer filtered 
with a custom bed file that had a 20 bp window flanking each predicted off-target site. 




clonal de novo indels. The identified indels in each clone corresponded to the previously 
identified on-target indels generated in UPF3A and UPF3B (Table 4-2b). By reducing 
stringency to also include ‘low quality’ SNVs, re-analysis identified only one off-target 
indel in LINC01865 in a single clone. Validation of this off-target variant was unable to 
be performed due to lack of suitable primers available for flanking regions.  
 
To determine if any of the unique de novo SVs detected in KO clones overlapped with 
predicted off-targets sites, BedTools was used to overlap each sample with the 
corresponding off-target sites, allowing for a 200 bp window around the predicted off-
target regions. Resulting SVs were de-duplicated/merged (since the provided off-target 
regions have overlapping records) and filtered to remove low quality variants (set 
FILTER=PASS). Table 4-2b shows the number of deletions and duplications of variants 
that overlapped with the off-target sites. The deletions were between 21-578 bp, with the 
largest detected being ~13 megabases and large duplications of between 294-626 bp 










































































































































































































































































































































































































































































































































































































































































































































































































Table 4-2: Off-target mutation analysis in CRISPR/Cas9 edited cells.  
a) The total numbers of predicted off-targets and b) the number of SVs (del, dup, ins) and 
SNVs (SNPs and indels) detected in each gene-edited clone that overlapped with the 





4.2.4 Mutational load in human embryonic stem cells 
hESCs are subjected to in-vitro culture conditions which can provide a ‘selective’ 
pressure by selecting cells with growth acceleration which can be underpinned by 
chromosomal alterations (Draper et al. 2004). Accumulation of CNVs detected in high 
passage hESCs results from a series of individual mutation events during prolonged 
culture periods. High resolution SNP genotyping on hESCs, iPSCs, somatic stem cells, 
primary cells and tissues reveal hESCs have a higher frequency of genome aberrations 
(Laurent et al. 2011). The unique de novo SNV variants detected in the gene-edited cells 
did not overlap with any of the off-target sites. The presence of mosaicism in the parental 
cell line, the CRISPR/Cas9 editing process and cell passaging i.e. the number of cell 
Predicted off-target mutations
Samples Off-targets-A Off-targets-B Total
UPF3A-G1 3256 21 3277
UPF3A-G2 3780 28 3808
UPF3A-G3 6148 31 6179
UPF3B-G1 3806 31 3837
UPF3B-G2 4064 32 4096
UPF3B-G3 4833 46 4879
Variants overlapping with predicted off targets
Sample DEL DUP INS SNPs INDELS
UPF3A-G1 13 8 0 0 0
UPF3A-G2 8 6 0 0 0
UPF3A-G3 7 5 0 0 1
UPF3B-G1 10 7 0 0 2
UPF3B-G2 10 7 0 0 1






divisions, - could be contributing to the mutational load in these cells. Newly introduced 
mutations are often present in a subgroup of cells in a given culture leading to mosaic 
mutations (Martincorena & Campbell 2015). Isolation and expansion of single cell clones 
from a pool of cells with mosaicism could lead to derivation of clonal lines with mutations 
that are present at very low frequencies in the parental pool of cells. An example of this 
was evident during validation of one of the low quality variants, which displayed 
mosaicism (Figure 4.5). The CRISPR/Cas9 genome editing process in hESCs could also 
possibly also lead to accumulation of novel mutations as this method includes steps that 
can be stressful to the cells. During editing, hESCs are passaged as single cells, 
nucleofected and selected with an antibiotic and clonally expanded. A strong selective 
pressure may arise that favours the surviving cells which may also be at least partly 
attributed to genomic alterations  in these cells (Figure 4.3a) (Peterson & Loring 2014). 
 
The Cas9- induced DNA DSBs are predominantly repaired by NHEJ to produce small 
indels (Yang, Luhan et al. 2014). To focus on mutations generated during cell culture and 
not CRISPR/Cas9, SNVs (with only H1 variants filtered out, and shared variants shared 
between two clones or more removed) were separated into SNPs and indels as the 
CRISPR/Cas9 does not typically introduce missense changes. There was no overt 
difference in the number of SNP or indels variants found in the control and the UPF3A 
KO clones (Figure 4.3b). However, in UPF3B KO clones, SNPs (which are more cell 
culture related) were more abundant when compared to the number of indels (Figure 
4.3b). It is noteworthy that UPF3B KO clones were more difficult to culture compared 
to the UPF3A KO clones and control clones. This difficulty could impact additional 
selective pressure and contribute to these cells acquiring more culture related mutations 








Figure 4.3: Passaging induced mutations and the CRISPR/Cas9 editing process 
are the main contributing factors to an increased mutational load in hESCs.  
a) Factors that contribute to a high mutational load in hESCs in higher passage number 
hESCs. b) Graph showing the number of SNVs in each CRISPR clones. SNVs were 




































4.2.5 Validation of variant calling confidence 
To confirm high quality variant calls, a total of fifteen variants were selected. The variants 
were validated by genomic PCR followed by Sanger sequencing with 100% overall 
confirmation (Figure 4.4 and Appendix 4). To verify the stringency in the filtering 
criteria and to ensure important variants were not filtered out, eight low quality variants 
were selected that were part of the variants that did not meet the PASS filtering criteria 
and were therefore removed from the analysis. Seven of the eight low quality variants did 
not validate (results not shown) as expected while one, TRAPPC8 showed low frequency 
mosaicism (~10.5% of a 3 bp deletion in the cells population) in clone UPF3B-G1 
























Figure 4.4: Validation of high quality variant in the WGS analysis.  
High quality variants were selected and validated through Sanger sequencing. UF3B-G2 
had a heterozygous mutation of the NCOR2 gene. TIDE revealed that the heterozygous 




























Figure 4.5: Validation of low quality variants in the WGS analysis.  
Low quality variants were reanalysed. Mosaicism of TRAPPC8 was discovered in one of 
the clones (UPF3B-G1) at a frequency of ~10.5% of the cells population. Sanger 
sequencing was performed using the a) forward and b) reverse primers. TIDE was used 











4.2.6 Relatedness of the CRISPR gene-edited clones and the parental cell line 
To ensure the KO clones had not genetically drifted apart from each other or the parental 
cell line due to the number of variants detected in each individual clone, an analysis was 
performed to compare how similar the gene-edited clones were to the parental cell line 
and an external published H1 clone (Yazdi, Puya G et al. 2015). The analysis used to 
determine the relatedness between the cell lines was the vcftools relatedness2 algorithm. 
The matrix (Table 4-3) shows how samples are related to each other and the closer to 0.5 
the closer the samples are to being identical. The value in each CRISPR clone confirms 
that the gene-edited clones, the parental cell line and an external published H1 cell line 





























































































































































































































































































































































































































































The CRISPR/Cas9 genome editing technology holds great promise in the field of gene 
therapy such as disrupting genes that cause cancer (Wang & Sun 2017) and repairing 
mutated genes that cause genetic disease (Bengtsson et al. 2017). The use of ex vivo gene 
therapy, where cells are corrected before transplantation back into a patient (Crudele & 
Chamberlain 2018) or in vivo gene therapy are emerging therapeutic strategies (Gregory-
Evans, Bashar & Tan 2012). However, a major concern with gene therapy and disease 
modelling using engineered nucleases is their potential to generate off-target mutations 
(Lockyer 2016; Veres et al. 2014). gRNAs tolerate up to five bp mismatches which may 
home Cas9 to undesired genomic locations and result in SVs such as insertions, deletions 
or translocations (Cho et al. 2014).  
 
WGS analysis of the gene-edited cells generated in this study revealed that none of the 
unique de novo SNVs  detected in each clone overlapped with the predicted off-target 
sites, suggesting that CRISPR/Cas9 editing technology did not introduce any detectable 
off-target mutations (Table 4-2a). The detected variants were mainly due to the 
accumulation of mutations during culturing the hESCs (passaging induced mutations) 
and/or the process of clonal selection including nucleofection and antibiotic selection 
which could create a strong selective pressure that may favour cells with genomic 
alterations that promote cell survival (Peterson & Loring 2014). Compared to a study by  
Veres et (2014) which detected an average of 193 variants in four gene-edited clones, the 
number of variants detected in this study were considerable high (detected an average of 
3083 variants across six clones). Perhaps one explanation for the higher number of 
variants detected in this study could be that WGS was performed at a higher passage 
number (~P20) after CRISPR/Cas9 editing while Veres et al (2014) performed WGS at 




analysis, Vere et al., WGS analysis included two TALEN edited clones and three controls 
(edited clones with wildtype alleles from both the TALEN and CRISPR experiment) and 
a parental cell line. The use of more samples compared to our studies (9 samples 
compared to 8) could have resulted in the lower variants they detected. The controls they 
used in their study are wildtype clones that were nucleofected with the same plasmid as 
the KO clones. This could have therefore reduced the variants further if the gRNA 
generated the same indels in the clones. Another study that performed WGS in 
CRISPR/Cas9-mediated gene-edited iPSCs, identified between 217 and 281 SNVs. This 
study also included TALEN edited iPSCs in their WGS analysis but did not include a 
control. WGS analysis was performed immediately after selection at passage 1 (P1) 
(Smith et al. 2014). The main pitfall of this study/analysis is that the parental cell line that 
was used (to filter out variants from the gene-edited clones) to analyse the WGS was 56 
passages lower than the control and gene-edited cells, and is contributing to a large 
number of variants being detected in each clone. Another study that analysed the WGS 
of six CRISPR/Cas9-mediated gene-edited clones compared to the parental iPSCs 
detected an average of 24 932 SNVs in each clone which is high compared to the variants 
detected in this study. This could be because they first reprogrammed fibroblasts into 
iPSCs and used CRISPR/Cas9 to correct the mutation (Lyu et al. 2018). iPSCs are known 
to acquire genetic mutations during reprogramming (Puri & Nagy 2012). This study 
however did not mention the passage number when gDNA was extracted for WGS. 
Despite the number of variants detected in the gene-edited clones in this study, when 
compared to the parental cell line and an external H1 cell line they were all similar with 
minor variations as analysed using the vcftools relatedness2 algorithm (Table 4-3). 
 
As indels and SVs cover almost all the mutations generated by CRISPR/Cas9 (Veres et 




bp, with the largest being 13 megabases) and duplications (294-626 bp) detected in the 
gene-edited cells overlapped with the predicted off-target sites. The validation of these 
deletions and duplications are in progress to determine if they are real. Large deletions 
(up to 600 bp) were detected in CRISPR edited mice (Shin, H. Y. et al. 2017) and other 
cell types such as mouse ESCs, mouse hematopoietic progenitors and human 
differentiated cell lines revealed deletions extending over kilobases (Kosicki, Tomberg 
& Bradley 2018). The CRISPR/Cas9 had minimal impact on coding regions outside of 
the target sites. Most clones had two to three genes affected with UPF3B-G1 clone having 
the most genes affected (six genes) and UPF3B-G3 having no genes affected (Table 
4-1a). In summary none of the unique de novo SNVs variants detected were likely due to 
off-target mutations generated by CRISPR/Cas9, but rather extended culturing of hESCs, 
the process of obtaining clonal populations of cells and mosaicism present in the parental 
cell line. De novo SVs (deletions and duplications) over lapping the off-target sites were 














Chapter 5 - Characterisation of UPF3A and 

























5.1  Introduction 
NMD is a posttranscriptional mRNA quality control pathway that identifies, targets and 
degrades mRNA that contain PTCs within their coding regions (Smith & Baker 2015).  
Approximately 12% of genetic disorders are caused by mutations that generate PTCs  in 
the respective genes (Mort, Matthew et al. 2008). NMD targets the majority, but not all 
of such PTC-containing mRNAs. In addition to the PTC containing transcripts, NMD 
also acts on a range of physiological targets with ‘endogenous’ PTC-like features 
introduced by means of alternative splicing, intron retention, uORF, intronic sequences 
within 3’ UTR and lengthy 3’UTRs (>1.5 Kbp) among others. Human mutations and 
CNVs in NMD and EJC factors which compromise NMD activity leads to unfavourable 
neurodevelopmental outcomes, reaffirming the importance of the NMD pathway in the 
regulation of the physiological transcriptome and normal cellular function.  
 
NMD factors, UPF3A and UPF3B both have a short and long isoform and share a highly 
similar protein sequence and are expressed in the same tissues but not at the same 
expression level (Tarpey et al. 2007). UPF3B is known to be a strong NMD activator and 
is important in neurodevelopment while the role of UPF3A has not yet been fully 
elucidated (Figure 5.1). On the path towards determining the molecular and cellular 
processes disrupted due to loss of UPF3A and UPF3B during neurodevelopment in a 
human brain model and the role of UPF3A in NMD, UPF3A and UPF3B KO hESCs 
were generated (Chapter 3). In this chapter the focus was to characterise UPF3A and 
UPF3B KO hESCs. The characterisation determined if the KO alleles produced any 
functional protein, and if the NMD pathway was disrupted in the hESCs KO clones by 
analysing NMD targets that are known to be deregulated when UPF3B is absent. As 




of hESC differentiation, analysis of cell cycle kinetics, pluripotency and differentiation 




Figure 5.1: Role of UPF3A and UPF3B in NMD 
During the divergence of the vertebrate and invertebrate lineage, a gene duplication event 
occurred that resulted in the emergence of the two gene paralogs UPF3A (duplicated) and 
UPF3B (ancestral). UPF3A is located on chromosome 13 and its role is uncertain, while 






5.2.1 Premature termination codons (PTC) were introduced early in the coding 
regions of UPF3A and UPF3B KO hESC clones. 
 
The gRNAs used to generate UPF3A and UPF3B KO hESCs clones were designed to 
target either exon one or two depending on which gRNA had the highest score from the 
CRISPR design tool (Chapter 3). Frameshift type mutations in these 5’regions of the gene 
are most likely to prevent the production of functional proteins. Table 5-1 shows the 




3.12 and Figure 3.13) and their mutation annotations. The mutations created in these 
clones all generated frameshift mutations and introduced PTCs early in their respective 
ORFs. Figure 5.2 shows the expected size of proteins from the mutant UPF3A and 
UPF3B alleles (a peptide translated from the start codon to the first PTC). The 
hypothetical truncated proteins are small and predicted non-functional as they lack the 
essential UPF2 and Y14 binding sites.  
 
 
Gene Clone Mutation annotation 
UPF3A UPF3A-G1 Allele 1: c.152_153insT 
Allele 2: c.153_156del 
UPF3A-G2 Allele 1: c.155_156del 
Allele 2: c.155_168del 
UPF3A-G3  Allele 1: c.135_141del 
Allele 2: c.138_154del 
















Figure 5.2:  Schematic of wildtype and hypothetical UPF3A and UPF3B proteins 
produced from wildtype and mutant alleles.  
UPF3A and UPF3B proteins have two similar binding domains located at the N- and C- 
terminus, a UPF2 and Y14 binding domain respectively. Numbers above the wildtype 
schematic represent amino acid residues. The hypothetical proteins produced from the 
alleles from the three UPF3A and three UPF3B KO hESC are represented.   






5.2.2 UPF3A transcript levels are reduced in UPF3A KO clones while UPF3B 
transcripts levels are unchanged in UPF3B KO clones. 
 
As the indels created in the UPF3A and UPF3B KO clones introduced PTCs in their 
respective transcripts, real time qPCR analysis was performed on mRNA extracted from 
the clones to determine UPF3A and UPF3B transcript levels. UPF3A KO clones had 
significantly reduced UPF3A transcript levels (29.1%) compared to the controls while 
UPF3B transcript levels in UPF3B KO clones were slightly upregulated, suggesting they 
escaped NMD (Figure 5.3). PTCs introduced in the UPF3A and UPF3B KO clones are 
located in exon 1 (near the initiation codon).  These PTCs are predicted to be degraded 
by NMD pathway as they are located more than 50-55 nts upstream of the last EJC. The 
50-55 nt rule states that PTCs located 50-55 nts upstream of the 3’most exon-exon 
junction are degraded by mRNA. However, they are exceptions to this rule as it has been 
shown that PTCs located close to the translation initiation codon escape being targeted 
by the NMD pathway despite being located 50-55 nts upstream of the EJC (Inacio et al. 
2004; Perrin-Vidoz et al. 2002) which is observed in the generated UPF3A and UPF3B 














Figure 5.3: UPF3A and UPF3B transcript levels in UPF3A and UPF3B KO clones.  
Real time qPCR was used to analyse the transcript levels of a) UPF3A and b) UPF3B in 
mRNA extracted from controls (n=4), UPF3A (n=3) and UPF3B (n=3) KO hESCs clones 
performed in triplicates.  All data normalised to ACTB mRNA expression. Graphs 
represent mean value for each genotype in each triplicate. *p<0.05 significantly different 
to controls by Student T-test assuming equal variance.  
a) 
UPF3A transcript in controls and mutant KO clones 






5.2.3 mRNA expressed from UPF3A KO alleles display usage of cryptic splicing 
sites.  
 
UPF3A KO clones were selected based on the results from the TIDE software which 
identifies the number of indels generated using Sanger sequencing of regions spanning 
across the target gRNA site (Figure 3.13). However, this software does not give any 
information regarding the actual position of the mutation on each allele. To determine the 
position of the mutation on each allele in the UPF3A KO clones, a PCR was performed 
using cDNA isolated from each clone as a template. The PCR spanned the region 
transcribed from the genomic site targeted by the gRNA. The PCR products were then 
ligated into the pGEM-T Easy vector and transformed into bacteria.  
 
Ten bacterial colonies were selected for each UPF3A KO clone. The plasmid DNA was 
isolated and the inserts sequenced. From each clone, half of the isolated plasmids had 
sequences that aligned with one allele of the hESC clone, and half from the other allele 
suggesting bi-allelic expression of the alleles in hESCs. The reason for observing an equal 
ratio of each allele could be due to only 29.1% of the transcript being degraded compared 
to controls. However, in addition to the two sequences detected (from each allele) in each 
clone, UPF3A-G2 and UPF3B-G3 KO clones had a third sequence detected, suggesting 
a third mRNA species was being produced  (occurred in 1:10 of the selected bacterial 
clones) (Figure 5.4a and Figure 5.4b). Sequences of the third mRNA species was 
generated from one of the two alleles as allelic mutation was clearly present (Table 5-1 
and Figure 5.4a-b). This sequencing revealed that this mRNA species reflected an 
incorrectly spliced product, harbouring an additional 17 bp and 110 bp from intron one 
sequence in UPF3A-G2 and UPF3A-G3 clones respectively. The aberrant splicing in 




mutations introduced by the CRISPR/Cas9 technology. This in-frame mutation can 
potentially produce a near full length protein, but with a partial deletion and additional 
‘intronic sequence derived’ amino acids. 
 
a) UPF3A-G2 allele 2 
 







Figure 5.4: Aberrant splicing in UPF3A KO hESCs clones.  
Sanger sequencing performed on bacterial cell colonies that were transformed with the 
PCR product from a) UPF3A-G2 and b) UPF3A-G3. In UPF3A-G2 and UPF3A-G3 




5.2.4 Expression from the UPF3A and UPF3B KO alleles did not produce 
protein. 
 
The ultimate measure to determine if the mutant alleles truly represented null alleles and 
as such confirming the generation of KO hESCs clones was to determine if any protein 
was being expressed. hESCs were harvested and protein lysates extracted and subjected 
to western blot analysis. UPF3A and UPF3B protein were absent from lysates from 
UPF3A and UPF3B KO hESCs clones respectively (Figure 5.5a and Figure 5.5b). 
Western blot analysis, even at a high exposure of the membrane did not detect any UPF3A 
protein (Figure 5.5a). This data thus confirm that the mutant alleles generated by 
CRISPR/Cas9 targeted disruption of UPF3A and UPF3B are truly null alleles unable to 
produce functional protein, and as such confirming the generation of UPF3A and UPF3B 





Figure 5.5: UPF3A and UPF3B KO clones had no protein expression.                                                      
Protein lysates from controls (n=4), UPF3A (n=3) and UPF3B (n=3) KO clones were 
harvested and subject to western blot analysis. Membranes were probed with the a) 
UPF3A antibody and b) UPF3B antibody. Asterisk marks on the UPF3A western blot 
indicates the two isoforms of UPF3A and the lower band which appears in all clones is 
non-specific. Bands that appear in all clones with the same intensity are non-specific in 











5.2.5 UPF3A protein is stabilised in UPF3B KO clones 
 
Western blot analysis of the UPF3A protein in UPF3B KO clones indicated that UPF3A 
protein was stabilised in the absence of the UPF3B protein (Figure 5.6a and b). This 
phenomena has been previously described as evidence of a compensatory NMD 
mechanism in other cell types (Chan et al. 2009; Jolly et al. 2013; Nguyen et al. 2012). 
UPF3A and UPF3B are highly similar proteins that bind to UPF2 using their N-terminal 
domain (Kunz et al. 2006; Lykke-Andersen, Shu & Steitz 2000). The UPF2 binding 
domain of UPF3A is important in stabilisation of this protein. UPF3A and UPF3B both 
compete to bind UPF2. When UPF3B is present, most of the available UPF2 protein is 
bound to UPF3B and unbound UPF3A is degraded. However when UPF3B protein is 









Figure 5.6: UPF3A protein is stabilised in UPF3B KO hESCs clones. 
a) When UPF3B is present it binds to UPF2 and UPF3A protein is degraded and vice 
versa. Protein lysates were extracted from the controls (n=4) and UPF3B KO clones 
(n=3) and subject to western blot analysis. Membranes were probed with the UPF3A and 
UPF3B antibody. b) Densitometry was performed directly on image captured with low 
exposure time and normalised against the level of the β-Actin protein in the same sample. 
Red cross indicates absence of the protein. 
 

























5.2.6 Evidence of an NMD negative feedback regulatory network in hESCs 
NMD has a dual role in regulating gene expression by degrading transcripts with PTCs 
generated from germline, somatic mutations, transcription errors and physiological 
transcripts from genes that contain NMD inducing features such as an uORF, long 3’-
UTR (>1.5 Kbp) (Boehm et al. 2014; Nicholson et al. 2010). Some of these endogenous 
NMD features are also present in transcripts which encode NMD factors themselves 
(Table 1-1). As a result when NMD is perturbed, the NMD factors are known to be 
upregulated suggesting a self-buffering mechanism exists to maintain NMD magnitude 
(Huang, L et al. 2011).  
 
To discover evidence of this buffering mechanism in UPF3A and UPF3B KO clones, real 
time qPCR was performed on mRNA isolated from the clones to test the expression of 
NMD and EJC genes. The UPF1 and UPF2 transcript levels were significantly 
upregulated in UPF3B KO clones and unaffected in UPF3A KO clones. SMG7 and 
MAGOH expression was downregulated in UPF3A KO clones while UPF3B KO clones 
only showed a reduction in MAGOH (Figure 5.7a). Western blot analysis showed there 
was no significant difference between UPF3A, UPF3B KO clones and controls for the 











                      
 
 
Figure 5.7: Loss of UPF3B and not UPF3A is involved in the buffering mechanism.                                                                                  
Analysis of mRNA and protein expression of genes encoding NMD and EJC factors. 
mRNA and protein lysates was isolated from n=4 controls and n=3 UPF3A and UPF3B 
KO clonal hESCs and analysed separately. a) Real time analysis of NMD and EJC factor 
mRNA. Real time analysis was performed in triplicates per sample. All data normalised 
to ACTB mRNA expression. Graphs represent as mean values of each genotype, error 
bars represent standard deviation. *p<0.05, **p<0.01, ***p<0.001 represent statistical 
difference compared to controls by Student-T test assuming equal variances. b) Western 






























NMD and EJC factors












5.2.7 NMD ‘targeted’ transcripts are deregulated in response to UPF3B deletion. 
 
Following the successful generation of UPF3A and UPF3B KO hESCs clones, evidence 
of altered NMD was sought, by testing the mRNA expression of a suite of endogenous 
NMD target mRNAs. mRNA was isolated from UPF3A and UPF3B KO clones and 
controls and the levels of NMD targeted mRNA sensitive to both the classical (UPF3B 
sensitive) and the alternate NMD (UPF3B in-sensitive) pathways were analysed. The 
mRNA expression of the classical NMD target genes GAS5 and ATF4 were upregulated 
in UPF3B KO clones, but not affected in UPF3A KO clones. Surprisingly, the mRNA of 
other NMD classical targets cJUN, GADD45B and ATF3 were significantly 
downregulated in both the UPF3A and UPF3B KO hESCs (Figure 5.8a). Intriguingly 
these genes all encode stress response proteins (Inoue et al. 2018; Jovaisaite, Mouchiroud 
& Auwerx 2014; Liebermann & Hoffman 2008). Alternative NMD pathway targeted 
mRNAs encoded by PANK2 and SMG5 were not affected in either UPF3A and UPF3B 
KO clones (Figure 5.8b).  
 
A second set of putative NMD-targeted mRNA for testing was selected from RNA Seq 
transcriptome data generated from an iPSC derived from a male individual with complete 
loss-of-function mutations in UPF3B (unpublished, provided by Prof. Miles Wilkinson, 
University of California, San Diego, CA, USA). Four deregulated transcripts (encoded 
by HIST1H2AC, ANXA1, HNMT, AUTS2) were selected and their expression analysed 
using real time qPCR performed on mRNA isolated from the UPF3A and UPF3B KO 
clones (Figure 5.8c). Three of the deregulated transcripts were validated in UPF3B KO 
clones (HIST1H2AC, ANXA1, HNMT) whilst AUTS2 was unchanged. This analysis was 
not a robust approach because a small number of transcripts (12 transcripts) were selected 




identification of transcriptome wide changes in these cells were subsequently performed 
by RNA seq (Chapter 6).  
 
 
    
  
Figure 5.8: Deregulation of NMD targets in response to loss of UPF3A and 
UPF3B.                                                                                                                                            
Real time qPCR analysis of mRNA known to be subjected to NMD in UPF3A and 
UPF3B KO hESCs compared to wildtype controls. a) Analysis of mRNAs targeted by 
the classical NMD pathway. b) Analysis of mRNAs targeted by the alternative NMD 
pathway. c) Analysis of mRNAs deregulated in UPF3B ‘complete knockout’ iPSCs. n=4 
independent control clonal lines compared to n=3 independent UPF3A KO and n=3 
UPF3B KO hESC lines done in triplicate. All data normalised to ACTB mRNA 
expression. Graphs represent mean value for each genotype, error bars represent standard 
deviation. *p<0.05, **p<0.001, ***p<0.0001 significantly different to controls by 










































































Deregulated genes in UPF3B 'complete KO' iPSCs 


















5.2.8 Cell culture environment /passage number have an impact on NMD activity 
variability.  
 
To investigate the unexpected results where the stress response transcripts were 
downregulated in both UPF3A and UPF3B KO hESC clones (section 5.2.7), cell pellets 
were collected at an earlier passage number, approximately a 10 passage difference 
between collections periods and mRNA extracted. Bona fide NMD targets and stress 
response transcripts were analysed. The bona fide NMD targets (GAS5, ATF4) and the 
NMD factors involved in the buffering feedback loop (UPF1, UPF2) were upregulated 
in both the high and low passage conditions suggesting that these are true and robust 
effects of a perturbed NMD pathway. However genes involved in the stress response 
(cJUN, GADD45B, ATF3) transcript levels changed between the low and high passage 
(Figure 5.9). In the earlier passage these transcripts were unaffected, suggesting that the 
use of NMD targeted genes that are also involved in the stress response pathways are not 
ideal indicators of NMD activity. For RNA Seq analysis and NSC differentiations cells 



















Figure 5.9: Impact of cell culture environment/passage number on NMD activity.    
             
Real time qPCR was performed on mRNA’s known to be regulated by NMD or are bona 
fide NMD targets in early and late passages of cell from controls (n=4), UPF3A KO 
hESCs clones (n=3) and UPF3B KO hESCs clones (n=3), performed in triplicates. All 
data normalised to ACTB mRNA expression. Graphs are represented as mean value for 
each genotype, error bars represent standard deviation. *p<0.05, **p<0.01, ***p<0.001 
significantly different to controls by student T-test assuming equal variance. 
 
 
5.2.9 NMD and the unfolded protein response (UPR) stress response pathway 
 
As NMD is important in degrading transcripts with PTCs to prevent truncated proteins to 
be produced, when NMD is perturbed these proteins can be made and may lead to the 
production of misfolded proteins. This in turn can lead to an unfolded protein response, 
(UPR) which is a stress response pathway activated by endoplasmic reticulum (ER) 
stress. This pathway helps cells to adapt to the excess levels of misfolded proteins (Figure 
5.10) (Goetz & Wilkinson 2017).  
 
To investigate if loss of UPF3A and UPF3B lead to activation of the UPR stress response 
pathway, three different mRNAs which encode UPR ‘sensors’ (i.e. normally upregulated 
by activation of the UPR pathway) were analysed using real time qPCR. Compared to 
controls, UPF3A and UPF3B KO clones had a reduction in EIF2AK3 and ERN2 
transcripts, however this was not significant. UPF3B KO clones had a slight insignificant 
increase in ATF6 transcript levels. DDIT3/CHOP (a downstream target of ATF4) was 
significantly downregulated in UPF3A KO clones (Figure 5.11). These results suggest 








Figure 5.10: The UPR pathway                                                                                                                    
ER stress leads to the activation of the UPR pathway. This pathway has three different 
branches which have different stress sensors namely, PERK, ATF6 and IRE1. The 
activation of these different branches is important to allow cells to adapt to the high levels 
of unfolded proteins and return the cells to normal homeostasis. Picture taken from 








Figure 5.11: UPR-stress response genes.                                                                                                     
Real time qPCR analysis of mRNA of the UPR transcripts sensors and targets in controls 
(n=4), UPF3A (n=3) and UPF3B (n=3) KO clones, performed in triplicate. All data is 
normalised to ACTB mRNA expression. Graphs are represented as mean and STDEV of 
number of clones. **p<0.01 significantly different to controls by student T-test assuming 
equal variance.       
 
 
       
5.2.10 Deletion of UPF3A or UPF3B lead to the initial stages of endoderm and 
mesoderm differentiation.  
 
NMD factors are highly expressed in human pluripotent stem cells and their levels 
decrease upon loss of pluripotency (Alrahbeni et al. 2015; Bruno et al. 2011; Cho et al. 
2012; Gong et al. 2009; Lou et al. 2016). Inhibition of NMD via UPF1 and UPF3B 
knockdown in P19 and H9 cells led to a reduction in the expression of the stem cell 
markers, - NANOG and OCT3/4, and triggered the initial stages of endodermal 
differentiation (Lou et al. 2016; Lou et al. 2014). To determine if loss of the NMD factor 
genes UPF3A and UPF3B also have a role in pluripotency maintenance in H1 hESCs, 
the expression of a suite of well characterised pluripotency marker genes NANOG, 
































In the first instance, real time qPCR was employed to determine mRNA expression levels. 
Loss of UPF3A or UPF3B was associated with significant reductions in transcript levels 
of SOX2 and OCT3/4 respectively, suggesting that the loss of UPF3A and UPF3B in 
hESCs triggered initial stages of differentiation (Figure 5.12a). To extend this analysis, 
the expression of early differentiation markers were assessed. Indeed loss of UPF3B leads 
to an increase in transcript levels of MESDC2, an early mesodermal marker (Laco et al. 
2018; Veltman et al. 2005) and CLDN6, an early endodermal marker (Anderson et al. 
2008), while loss of UPF3A lead to an upregulation of CLDN6 only (Figure 5.12b). 
Finally, to assess the expression of pluripotency markers with single cell resolution, 
immunofluorescence detection of their protein expression was employed. This analysis 
revealed broad expression of the markers in all cells in the culture, revealing that the 
reduction in the pluripotency markers is not due to overt differentiation of particular 
subsets of cells in culture (Figure 5.12c).  

































































Figure 5.12: Loss of UPF3A and UPF3B impact the expression of pluripotency and 
early differentiation marker genes in hESCs.   
a) Real time qPCR analysis of pluripotent markers, NANOG, OCT3/4 and SOX2 mRNA 
and b) early lineage markers mRNA in controls (n=4), UPF3A KO hESCs (n=3) and 
UPF3B KO hESCs (n=3) performed in triplicate. All data normalised to ACTB mRNA 
expression. Graph values represent mean value derived for each genotype, error bars 
represent standard deviation. *p<0.05, **p<0.01 significantly different to controls by 
student T-test assuming equal variances. c) hESCs were fixed and stained with 
pluripotency markers, OCT3/4 (green), NANOG (red), SOX2 (far red) and DAPI (blue). 
















5.2.11 UPF3A and UPF3B are important for cell cycle progression and 
proliferation 
 
In this section the cell cycle kinetics of UPF3A and UPF3B KO hESCs were analysed. 
hESCs have a short cell cycle, highlighted by short G phase’s and a high proportion of 
cells in the S phase (White & Dalton 2005). Upon differentiation, this ratio changes 
leading to an enrichment of cells in the G1 phase (Barta et al. 2013). NMD is known to 
impact cell cycle and target mRNAs encoding regulators of the cell cycle (Lou et al. 2016; 
Lou et al. 2014). UPF3B KO (and to a lesser extend UPF3A KO) hESCs were shown to 
have reduced OCT3/4 mRNA expression encoding a pluripotency cell marker which is 
important in cell cycle progression (Figure 5.12a). Downregulation of OCT3/4 prevents 
proliferation by blocking the G1 cell progression (Lee et al. 2010). Collectively this 
suggests that loss of UPF3A and UPF3B and a compromised NMD in general may impact 
cell cycle progress in hESCs.  
 
Single cells from controls, UPF3A and UPF3B KO hESCs were collected for cell cycle 
analysis just prior to a normal passaging event. Cell cycle analysis by DNA content using 
propidium iodide (PI) was used to determine cycle phase by FACS. Both loss of UPF3A 
and UPF3B had an impact on the cell cycle kinetics, however the differences were 
distinct. Loss of UPF3A led to a significant reduction in the percentage of cells in the G1 
phase and an enrichment of cells in the G2/M phase. In contrast, loss of UPF3B had the 
reciprocal effect, with an enrichment of cells in the G1 phase (although not significant) 
and a significant reduction of cells in the G2/M phase (Figure 5.13a). Next, the mRNA 
expression genes encoding the cell cycle inhibitors CDKN1A and CDKN2A were 
analysed. CDKN1A and CDKN2A cause an increase in cells at the G1 phase by preventing 
cells to enter the S phase by inhibiting the phosphorylation of retinoblastoma proteins 




1995; Zhao et al. 2016). These transcripts have been shown to be upregulated when UPF1 
and UPF3B is downregulated in hESCs (Lou et al. 2016). Both transcripts were 
deregulated (CDKN1A downregulated and CDKN2A upregulated) in UPF3B KO clones. 
The CDKN1A transcript level in UPF3A KO hESCs were also downregulated, however 
it was not significant (Figure 5.13b).  
 
To determine if the defects in cell cycle progression had an impact on proliferation, the 
MTS proliferation assay was performed on the cells. Equivalent number of cells from 
controls, UPF3A and UPF3B KO hESCs were plated in quadruplicates and assay 
readings taken from day zero and every two days for six days. Both UPF3A and UPF3B 
KO clones showed reduced proliferation rates compared to the controls, but statistical 










                                                                       
 
Figure 5.13: Loss of UPF3A and UPF3B leads to delayed cell cycle progression. 
           
a) Cell cycle analysis of UPF3A and UPF3B KO hESCs. Single cells were collected prior 
to passaging. Cells were fixed and nuclear stained with PI and FACS analysis performed 
n=4 independent control clonal lines compared to n=3 independent UPF3A KO and n=3 
UPF3B KO hESC lines. b) Real time qPCR analysis of mRNA cell cycle inhibitors. n=4 
independent control clonal lines compared to n=3 independent UPF3A KO and n=3 
UPF3B KO hESC lines performed in triplicate. All data normalised to ACTB mRNA 
expression. c) Cell proliferation assay was performed using the MTS proliferation kit. 
n=4 independent control clonal lines compared to n=3 independent UPF3A KO and n=3 
UPF3B KO hESC lines. Experiment was performed in quadruplicate. Graphs represent 
mean value for each genotype, error bars represent standard deviation. *p<0.05, 
**p<0.001, ***p<0.0001significantlly different to controls by student T-test assuming 
equal variance. 
G1 S G2/M
Controls 25.0 40.8 34.2
UPF3A KO 18.6 35.8 45.5



















































































5.3 Discussion  
 
Null mutations in NMD factors Upf1, Upf2, Upf3a, Smg1 and Smg6 result in early 
embryonic lethality in mice. Death has been shown to occur after the immediate 
implantation stage to between embryonic stage (E) 9.5 (Li et al. 2015; McIlwain et al. 
2010; Medghalchi et al. 2001; Shum et al. 2016; Weischenfeldt et al. 2008). This indicates 
that these NMD factors are not essential at the blastocyst or epiblast stage but are however 
required during gastrulation. This suggests that even though these NMD factors are 
embryonic lethal, it is possible to generate viable KO hESCs of these NMD factors.  
 
To determine the role of UPF3A and UPF3B in neurodevelopment, and the role of 
UPF3A in NMD, UPF3A and UPF3B KO hESCs were generated using CRISPR/Cas9 
genome editing technology (Chapter 3). The insertions and deletions (indels) created in 
the UPF3A and UPF3B KO hESC clones resulted in the introduction of PTCs in their 
respective ORFs. UPF3A KO clones had reduced UPF3A mRNA levels compared to 
the controls. UPF3B mRNA levels were slightly upregulated and not degraded in 
UPF3B KO clones, suggesting they were escaping NMD. Western blot analysis of 
protein lysates extracted from UPF3A and UPF3B KO hESCs indicated that the 
frameshift mutations did completely inhibit functional full-length protein production 
(Figure 5.5). UPF3A protein was stabilised in UPF3B KO clones validating the 
existence of the posttranscriptional regulatory switch originally discovered in non-
hESCs (Chan et al. 2009) (Figure 5.6). This stabilisation is thought to compensate for 
loss of UPF3B as UPF3A is a ‘weak NMD activator’. For example in patients with loss 
of function mutations in UPF3B, UPF3A is stabilised. The level of UPF3A stabilised 
was different between patients. Patients with more UPF3A stabilised generally 




NMD is self-regulated by a negative feedback regulatory network. When NMD is 
perturbed, the NMD factors are upregulated suggesting a buffering mechanism that 
regulates the NMD magnitude (Huang, L et al. 2011). UPF1 and UPF2 transcript levels 
were significantly upregulated only in UPF3B KO clones and unaffected in UPF3A KO 
clones (Figure 5.7). This implies that loss of UPF3A does not exert a strong reduction in 
NMD (as seen by it not having an impact on the classical NMD targets (ATF4 and GAS)), 
or that it operates in a separate NMD pathway branch (e.g. alternative branch) or fashion 
that does not target UPF1 and UPF2 (Huang, L et al. 2011). The NMD factor transcripts 
that were upregulated have NMD inducing features (Huang & Wilkinson 2012; 
Yepiskoposyan et al. 2011).  
 
The NMD substrate genes involved in the stress response pathway (cJUN, GADD45B, 
ATF3) were significantly downregulated in both the UPF3A and UPF3B KO clones while 
GAS5 and ATF4 were only upregulated in UPF3B KO clones. GADD45B and ATF3 were 
surprisingly downregulated rather than upregulated (Figure 5.8). These two genes are 
known bona fide NMD targets. A reason for this could be attributed to culture conditions 
(i.e. presences of stress factors)/passage number as these genes are also involved in the 
stress response pathway. Cells at a lower passage number were collected and the 
transcripts levels of cJUN, GADD45B, ATF3 were re-analysed. These transcripts were 
unaffected at the lower passage number. This suggest that either the passage number or 
culture conditions had an impact on the expression of these genes. Extended cell culture 
can also have a considerable influence on the gene expression profile and subsequent 
characterisation of hESCs (Allegrucci et al. 2007). DMEM based media used for 
culturing hESCs contain 500-1500 fold more of physiological concentrations of 
methionine/folate cycle components (Steele et al. 2005) an environment that would 




PANK2 and SMG5 which are the alternative NMD substrates were not affected in both 
UPF3A and UPF3B KO clones indicating that UPF3A and UPF3B do not have a role in 
the alternative NMD pathway. From RNA Seq data from UPF3B iPSCs (Miles 
Wilkinson, personal communication), three (HIST1H2AC, ANXA1, HNMT) of the 
deregulated transcripts could be validated in the UPF3B KO clones. As this analysis was 
not robust enough to be able to effectively analyse the impact of UPF3A and UPF3B on 
the transcriptome in hESCs, RNA Seq analysis was performed which is presented in 
Chapter 6.  
 
Loss of UPF3A and UPF3B NMD factor genes were predicted to have an impact on the 
UPR stress response pathway as protein coding mutations can increase the levels of 
misfolded proteins in the ER (Hetz et al. 2003; Valastyan & Lindquist 2014). NMD is a 
quality control pathway that degrades transcripts with PTCs to prevent the production of 
truncated proteins (Popp & Maquat 2014). A defective NMD pathway could therefore 
lead to accumulation of transcripts with PTCs due to mutations or aberrant/alternative 
splicing that could potentially lead to excess misfolded proteins in the ER. NMD is known 
to play a role in regulating NMD targets ATF3 and ATF4 (Mendell et al. 2004) which 
encode transcription factors involved in the UPR pathway (Goetz & Wilkinson 2017). 
upf1 and upf2 mutant yeast had protein aggregates that were similar to protein aggregates 
caused by misfolding (Jamar, Kritsiligkou & Grant 2018). The transcript levels of three 
different sensors that are normally upregulated by activation of the UPR pathway were 
analysed using real time qPCR. UPF3A and UPF3B KO clones had a reduction in 
EIF2AK3 and ERN2 transcripts, however this was not significant. UPF3B KO clones had 
a slight insignificant increase in ATF6 transcript levels. DDIT3 a downstream target of 
ATF4 was significantly downregulated in UPF3A KO clones (Figure 5.11). These results 




UPR pathway in hESCs. This suggests that the perturbation of the classical NMD 
pathway elicits no significant ER stress in hESCs.  
 
Loss of either UPF3A or UPF3B in hESC cells was able to trigger the initial stages of 
differentiation by causing a reduction in transcript levels of the human embryonic stem 
cell markers SOX2 and OCT3/4 respectively. Loss of UPF3B led to an increase in 
transcript levels of MESDC2, an early mesodermal marker and CLDN6 which is an early 
endodermal marker, while loss of UPF3A lead to an upregulation of CLDN6 only. High 
NMD activity is maintained during hESCs differentiation into the mesodermal and 
ectodermal cell lineages, whilst NMD activity is downregulated during hESCs 
differentiation into the endoderm (Lou et al. 2016). Loss of both UPF3A and UPF3B 
triggered the initial stages of endoderm differentiation (Figure 5.12). The WNT pathway 
inhibits the endoderm lineage differentiation (Loh et al. 2014). Inhibition of NMD causes 
an upregulation of negative regulators of the WNT signalling pathway (Lou et al. 2016). 
MESDC2, an early mesodermal lineage marker (Holdener et al. 1994) is also known to 
inhibit WNT/β-catenin signalling (Lin et al. 2011) and therefore could be playing a role 
in driving the UPF3B KO clones towards the endoderm differentiation. The initial stages 
of differentiation that was caused by loss of UPF3A and UPF3B was supported by a 
significant impact on cell cycle progression and cell proliferation albeit insignificant. The 
cell cycle defects in both the clones could also be attributed to loss of pluripotency. In the 
UPF3B KO hESCs clones, the cell cycle was slightly but not significantly blocked at the 
G1 phase and downregulation of OCT3/4 was also observed (Figure 5.12a, Figure 
5.13a). OCT3/4 a pluripotency cell marker is important in cell cycle progression and its 
downregulation prevents proliferation by blocking the G1 cell progression (Lee et al. 
2010). In addition to causing an enrichment in the G1 phase, cells were reduced in the 




phase, and had an enrichment of cells in the G2/M phase (Figure 5.13a). The cell cycle 
inhibitors CDKN1A and CDKN2A were deregulated only in UPF3B KO hESCs clones 
and unaffected in UPF3A KO hESCs clones suggesting that the defect in cell cycle in 
UPF3A KO hESCs could be attributed to other factors other than deregulation in cell 
cycle inhibitors (Figure 5.13b). 
 
In conclusion CRISPR/Cas9 genome editing technology was faithful in generating 
UPF3A and UPF3B KO hESCs with no protein expression. In UPF3B KO hESCs 
UPF3A protein was stabilised, a phenomena been previously described as evidence of a 
compensatory NMD mechanism in other cell types which occurs in UPF3B depleted cells 
(Chan et al. 2009; Jolly et al. 2013; Nguyen et al. 2012)  Loss of UPF3A in hESCs had 
no impact on the buffering feedback loop mechanism and the classical NMD targets such 
as ATF4 and GAS5, which were regulated by UPF3B. However, both the genes caused a 
defect in cell cycle progression although distinct and induced the initial stages of 
endoderm differentiation. The stress response genes which are bona fide NMD targets 
are not ideal indicators of NMD as cell culture conditions/passage number can impact 
their expression. As the main aim of this study was to study UPF3A and UPF3B in a 
human brain model, in the next chapter UPF3A and UPF3B KO hESCs were 
differentiated into NSC and RNA Seq analysis performed at both hESC and NSC stage 









Chapter 6 – Transcriptome-wide impact of loss of 































Neural differentiation of hESCs lacking UPF3A or UPF3B in vitro can provide an 
understanding on the role of NMD in human neurodevelopment. Loss of UPF3B causes 
a broad spectrum of NDDs in humans and leads to defects in learning and neurogenesis 
in mice while heterozygous copy number losses of UPF3A is associated with neural tube 
defect (Addington et al. 2011; Huang et al. 2018; Laumonnier et al. 2010; Luo et al. 2000; 
Nguyen et al. 2012; Tarpey et al. 2007). Mutations in other NMD and EJC factors also 
have effects on neurogenesis and behaviour (Alachkar et al. 2013; Colak et al. 2013; Long 
et al. 2010; Silver et al. 2010; Wittkopp et al. 2009).  
 
To begin to determine the role of UPF3A and UPF3B in human neurodevelopment, in 
this chapter UPF3A and UPF3B KO hESCs were successfully differentiated into NSCs 
using the dual SMAD inhibition method (Shi, Kirwan & Livesey 2012). The generated 
NSCs exhibited reduced pluripotency markers and an increase in NSC markers.  
Transcriptome profiling was performed on mRNA extracted from UPF3A and UPF3B 
KO hESCs and NSCs. Validation of the RNA Seq analysis was performed on the same 












6.2.1 Neural differentiation of UPF3A and UPF3B-deficient NMD hESCs into 
NSCs. 
 
UPF3A and UPF3B KO hESCs were differentiated into NSC lines using the dual SMAD 
inhibition method (Shi, Kirwan & Livesey 2012) . The synergistic action of the SMAD 
inhibitors Noggin and SB431542 are efficient in driving the differentiation of hESCs to 
NSCs through inhibiting the Activin/Nodal/BMP kinase receptors. Inhibition of these 
kinase receptors inhibits downstream SMAD signalling and drives neuroectodermal 
differentiation. This method recapitulates temporal development of neural cell 
populations in vivo in a step wise manner and generates dorsal cortical excitatory neurons 
(Chambers et al. 2009; Shi, Kirwan & Livesey 2012; Shi et al. 2012).  
 
The first observable neural cell population derived from hESCs after neural induction is 
reminiscent of the neuroepithelia of the neural plate and occurs approximately 8 to 12 
days after neural induction. These NSCs maintain the expression of SOX2 and begin 
expressing neuroepithelial markers such as Nestin, SOX1, SOX3, PSA-NCAM and 
MUSASHI-1 (Dhara & Stice 2008). The neuroepithelial layer is subsequently replaced 
by a second population of NSCs, ‘neural rosettes structures’ and occurs between days 12-
17 of neural differentiation (Shi, Kirwan & Livesey 2012). Neural rosette structures are 
NSCs that express markers of the neuroepithelial cells of the neural plate in vivo and 
arrange radially forming structures reminiscent of the in vivo structural formation of the 
developing neural tube (Figure 6.1) (O'Rahilly & Müller 2007).  
 
NSCs are derived from single cell dissociation of neural rosettes and serial passaging in 




have the ability to divide over extended periods in culture. They maintain the expression 
of marker genes that define NSCs rosettes (PAX6, Nestin) but loose the radial 
arrangement of rosette structure NSCs. Cells are instead found in random/lattice like 
arrangements. Upon withdrawal of mitogens, these NSCs have the capacity to 




Figure 6.1: Neural induction using the dual SMAD inhibition method.  
Addition of the SMAD inhibitors Noggin and SB431542 to high density hESC cultures 
prevents differentiation into the trophectoderm, mesendoderm and ectoderm leading to 
the neural default state. Efficient generation of neural cells from hESCs leads to 
neuropithelial cells and subsequently neural rosettes. As the differentiation progresses it 
leads to the reduction in pluripotency markers (OCT4) and upregulation of neural 
markers (SOX1, PAX6). Image modified from (Chambers et al. 2009). 
 
 
Controls, UPF3A and UPF3B KO hESCs were differentiated by plating hESCs as 
colonies on Vitronectin Nunc coated 35 mm dishes. Approximately 5 to 6 days post 
passaging, cultures were differentiated using the above described dual SMAD inhibition 
method (Shi, Kirwan & Livesey 2012). After the appearance of neural rosettes at day 13 
and their expansion (section 2.1.4.3), NSCs were generated by dissociating neural 




bFGF and 20 ng/mL EGF. Neural rosettes (day 15) and NSCs (P4) were collected and 
fixed for immunofluorescence and RNA collected from NSCs at both the neural rosette 
stage and from derived NSC lines for analysis. Only NSCs RNA was submitted for 
analysis. Immunofluorescence was used to visualise the expression of marker gene 
proteins which define the NSCs at the neural rosette and NSC stage. Figure 6.2 shows 
representative images of neural rosettes and NSCs derived from hESC controls, UPF3A 
and UPF3B KO clones. The controls and KO clones all differentiated efficiently to NSCs 
with no overt differences morphologically.  
 
To further analyse the neural differentiation experiment, RNA Seq data was used to 
analyse markers of pluripotency, endoderm, mesoderm and ectoderm lineages in hESCs 
and NSCs. The results indicated a reduction in the pluripotent markers and an increase in 
expression of neural markers in NSCs as expected. Most of the mesoderm and endoderm 
markers remained unchanged in both hESCs and NSCs or either downregulated in NSCs 








Figure 6.2: UPF3A and UPF3B KO neural rosettes and neural stem cells.  
Neural rosettes and NSCs were generated from controls, UPF3A and UPF3B KO hESCs. 
hESC clones were directed to differentiate to NSCs via the 2D dual-SMAD inhibition 
culture system. After 15 days neural rosettes were fixed and stained with N-Cadherin to 
identify the neural rosette structures, and DAPI and PAX6 to identify the cell type. After 




and stained with neural cell markers Nestin and PAX6. a) Representative 
immunofluorescent images of neural rosettes stained with DAPI (blue), PAX6 (red) and 
N-Cadherin (green). b) Representative immunofluorescent images of NSCs stained with 






Figure 6.3: Genome-wide analysis of pluripotent and tri-lineage markers in 
UPF3A and UPF3B KO clones in hESCs and NSCs.  
The mRNA expression level of the pluripotency, endoderm, mesoderm and ectoderm 
germ layers genes extracted from RNA Seq analysis of hESCs and NSCs clones and 
visualised using a heatmap. hESCs (controls n=4, UPF3A KO n=3, UPF3B KO n=3). 













































Another way to determine the success of the neural differentiation in addition to staining 
the NSCs with neural markers was using the RNA-Seq data that was generated from 
analysing the transcriptome changes from hESCs to NSCs in the three genotypes 
(controls (wildtype), UPF3A and UPF3B KO) individually. The principal component 
analysis (PCA) of the global gene expression profiles of all data sets showed that the 
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Figure 6.4: Gene-edited KO hESCs and NSCs have different global gene 
expression profiles  
Principal component analysis (PCA) of gene expression profiles of hESCs and NSCs. 
RNA was extracted from control (n=4), UPF3A KO (n=3) and UPF3B KO (n=3) hESCs 
and controls (n=3), UPF3A KO (n=3) and UPF3B KO (n=2) NSCs. The RNA was 
subjected to RNA Seq. Samples are coloured based on their genotype and shapes 
represent the different cell types. 
 
Changes in the transcriptome in hESCs and NSCs were compared between the three 
genotypes to determine shared genes.  The differentially expressed genes that were shared 
with a log fold change of 2 and p<0.05 (3735 genes) were considered to represent genes 
involved in the differentiation process (Figure 6.5a). These genes were subjected to Gene 
ontology (GO) analysis (Yu et al. 2012). The highest top ten significant GO terms 
associated with these commonly differentially expressed genes between hESCs and 
NSCs identified pathways involved in neuron differentiation, axogenesis, neuronal cell 
body and neuron to neuron synapse, which aligns with successful neural differentiation 





Control hESC vs Control NSC UPF3A KO hESC vs UPF3A KO NSC 














Figure 6.5: The common genes shared between the genotypes from the hESCs and 
NSCs stage had GO terms for neural cell function and development.  
RNA was extracted from control (n=4), UPF3A KO (n=3) and UPF3B KO (n=3) hESCs 
and controls (n=3), UPF3A KO (n=3) and UPF3B KO (n=2) NSCs. The RNA was 
subjected to RNA Seq. The transcriptome changes in the three separate genotypes 
(controls, UPF3A KO and UPF3B KO) were analysed in hESCs and NSCs. Changes 
were compared between genotypes to identify shared genes. a) Venn diagram showing 
the shared genes between controls, UPF3A and UPF3B KO clones. b) Shared genes with 
a log fold of 2 and p<0.05 (3735) highlighted with a red circle in (a) were analysed using 
GO analysis to identified the pathways the differentially expressed genes are involved in. 
 
 
Even though the neural differentiation was successful based on IF and 
transcriptome analysis, the principal component analysis (PCA) of the global 
expression of NSCs showed variation between the controls (Figure 6.6). Because 
the differentiation of NSCs from hESCs protocol requires approximately a month 
this may increase heterogeneity of the final neural cell population (Kim et al. 2014). 







Figure 6.6: PCA plot showing controls, UPF3A and UPF3B KO NSCs. 
Principal component analysis (PCA) of gene expression profiles of NSCs. Samples are 





6.2.2 NMD factors are differentially expressed in hESCs and NSCs  
 
UPF1, UPF2 and UPF3B are highly expressed in hESCs compared to differentiated 
human cells and their level decreases upon loss of pluripotency (Lou et al. 2016). UPF1 
has been shown to be downregulated by microRNA-128 (miR-128), a neural expressed 
miRNA during neural differentiation (Karam & Wilkinson 2012). Downregulation of 
NMD also occurs to permit muscle (Gong et al. 2009), epidermal keratinocyte and human 
pancreatic progenitor cell differentiation (Lou et al. 2016). The expression of NMD and 
EJC factors were compared in hESCs and NSCs using the RNA Seq data. Indeed the 
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NMD factors, UPF2 and UPF3B were reduced in NSCs compared to hESCs, while UPF1 
levels were variable. However other NMD (SMG1, SMG6, SMG7 and SMG9) and EJC 
factors (NBAS and RMB8A) were increased in NSCs (Figure 6.7). This difference in 
NMD and EJC factors across the hESCs and NSCs may possibly be due to the different 
NMD pathways operating in the different cell types. NMD efficiency has been shown to 
differ across cell and tissue type (Bateman et al. 2003; Huang, L et al. 2011; Zetoune et 
al. 2008).  
 
 
    
 
Figure 6.7 NMD factors are differential expressed in hESCs and NSCs. 
The mRNA expression levels of NMD and EJC genes were extracted from the RNA Seq 
data of hESCs and NSCs clones and visualised using a heatmap. hESCs (controls n=4, 
UPF3A KO n=3, UPF3B KO n=3). NSCs (controls n=3, UPF3A KO n=3, UPF3B KO 





















6.2.3 UPF3A is important in regulating early embryonic development.  
 
The function of UPF3A in the NMD mechanism has not yet been elucidated with data 
suggesting conflicting roles. Studies suggests it may act as a weak NMD activator (Kunz 
et al. 2006; Lykke-Andersen, Shu & Steitz 2000), while others suggest it is an NMD 
inhibitor with some residual NMD activity (Shum et al. 2016). Another study suggested 
it does not have a role in NMD as UPF3A knockdown in HeLa cells had little no effect 
on the transcripts that were affected by either knockdown of UPF1 and UPF3B (Chan et 
al. 2007). To determine the role of UPF3A in NMD in hESCs and NSCs, differentially 
expressed genes were identified in UPF3A KO hESCs and NSCs compared to controls. 
Genes that were differentially expressed by at least two-fold with a p<0.05 were used for 
downstream analysis.  
 
The principal component analysis (PCA) of the global gene expression profiles of hESCs 
showed that the three genotypes (controls, UPF3A KO and UPF3B KO) clustered into 
three distinct groups with collection dates having an impact on the clustering of UPF3A 
KO and control hESCs (Figure 6.8). In hESCs, loss of UPF3A had no impact on the 
transcriptome. This suggests that UPF3A is not important or has no role in the embryonic 
stem cell state. However, loss of UPF3A in NSCs led to a 3.03% deregulation of the 
transcriptome (425 of 14022 of genes expressed). Of the 425 genes that were 
differentially expressed, 2.96% (415 of the 14022 transcripts expressed) were 
downregulated, whereas only 0.07% transcripts (10 of the 14022) were upregulated 
(Figure 6.9a). The top 40 upregulated and downregulated genes are presented in 
Appendix 5 and 6. Some of the deregulated transcripts (BMP2, BMP4, SMAD7, TGFB1, 
TGFB, TGFBR2) are involved in the transforming growth factor β (TGF-β) pathway. GO 




signalling pathways regulated by the TGF-β superfamily pathway. Genes important in 
cell cycle progression (CDKN1A, CDKN2A, CDKN2B) were also deregulated (Figure 




Figure 6.8: PCA plot showing controls, UPF3A and UPF3B KO hESCs. 
Principal component analysis (PCA) of gene expression profiles of hESCs. Samples are 
coloured based on their genotype and shapes indicate the two different dates of cell pellet 
collection. Controls hESCs n=4, UPF3A KO hESCs n=3, UPF3B KO hESCs n=3. 
 
 
The TGF-β superfamily is a regulator of embryonic development (Gordon & Blobe 
2008). It is important to regulate embryonic development and cellular homeostasis such 
as regulation of proliferation, differentiation, apoptosis and extracellular matrix (ECM) 
remodelling in a cell (Battegay et al. 1990; De Caestecker 2004; Massague 2000; 
Massagué & Gomis 2006; Siegel & Massague 2003). A defective TGF-β pathway leads 
Control, Group 1 
Control, Group2 
UPF3A KO, Group 1 
UPF3A KO, Group 2 
UPF3B KO, Group 1 





to developmental disorders, vascular diseases and cancer (Blobe, Schiemann & Lodish 
2000; Massagué, Blain & Lo 2000). The top 3 biological processes affected by loss of 
UPF3A in NSCs are ECM, extracellular structure organisation and blood vessel 
development. GO analysis performed on genes expressed on cortical neurons after 
differentiation revealed that approximately 45.3% of GO terms were enriched in 
categories involved in nervous system development and central nervous system 
development while 29.47% of GO terms were enriched in categories involved in embryo 
development, organ morphogenesis and circulatory system development (van de 
Leemput et al. 2014). Therefore it is not unexpected to see such GO terms in the UPF3A 
KO clones. ECM is generated in early life and mutations in genes that encode ECM 
components can lead to embryonic lethality (Bateman, Boot-Handford & Lamande 2009; 
Hynes 2009). Lack of TGF-β signalling due to TGF-β receptor mutations in mouse 
embryonic cells causes embryonic lethality at around E10.5 (Carvalho et al. 2007), while 
deletion of either the TGF-β 1 ligand in mice severely disturbs vasculogenesis in the yolk 
sac and leads to embryonic lethality at mid gestation (Arthur et al. 2000; Carvalho et al. 
2004; Dickson et al. 1995; Larsson et al. 2001; Leveen et al. 2002). Loss of UPF3A in 
NSCs suggests that it may have a negative impact on TGF-β pathway signalling and loss 
of UPF3A leads to defects in early development. The deregulated genes in NSCs do not 
have an impact on neural development or function but are however involved in pathways 





















b) Biological processes 
 
 
Figure 6.9: Loss of UPF3A has a negative impact of pathways that are regulated 
by the TGF-β pathway  
RNA was extracted from NSCs from controls (n=3), UPF3A KO (n=3) and UPF3B KO 
(n=2) clones and subject to RNA Seq analysis. a) Volcano plot showing all deregulated 
genes with p<0.05. b) GO analysis was performed on differentially expressed genes with 
a log fold change of 2 and p<0.05 presented using ClusterProfiler to visualise the genes 
and pathways affected. Red boxes highlight genes that are deregulated that are involved 
in the TGF-β pathway and black boxes highlight genes that are deregulated in UPF3A 












6.2.4 Loss of UPF3B in hESCs and NSCs lead to a deregulation of pathways 
involved in neural function.  
 
To determine the changes in the transcriptome due to loss of UPF3B in hESCs and NSC, 
RNA Seq analysis was performed on RNA extracted from the UPF3B KO hESCs and 
NSCs. Genes that were differentially expressed by at least two-fold with a p<0.05 were 
used for analysis. The deregulated genes in the UPF3B KO hESCs had roles in neural 
function and brain development. Loss of UPF3B in hESCs also resulted in deregulation 
of genes involved in cell cycle progression such as CDKN1A. GREM1, an inhibitor of the 
bone morphogenetic proteins (BMPs) (Walsh et al. 2010) has been shown to have a role 
in cell proliferation and growth was upregulated (Curran et al. 2012; Frank et al. 2006; 
Maciel, Melo & Campos 2009; Maciel et al. 2008; Sneddon et al. 2006) (Figure 6.10 and 
Appendix 10).  
 
Loss of UPF3B in hESCs resulted in a deregulation of 0.62% (90 of the 14569 expressed 
genes) of the transcriptome. From the deregulated genes, 0.21% (31 of 14569) were 
upregulated while 0.41% (59 of 14569) were downregulated. The top 40 down and 
upregulated genes are presented in Appendix 5 and 6. GO analysis of genes that were 
deregulated had GO terms that were involved in neural function and brain development 
such as regulation of post synaptic membrane potential, synapse assemble and calcium 
ion binding. (Figure 6.10 and Appendix 10). Despite these genes involvement in neural 
function and development, they are normally expressed in hESCs such as ADGL3 
(LPHN3), SHANK1, GABBR1, NETO1 and PCDH10. The top two significant biological 
GO terms were homophillic cell adhesion via plasma membrane adhesion molecules and 
cell-cell adhesion via plasma membrane adhesion molecules and the top deregulated 
pathway in molecular functions was calcium ion binding (Figure 6.10). The affected 




Protocadherins are a subgroup of cadherins superfamily (Sano et al. 1993). 
Protocadherins are transmembrane proteins with β folds connected by a linker that binds 
2-3 calcium ions. Cadherin-mediated interactions are calcium ion dependent and mediate 
calcium-dependent homophilic cell-cell recognition and adhesion (Chitaev & 
Troyanovsky 1998). The deregulated genes involved in homophillic cell adhesion via 
plasma membrane adhesion molecules and cell-cell adhesion via plasma membrane 
adhesion molecules are also involved in synapse assembly. Synapses are site of cell-cell 
adhesion and intercellular communication (Missler, Sudhof & Biederer 2012). Cadherin 
are also known synaptic cell adhesion molecules. (Pokutta & Weis 2007).  
 
NETO1 is a gene required for synaptic plasticity and learning in mice (Ng et al. 2009), 
while SHANK1 is involved in synapse assembly and neuronal signalling (Naisbitt et al. 
1999). LRRC4B, amongst the deregulated gene is implicated in ASD (Jiang et al. 2013), 
schizophrenia (Kirov et al. 2012; Purcell et al. 2014) and ID (Sangu et al. 2017). LRRC4B 
is a member of the Netrin-G ligand 2 (NGL-2), which belongs to the NGL family of 
synaptic adhesion molecules (Woo, Kwon & Kim 2009). NGL-2 is detected at 
postsynaptic locations (Um et al. 2018) and is important in regulating the strength of 
synaptic transmission (DeNardo et al. 2012). Neurotransmitter level regulation at the site 
of release is essential for proper neuronal function (Anbalagan et al. 2019). LPHN3 
(ADGRL3) a gene that was also upregulated is associated with ADHD (Choudhry et al. 
2012). LPHN3 is a brain specific member of the LPHN subfamily of G-protein coupled 
receptors which are important in regulation of neurotransmitters exocytosis (Linets'ka, 
Storchak & Himmelreich 2002) and synaptic development (O'Sullivan et al. 2014). In 
addition to the involvement in cell to cell contacts and in synapse assembly, some of the 
deregulated genes were also implicated in NDDs for example SCG2, a schizophrenia 




et al. 2013; O'Donnell et al. 2010) and SHANK1 (Gong & Wang 2015; Sato et al. 2012) 
which are ASD associated genes. Loss of UPF3B in hESCs resulted in deregulation of 
















b) GO analysis of differentially expressed genes in UPF3B KO clones 
 
 
Figure 6.10 UPF3B is important in neurodevelopment and function. 
RNA was extracted from hESCs from controls (n=4), UPF3A KO (n=3) and UPF3B KO 
(n=3) clones and subject to RNA Seq analysis. Deregulated genes with a p<0.05 were 
presented on a volcano plot while deregulated genes with a log fold change of 2 and 
p<0.05 were used for GO analysis using ClusterProfiler. a) Volcano plots showing the 
changes in the transcriptome in UPF3B KO hESCs. b) Gene ontology analysis using 






Loss of UPF3B in NSCs lead to a deregulation of 0.29% (41 of 14022 expressed genes) 
of the transcriptome. From the deregulated genes, 0.07% (10 of 14022 expressed genes) 
were upregulated and 0.22% (31 of 14022 expressed genes) downregulated (Figure 
6.11). This was unexpected as more genes would be expected to be upregulate. RNA seq 
analysis of the UPF3B deficient NSCs also revealed that some of the genes that were 
deregulated had important functions in neurodevelopment (ROBO2, NRXN1) and were 
implicated in NDDs such as ARX, MAP6 and RELN. Neurexin 1 (NRXN1) is a 
presynaptic neuronal adhesion molecule that interacts with postsynaptic neuroligins in 
both glutamatergic and GABAergic synapses and is important in synaptic formation and 
function (Reissner et al. 2008) while ROBO2 promotes axon interaction and guidance 
(Hocking et al. 2010). However no GO terms were identified from this data. This could 
have been that they were no genes that were enriched for a particular pathway. The results 
from UPF3B KO hESCs and NSCs suggest UPF3B is important for normal 
neurodevelopment and loss of UPF3B results in deregulation of genes important for 
synaptic strength regulation and neural activity.  






Figure 6.11 Volcano plot showing the UPF3B KO NSCs transcriptome. 
RNA was extracted from NSCs from controls (n=3), UPF3A KO n=3 and UPF3B KO 
(n=2) clones and subject to RNA Seq analysis. Deregulated genes with a p<0.05 were 




6.2.5 Impact of loss of UPF3A and UPF3B on neural differentiation  
 
To determine how the changes in the transcriptome from hESCs to NSCs was affected 
by loss of either UPF3A or UPF3B, the three genotypes (control (wildtype), UPF3A KO 
and UPF3B KO) were compared from hESCs Vs NSCs. These changes were then 
compared between genotypes. The Venn diagram shows the number of unique and shared 
genes that were identified in this analysis (Figure 6.5a) in controls, UPF3A and UPF3B 
KO clones. The common 3735 genes in the three genotypes showed an enrichment of 




genes specific for neuronal cells (Figure 6.5b). When GO analysis was performed using 
the unique genes in the UPF3A and UPF3B KO clones only five GO terms were 
identified in UPF3A KO clones and none in UPF3B KO clones. The UPF3A KO clones 
had GO terms enriched with genes involved in the inflammatory response (Figure 6.12).  
 
The inflammatory response like the other intracellular signalling pathways regulated by 
the TGF-β superfamily pathway was affected by loss of UPF3A in NSCs. This pathway 
regulates the generation and effector functions of immune cell types (Flavell et al. 2010; 
Sanjabi, Oh & Li 2017). TGF-β is a pleiotropic cytokine involved in both suppressive 
and inflammatory immune responses (Sanjabi, Oh & Li 2017) and controls immune cell 
function (Kehrl et al. 1986). TGF-β is known to supress T cell proliferation and controls 
its effector functions. TGF-β also inhibits the expression of effector molecules by CTLs 
such as IFN-γ and perforin (Ahmadzadeh & Rosenberg 2005; Bonig et al. 1999; Ranges 









Figure 6.12 Loss of UPF3A affected the inflammatory response pathway during 
the differentiation of hESCs to NSCs. 
RNA was extracted from control (n=4), UPF3A KO (n=3) and UPF3B KO (n=3) hESCs 
and controls (n=3), UPF3A KO (n=3) and UPF3B KO (n=2) NSCs. The RNA was 
subjected to RNA Seq. The transcriptome changes in the three genotypes (controls, 
UPF3A KO and UPF3B KO) were analysed in hESCs Vs. NSCs. Changes were 
compared in each genotype from hESCs to NSCs, the changes were then compared 
between the genotypes to identify shared and unique genes. ClusterProfiler to visualise 
the unique genes and pathways affected from UPF3A KO during the differentiation of 











6.2.6 Validation of RNA Seq data 
 
To validate the RNA Seq analysis data, 5 genes were selected from the analysis and 
Taqman RT-qPCR performed on the mRNA that was sent for RNA Seq (hESCs and 
NSCs) and the additional RNA samples collected from the neural rosette stage cultures. 
NETO1 and LRRC4B were two genes that were deregulated in UPF3B KO hESCs that 
have a role in neurodevelopment and are associated with NDDs. NETO1 was upregulated 
and LRRC4B downregulated in hESCs as shown in the RNA Seq data. LLRC4B was also 
significantly downregulated at the neural rosette stage, while NETO1 was significantly 
upregulated in NSCs in addition to hESCs. ARX and ROBO2 were selected in UPF3B 
KO NSCs, and were significantly downregulated in NSCs. ARX was not detected in 
hESCs and was significantly downregulated in neural rosettes and NSCs while ROBO2 
was downregulated only in NSCs. For UFP3A KO NSCs HAS2, an important enzyme for 
hyaluronic acid synthesis (Cai, Li & Na 2011) was selected for validation. HAS2 is 
important for mesendoderm differentiation in human (Xu et al. 2018) and Has2 null mice 
die mid gestation with a reduced body size and severe cardiac and vascular abnormalities 
(Camenisch et al. 2000). This gene was also significantly upregulated in UPF3A KO 
hESCs and in UPF3B KO neural rosettes. From the 5 genes that were selected all 












Figure 6.13: Validation of RNA Seq analysis 
RNA expression levels of five genes selected to validate RNA Seq analysis using 
Taqman.  Gene expression was analysed on mRNA extracted from hESCs (controls n=4, 
compared to UPF3A KO n=3, UPF3B KO n=3, experiment performed in triplicate), 
neural rosettes (controls n=4, compared to UPF3A KO n=3, UPF3B KO n=3, experiment 
performed in triplicate) and NSCs stage (controls n=3, compared to UPF3A KO n=3, 
UPF3B KO n=2, experiment performed in triplicate, done in duplicate. All data 
normalised to ACTB mRNA expression. Graphs represent mean value of each genotype, 
errors bars represent standard deviation. *p<0.05, **p<0.01 significantly different to 




6.3 Discussion  
 
To determine the function of UPF3A and UPF3B in NMD in hESCs and in 
neurodevelopment, UPF3A and UPF3B KO hESCs were differentiated into NSCs and 
transcriptome profiling performed on mRNA extracted from UPF3A and UPF3B KO 
hESCs and NSCs. Transcriptome profiling of UPF3A KO hESCs revealed that UPF3A 
most likely, by these measures, does not have a role in hESCs, which are cells derived 
from the inner cell mass of the blastocyst (Guo et al. 2016). hESCs are similar to mouse 
post-implantation epiblast derived stem cells (Brons et al. 2007; Tesar et al. 2007). The 
reason why no genes were deregulated in UPF3A KO hESCs by RNA seq despite having 
an effect on pluripotency (lead to a reduction in SOX2 mRNA and an increase in CLDN6, 
an early endoderm marker) could be speculative (Figure 5.12). This could have been that 
the mRNA expression of the pluripotent markers was performed on different cell pellets. 
However, even in mRNA extracted from UPF3A KO hESCs that was sent for RNA Seq 
analysis, HAS2 a deregulated gene in UPF3A KO NSCs was significantly upregulated in 
UPF3A KO hESCs but not detected in the RNA seq analysis (Figure 6.13). HAS2 is a 
gene important for mesendoderm differentiation in humans (Xu et al. 2018) and its 
upregulation in UPF3A KO hESCs is in support of triggering the initial stages of 
endoderm differentiation. The reason why this is occurring could be due to the 
sensitivities of the different methods.  
 
Transcriptome profiling of UPF3A KO NSCs, however, revealed that loss of UPF3A 
caused a 3.03% deregulation in the transcriptome of which 2.96% were downregulated 
and only 0.07% were upregulated (Figure 6.9). These results suggest that UPF3A may 
act in inhibiting NMD. However, from these genes it was not possible to identify if they 




level as NMD only acts post transcriptionally on mRNAs that contain NMD inducing 
features such as an uORF, alternatively spliced mRNA and long 3’-UTR (>1.5 Kbp). The 
genes that were deregulated are involved in intracellular signalling pathways regulated 
by the TGF-β superfamily pathway (Figure 6.9, Appendices 7-9). In addition to the top 
5 GO terms that were affected, the transmembrane receptor protein serine/threonine 
kinase signalling pathway, wound healing, embryonic morphogenesis and gastrulation 
pathways were also affected. From the genes that were differentially expressed, 3 genes 
were identified (TNFRSF21, TWIST1, GATA6) (Figure 6.9b) that were also deregulated 
in P19 cells were UPF3A was knocked down (Shum et al. 2016).  
 
The suggested deregulation of the TGF-β superfamily pathway in these UPF3A KO 
NSCs may partly explain embryonic lethality in UPF3A null mice. Twist1 null mice are 
embryonic lethal and die at E11.5 with failed fusion of the cranial neural folds (Chen & 
Behringer 1995) and Gata6 null mice die before E7.5 due to failure of visceral endoderm 
differentiation (Xin et al. 2006). These results suggest that even though UPF3A is 
expressed as early as in the one cell stage it is only required later in embryonic 
development. UPF3A null mice death occurs around E4.5 to E8.5 (Shum et al. 2016). 
This may suggest that UPF3A has a critical role during the epiblast stage (when the 
primitive endoderm cells form) and gastrulation (E4.5-E7.5) (Nowotschin & 
Hadjantonakis 2010; Solnica-Krezel & Sepich 2012). The ECM and structure 
organisation were the top two GO terms. ECM is present in all cells and is generated 
early in embryonic life (Hynes 2009). It regulates cellular processes such as adhesion, 
migration, proliferation, differentiation and survival (Daley, Peters & Larsen 2008). 
Among the specific growth factors that control ECM synthesis, the TGF-β is the most 
important (Border & Noble 1994; Verrecchia & Mauviel 2007). ECM is essential and 




(Bateman, Boot-Handford & Lamande 2009). Mutations in ECM protein also lead to 
defects in blood vessel development and affect endoderm differentiation (Alpy et al. 
2005; Lohler, Timpl & Jaenisch 1984; Schnieke, Harbers & Jaenisch 1983; Smyth et al. 
1999). Blood vessel development was the third statistically GO term with the most 
deregulated genes. The cardiovascular system is the first functional organ system to form 
and failure of the proper establishment of this network affects organ development and 
embryo viability (Coultas, Chawengsaksophak & Rossant 2005; Udan, Culver & 
Dickinson 2013). Deletion of SMG1, an NMD factor in mice causes embryonic lethality 
due to embryos failing to form a vascular system and die at E8.5 However, additional 
studies will need to be performed to confirm this hypothesis about the role of UPF3A in 
early embryonic development and the TGF-β superfamily signalling pathway.    
 
Loss of UPF3B in hESCs and NSCs resulted in a deregulation of genes that are involved 
in neural function and brain development (Figure 6.10 and Appendix 10). In hESCs, GO 
terms for cell-cell adhesion via plasma membrane adhesion molecules were observed. 
The cell-cell adhesion system is involved in many aspects of neuronal development 
including cell migration, axon-bundle formation, synapse formation and formation of 
complex glia networks which surround axons and synapses (Togashi, Sakisaka & Takai 
2009). Defects in synapse formation has been shown to lead to NDDs (Verpelli & Sala 
2012). From the genes that were identified in both UPF3B KO hESCs and UPF3B KO 
NSCs, deregulated genes were identified that are important in synapse formation and 
plasticity such as SHANK1, NRXN1, RELN, LRRC4B, LPPHN3 and NETO1 among 





The adhesion systems are important for brain morphology and highly coordinated brain 
functions such as memory and learning (Sanes & Yamagata 1999; Washbourne et al. 
2004; Yamagata, Sanes & Weiner 2003). In early development of the nervous system, 
neurons migrate to their location and elongate their axons towards their target. Growing 
axons are guided by various attractive or repulse target derived cues (Tessier-Lavigne & 
Goodman 1996). After reaching the final destination axonal growth cones recognise their 
target cells and form synapses (Scheiffele 2003). ROBO2, which was downregulated in 
NSCs is the main receptor for directing axons within the dorsal tracts and repels neuron 
cell bodies from the floor plate (Kim, M et al. 2011). Loss of UPF3B in NSCs and neural 
rosettes also lead to a deregulation of genes associated with ID such as ARX. Patients 
with ARX have ID and epilepsy with or without structural defects in the brain such as 
lissencephaly, microcephaly and agenesis of the corpus callosum as well as abnormal 
genitalia (Kato et al. 2004; Katsarou, Moshe & Galanopoulou 2017; Shoubridge, Fullston 
& Gecz 2010).  
 
Transcriptome profiling of UPF3B KO NSCs only led to a 0.29% deregulation in the 
transcriptome. This may be due to the sample size (controls n=3 and UPF3B KO NSCs 
n=2) or the variation in the control samples (Figure 6.6). Even though this would have 
had an impact on analysing the effects of loss of UPF3B in NSCs, there is confidence in 
the results obtained as for example ARX which is downregulated in NSCs is also 
downregulated in neural rosettes (controls n=4 and UPF3B KO neural rosettes n=3) and 
NETO1 which is also deregulated in both UPF3B KO hESCs and NSCs (Figure 6.13).  
 
NMD is known to impact cell cycle and target mRNAs encoding regulators of the cell 




(Azzalin & Lingner 2006; Lou et al. 2016; Lou et al. 2014; Rehwinkel et al. 2005). In 
this study loss of UPF3B in hESCs and UPF3A in NSCs deregulated genes that are 
important in cell cycle progression such as CDKN1A, CDKN2A and CDKN2B which 
encode for proteins that inhibitor cell cycle progression at the G1 phase (Harper et al. 
1995; Zhao et al. 2016). CDKN1A was downregulated in UPF3B KO hESCs, while in 
UPF3A KO NSCs, downregulation of CDKN1A, CDKN2A and CDKN2B was observed.  
 
These results suggest that UPF3B is important in neurodevelopment and the NDDs seen 
in patients with UPF3B mutations could be due to the deregulation of genes that are 
important in neural function and brain development. From the neural genes that were 
affected most of them were involved in cell adhesion and synapse assembly and were 
associated with NDDs. Loss of UPF3A in hESCs did not have any impact in hESCs, 
however, loss of UPF3A in NSCs lead to a 3.03% deregulation of the transcriptome, and 
2.96% of that was downregulated implying that UPF3A may acting as an NMD inhibitor. 
Loss of UPF3A had an impact on the TGF-β signalling pathway. This pathway is 
important in early development and perturbation of this signalling pathway leads to 
embryonic lethality (Carvalho et al. 2007). These results together with the fact that loss 
of UPF3A in mice leads to embryonic lethality, suggests that UPF3A plays an important 
role in early intracellular pathways important in early embryonic development. 
 
From the overall results UP3FA and UPF3B seem to have difference roles. UPF3B is 
important in early embryonic development (hESCs) and leads to NDDs by deregulating 
genes that are important in neurodevelopment and function, thus learning and memory.  
However, UPF3A seems to be important during early development and loss of UPF3A 




support of these genes not acting redundantly, only two genes were shared between 
UPF3A KO NSCs and UPF3B KO hESCs. As UPF3A is postulated to act like an NMD 
inhibitor, its stabilisation in patients with UPF3B mutations is important for the 
downregulations of transcripts that are upregulated in response to loss of NMD activity, 



















































The role of UPF3A and UPF3B in neurodevelopment and the role of UPF3A in NMD 
was elucidated by generating UPF3A and UPF3B KO hESC clones using CRISPR/Cas9 
genome editing technology. A neurodevelopmental model was developed by 
differentiating UPF3A and UPF3B KO hESCs into NSCs. Studies to determine the role 
of UPF3B in neurodevelopment has been performed on patient LCLs, mice, rat and 
Drosophila (Alrahbeni et al. 2015; Huang et al. 2018; Jolly et al. 2013; Nguyen et al. 
2012; Nguyen et al. 2013; Rehwinkel et al. 2005; Tarpey et al. 2007). However, it is 
important to study the molecular basis of a disease using the most appropriate models 
reflecting the affected cells or tissue types as molecular pathways are shaped by cell type 
specific gene expression (Handley et al. 2015). NMD targets are also not conserved 
across species. For example ARHGAP24 which is an NMD target in humans does not 
have an uORF in mice (Jolly et al. 2013). 
 
CRISPR/Cas9 editing technology faithfully generated UPF3A and UPF3B null hESCs 
(Chapter 3). WGS analysis of the gene-edited clones detected an average of 3083 unique 
de novo SNVs in each UPF3A and UPF3B KO clone (Table 4-1). None of the detected 
SNVs were due to off-target mutations but could most likely be attributed to cell culture 
and the presence of mosaicism in the parental cell line as discussed in section 4.2.4. 
Another reason for detecting a high number of SNVs in these clones is that the parental 
cell line H1, which was used for filtering out variants in the gene-edited clones, was at a 
lower passage (56 passages lower). The identification of off-target mutations from unique 
de novo SVs detected large deletions and duplications that overlapped with the predicted 
off-target sites (Table 4-2, Appendix 3). Validation of these variants are still in progress 
to determine if they are real. Despite such a large number of unique de novo SNVs 
detected in each clone, the gene-edited clones, the parental cell line (H1) and an H1 cell 




minor variation between them, when tested using the vcftools relatedness algorithm 
(Table 4-3). 
  
To determine the impact of loss of UPF3A in neurodevelopment and NMD, transcriptome 
profiling was performed on UPF3A KO hESCs and NSCs. Loss of UPF3A causes 
embryonic lethality in mice and embryos die at around E4.5 and E8.5 (Shum et al. 2016). 
This suggests that UPF3A is important between the period of epiblast formation and 
during gastrulation and not at the earlier stages (Tam & Behringer 1997; Tam & Loebel 
2007). Loss of UPF3A in hESCs triggered the initial stages of endoderm differentiation 
and led to defects in cycle cell progression (Figure 5.12, Figure 5.13). Loss of UPF3A 
did not have an impact on UPF1 and UPF2 which are involved in the NMD buffering 
mechanism and did not affect the classical NMD targets GAS5 and ATF4, which were 
upregulated in response to loss of UF3B (Figure 5.7, Figure 5.8).  
 
Transcriptome analysis of UPF3A KO NSCs, revealed that UPF3A led a 3.03% 
deregulation in the transcriptome of NSCs (Figure 6.9). From the genes that were 
deregulated, 97.6% of those were downregulated. This is similar to a study where UPF3A 
was knocked down in P19 cells and found that 83% of the deregulated genes were down 
regulated (Shum et al. 2016). Pluripotency analysis in UPF3A KO hESCs, revealed that 
loss of UPF3A triggered the initial stages of endodermal differentiation (Figure 5.12). 
There is evidence that during endoderm differentiation, NMD activity is reduced. 
Assuming that if indeed UPF3A is an NMD inhibitor, it could be acting as an inhibitor 
during endoderm differentiation. GO analysis showed an enrichment of genes involved 
intracellular signalling pathways regulated by TGF-β superfamily pathway (Figure 6.9, 




Knockdown of UPF3A in P19 cells had GO terms with enriched genes in chordate 
embryonic development, embryonic organ development and neural tube development 
(Shum et al. 2016).  
 
UPF3B is important in hESCs and NSCs. Loss of UPF3B in hESCs resulted in 
upregulation of the classical NMD targets GAS5 and ATF4 and transcripts involved in 
the NMD feedback loop (UPF1 and UPF2) (Figure 5.7, Figure 5.8). Loss of UPF3B 
also led to a reduction in OCT3/4 and upregulation of early markers of the mesoderm and 
endoderm, MEDC2 and CLDN6 respectively (Figure 5.12). This triggering of the initial 
stages of differentiation was supported by defects in cells cycle progression (Figure 
5.13). Transcriptome profiling of UPF3B KO hESCs and NSCs showed that the 
deregulated genes in both the hESCs and NSCs had important roles in neural function 
(LRRC4B, LPHN3, GABBR1, SHANK1) and brain development (ARX, ROBO2) and are 
associated with NDDs. The genes that were deregulated in hESCs were enriched with 
GO terms related to cell-cell adhesion via plasma membrane adhesion molecules, 
regulation of signalling receptor activity, calcium ion binding, intrinsic component of 
postsynaptic membrane and synapse assembly (Figure 6.10 and Appendix 10).  
 
Future Directions     
Loss of UPF3B in hESCs and NSCs lead to deregulated genes that are involved in 
neurodevelopment, neural function and are associated with NDDs. Genes deregulated in 
hESCs affected pathways involved in cell-cell adhesion and homophilic cell adhesion via 
plasma membrane adhesion molecule, regulation of signalling receptor activity, synapse 
assembly and signalling receptor activity. Differentiation of UPF3B KO hESCs into 




are affecting normal neurodevelopment. As synapse assembly was compromised due to 
defects in cell-cell adhesion and homophillic cell adhesion via plasma membrane 
adhesion molecules, performing electrophysiology and microelectrode arrays to study 
cultural networks would be essential. Differentiation of hESCs into neurons would also 
be important for analysing the morphology of neuron structures such as neuritic 
outgrowth, as there is compiling evidence that shows that, loss of UPF3B in neurons lead 
to defects in dendritic spine maturation (Huang et al. 2018) and neurite growth (Alrahbeni 
et al. 2015; Jolly et al. 2013).  
 
Loss of UPF3A in NSCs had a much broader impact, affecting the intracellular pathways 
regulated by the TGF-β superfamily pathway which are important in early development. 
As loss of UPF3A is embryonically lethal, with death occurring around E4.5-E6.5 (period 
between epiblast formation and gastrulation), and mutations in proteins involved in the 
intracellular signalling regulated TGF-β superfamily leading to embryonic lethality at 
around the same period, it could be speculated that UPF3A is important during this 
period, when the epiblast starts to different into the three germ layers. This study revealed 
that UPF3A could be acting like an NMD inhibitor, as NMD activity is normally reduced 
during endoderm differentiation. This suggests that UPF3A might be important for this 
reduction in NMD activity during endoderm differentiation as the primitive endoderm 
occurs as early as E4.5. Differentiating UPF3A KO hESCs into the different lineages and 
performing transcriptome analysis would elucidate the role of UPF3A during 








CRISPR/Cas9 genome editing technology is a suitable and easy method to generate 
mutations in hESCs to model disease. The generated UPF3A and UPF3A KO clones 
faithfully modelled ‘some’ disease pathology already shown to occur in these cells. For 
example, in UPF3B KO hESCs, stabilisation of UPF3A protein was detected, validating 
the existence of the posttranscriptional regulatory switch originally discovered in non-
hESCs (Chan et al. 2009; Jolly et al. 2013; Nguyen et al. 2012)   Our results suggest that 
UPF3A and UPF3B have different roles in NMD and do not act redundantly as loss of 
UPF3A had no impact on the transcripts involved in the NMD feedback loop (UPF1, 
UPF2) and the classical NMD targets (GAS5, ATF4) which were upregulated in UPF3B 
KO hESCs. Even though both loss of UPF3A and UPF3B affected pluripotency and cell 
cycle analysis, the effects were distinct, for example loss of UPF3A affected SOX2, and 
the early marker for endoderm differentiation, while loss of UPF3B caused a reduction 
in OCT3/4 and upregulation of an early marker of the mesoderm and endoderm. In cell 
cycle progression, these paralogs had opposite effects. Loss of UPF3A led to a reduction 
in cells at the G1 phase and enrichment of cells in the G2/M phase, while loss of UPF3B 
led to an enrichment of cells in the G1 phase (although insignificant) and a reduction in 
the G2/M phase. Genes deregulated in UPF3A and UPF3B KO NSC clones also had two 
genes shared, further implying that these gene paralogs are acting on separate pathways. 
The UPF3A and UPF3B KO hESCs in this study are the first to be generated. Extensive 
analysis (WGS, pluripotency, karyotype analysis) has been performed on these CRISPR 








Appendix 1: Optimised CRISPR/Cas9 editing technology in hESCs 
Steps 1-3: Culturing hESCs for CRISPR/Cas9 editing  
1. Culture hESCs as described in section 2.1.1 on an iMEF feeder layer.  
2. Once hESCs are growing well on iMEFs with little differentiation transition to 
feeder free conditions as described in section 2.1.2 
3. Expand cultures for CRISPR/Cas9 genome editing depending on the size of the 
experiment. 
 
Steps 4-17: Preparation of hESCs for CRISPR/Cas9 editing 
4. Coat 100 mm cell culture dishes with 0.1% gelatin for a minimum of 2 hrs or 
overnight at 37°C.  
5. Aspirated gelatin and leave dishes in the hood to dry for an hr. 
6. Thaw iMEFs and plate at a density of 1x106 in a 100 mm culture dish with MEF 
medium. 
7. The following day aspirate iMEF medium and rinse once with DPBS.  
8. 11 mL of complete hESC medium with 10 μM ROCK inhibitor was added to each 
100 mm dish and transfer into the incubator to equilibrate for 1 hr. 
9. Inspect hESC cultures for differentiation under a dissecting microscope in a 
biological safety cabinet class II under sterile conditions. Differentiated colonies 
typically lose the defined edges and have large differentiated cells appearing at 
the border.  
10. Remove any regions of differentiation by cutting the differentiating cells using a 
21 G needle using a dissecting microscope in a biological safety cabinet class II 
under stile conditions and scrapping with a pipette tip.  




12. Add 2 mL of complete hESCs conditioned medium with 10 μM ROCK inhibitor 
and leave for 2 hrs before nucleofection. 
13. After 2 hrs single cell passage hESCs using Accutase as described in section 
2.1.2.3.  
14. Perform a viable cell count with trypan blue using the automated cell counter. 
15. Collect 1x106 cells per nucleofection (pGFPmax (negative control), PX459 V2 
(positive control), G1, G2 and G3 (for each gene)) and spin at 115 g for 3 mins 
break 1. 
16. Aspirate and resuspended cells carefully in 100 μL room temperature 
nucleofection solution (82 μL of nucleofector solution and 18 μL of the 
supplement) and then in 2 μg of plasmid DNA. 
17. Transfer the 100 μL cell suspension into a nucleocuvette vessel and gently tap to 
make sure the sample covers the bottom of the cuvette. 
18. Place the nucleocuvette vessel with the lid closed into the retainer of the Lonza 
4D nucleofectorTM unit. 
19. Start the nucleofection process using the CB-150 program. 
20. After completion, resuspend cells immediately in 500 μL of pre-equilibrated 
hESC medium with 10 μM ROCK inhibitor from the 100 mm culture dishes. 
21. Mix cells gently by pipetting up and down three times using the supplied Pasteur 
pipettes in the kit and place in 100 mm iMEF coated dishes. Evenly distributed 
cells in the wells and place in the incubator. 
 
Step 22-33: Selecting and expansion of CRISPR/Cas9 edited clones. 
22. After 24 hrs, aspirate medium and rinse once with DPBS. 
23. Add 11 mL of complete iMEF CM supplemented with 1 μg/mL puromycin to the 




24. After 24 hrs, aspirate medium and rinse once with DPBS and add complete hESC 
medium supplemented with SMC4 (Cat# FAL354537, BD Biosciences) for 6 
days. 
25. Perform daily medium changes with complete hESC medium supplemented with 
SMC4. 
26.  Approximately 10 days post nucleofection colonies are ready to be passaged.  
27. Prepare 6-well iMEF plates ready for a manual passage. 
28. Cut single colonies and place in individual wells of a 6-well plate. Care should be 
taken to collect all pieces that belong to a single colony to generate a clonal cell 
population.  
29. 6-7 days after the passage a small section of the colony is scrapped off and gDNA 
extracted using the QuickExtract DNA Extraction solution. 
30. Perform a gDNA PCR using primers that flank the region where the gRNA is 
targeted and sequence the PCR product. 
31. Select clones with indels that generate a frameshift and expand further. 
32. Perform karyotype analysis on the selected clones. Discard clones with an 
abnormal karyotype.  



































SV chrom SV start SV end SV length SV type VARIANT ID
10 34293405 34293729 324 deletion DEL00422905
12 53347832 66451463 13103631 duplication DUP00519678
13 62303996 62304208 212 deletion DEL00559774
13 115047251 115047269 18 deletion DEL00571862
16 18043642 18043665 23 deletion DEL00633493
16 18043659 18043680 21 deletion DEL00633494
17 216825 217125 300 duplication DUP00666849
17 216858 217259 401 duplication DUP00666850
17 216925 217551 626 duplication DUP00666853
17 76623469 76623880 411 deletion DEL00699564
19 14869542 14869697 155 deletion DEL00736899
2 2796485 2796952 467 duplication DUP00052770
2 2796643 2796937 294 duplication DUP00052772
20 44658049 44658065 16 deletion DEL00781369
21 44456026 44456344 318 deletion DEL00806515
21 44456027 44456180 153 deletion DEL00806516
22 48647705 48647801 96 deletion DEL00826081
22 48648234 48648695 461 deletion DEL00826087
22 48648550 48648713 163 deletion DEL00826091
22 48648627 48648695 68 deletion DEL00826093
22 48648650 48648985 335 deletion DEL00826094
3 75683342 75683479 137 deletion DEL00146487
4 91488716 91489034 318 deletion DEL00195393
4 185575620 185575772 152 deletion DEL00210684
7 1944553 1945131 578 deletion DEL00291822
7 79428569 79428614 45 deletion DEL00320977
7 154467755 154468189 434 deletion DEL00338865

































Appendix 4: Whole genome sequencing validation.  












UPF3B KO hESCs UPF3A KO NSCs UPF3B KO NSCs  
SYT3 COL1A1 MEGF6 
EGR4 HOXB2 TRMT9B 
FAM229A TGFBI APOM 
DUSP8 IGFBP7 SLC1A2 
EGFL8 ITGA1 LMO3 
LIF TNC BLOC1S5-TXNDC5 
CLEC11A INHBA ITGA2B 
VAV1 FAP CNR1 
NFKBID COL3A1 CKMT1B 
ZFP36 ADAMTS14 ROBO2 
FAM222A CDKN2B LINGO1 
KCNA1 EDNRA RELN 
PCDH10 HTRA1 SYT10 
CDKN1A HAS2 ACACB 
FOSL1 BNC2 TEK 
TMEM132E CXCL6 FCHO1 
SPRY4 COL6A2 ELN 
ISG20 HOXB5 LOC400499 
CYP1B1 PAMR1 GADD45G 
LRRC4B PLPP4 ANO5 
ST8SIA3 COL1A2 ACSBG1 
EGR2 CFH LRRTM3 
ATP2A1 CDH11 DLL1 
WNT2B NFIX PELI2 
SLA TNFAIP6 OLFM3 
C19orf81 EGFL8 FBN3 
C3 FMN1 ONECUT2 
SAP25 MXRA5 ARX 
LIME1 SRPX2 CELF3 
HSPA12A MFAP4  
GDF15 FXYD5  
RING1 RUNX1  
NPAS4 GXYLT2  
FOXD3 CEBPD  
RGS11 HOXB3  
SHANK1 COL16A1  
ZNF648 TGFB2  
GRIN2A WISP1  
VWA7 TNFSF4  
NXPH2 GPNMB  
 
Appendix 5: Table showing downregulated genes in UPF3A KO NSCs and UPF3B 





UPF3B KO hESCs UPF3A KO NSCs UPF3B KO NSCs  
LCP1 RAB11FIP4 PCDHA6 
TXNIP OTX1 PCDHB5 
POMZP3 ZNF813 RHEX 
LOC645513 DLGAP3 FIBIN 
PCDHB12 RIMS4 PLCG2 
PCDHA6 ONECUT2 HOXB2 
GOLGA2P10 ONECUT1 IRAK1 
LOC730268  SEMA3C 
PCDHB3  OGFRL1 
PCDHA3   
SCG2   
PIWIL2   
NBPF9   
PCDHA7   
PCDHA1   
GADD45G   
TRDN   
PKIB   
PCDHGB3   
PCDHB18P   
NETO1   
GABBR1   
PCDHGA8   
GREM1   
EIF4E1B   
GSAP   
PCDHGA5   
SLITRK1   
UNC5C   
ZBED6CL   
ADGRL3   
 
Appendix 6: Table showing upregulated genes in UPF3A KO NSCs and UPF3B 











ID Description DERatio BGRatio adjp 
GO:0030198 extracellular matrix organization 61/395 240/11586 4.02E-33 
GO:0043062 extracellular structure 
organization 
62/395 273/11586 1.23E-30 
GO:0001568 blood vessel development 68/395 477/11586 4.59E-21 
GO:0030155 regulation of cell adhesion 61/395 449/11586 1.95E-17 
GO:0048514 blood vessel morphogenesis 58/395 414/11586 4.39E-17 
GO:0001525 angiogenesis 50/395 349/11586 9.92E-15 
GO:0001501 skeletal system development 48/395 346/11586 1.89E-13 
GO:0032963 collagen metabolic process 22/395 65/11586 3.49E-13 
GO:0090287 regulation of cellular response to 
growth factor stimulus 
35/395 201/11586 3.71E-12 
GO:0048705 skeletal system morphogenesis 31/395 157/11586 4.55E-12 
GO:0090092 regulation of transmembrane 
receptor protein serine/threonine 
kinase signaling pathway 
31/395 167/11586 2.77E-11 
GO:1901342 regulation of vasculature 
development 
35/395 219/11586 5.60E-11 
GO:0007178 transmembrane receptor protein 
serine/threonine kinase signaling 
pathway 
37/395 245/11586 6.07E-11 
GO:0008285 negative regulation of cell 
proliferation 
52/395 474/11586 1.81E-10 
GO:0032101 regulation of response to external 
stimulus 
50/395 446/11586 2.51E-10 
GO:0030199 collagen fibril organization 16/395 40/11586 2.76E-10 
GO:0045765 regulation of angiogenesis 32/395 196/11586 4.31E-10 
GO:0061448 connective tissue development 31/395 186/11586 5.96E-10 
GO:0007162 negative regulation of cell 
adhesion 
30/395 179/11586 1.28E-09 
GO:0031589 cell-substrate adhesion 36/395 256/11586 1.29E-09 
GO:0051272 positive regulation of cellular 
component movement 
44/395 378/11586 2.47E-09 
GO:2000147 positive regulation of cell motility 43/395 368/11586 4.04E-09 
GO:0060349 bone morphogenesis 20/395 80/11586 5.67E-09 
GO:0002062 chondrocyte differentiation 21/395 91/11586 8.40E-09 
GO:0040017 positive regulation of locomotion 44/395 393/11586 9.54E-09 
GO:0060348 bone development 26/395 147/11586 1.41E-08 
GO:0048729 tissue morphogenesis 47/395 447/11586 1.57E-08 
GO:0071559 response to transforming growth 
factor beta 
29/395 186/11586 2.10E-08 
GO:0007492 endoderm development 16/395 51/11586 2.23E-08 
GO:0007160 cell-matrix adhesion 27/395 164/11586 3.12E-08 
GO:0030335 positive regulation of cell 
migration 
41/395 360/11586 3.25E-08 
GO:0051216 cartilage development 25/395 143/11586 4.85E-08 
GO:0035987 endodermal cell differentiation 13/395 32/11586 5.01E-08 
GO:0001503 ossification 35/395 275/11586 5.22E-08 
GO:0071560 cellular response to transforming 
growth factor beta stimulus 
28/395 181/11586 5.98E-08 




GO:0007179 transforming growth factor beta 
receptor signaling pathway 
25/395 147/11586 9.09E-08 
GO:0006954 inflammatory response 39/395 347/11586 1.63E-07 
GO:0009611 response to wounding 43/395 412/11586 1.77E-07 
GO:0001706 endoderm formation 13/395 35/11586 1.94E-07 
GO:0060485 mesenchyme development 28/395 190/11586 1.96E-07 
GO:0017015 regulation of transforming growth 
factor beta receptor signaling 
pathway 
19/395 90/11586 5.02E-07 
GO:0048598 embryonic morphogenesis 42/395 409/11586 5.06E-07 
GO:0003416 endochondral bone growth 12/395 31/11586 6.16E-07 
GO:0045766 positive regulation of angiogenesis 21/395 113/11586 6.69E-07 
GO:0060350 endochondral bone morphogenesis 15/395 54/11586 7.24E-07 
GO:1903844 regulation of cellular response to 
transforming growth factor beta 
stimulus 
19/395 92/11586 7.51E-07 
GO:0098868 bone growth 12/395 32/11586 9.56E-07 
GO:1904018 positive regulation of vasculature 
development 
22/395 127/11586 1.02E-06 
GO:0061061 muscle structure development 43/395 443/11586 1.80E-06 
GO:0045785 positive regulation of cell 
adhesion 
31/395 252/11586 1.91E-06 
GO:0048704 embryonic skeletal system 
morphogenesis 
15/395 59/11586 2.86E-06 
GO:0050900 leukocyte migration 28/395 213/11586 2.96E-06 
GO:0048706 embryonic skeletal system 
development 
17/395 79/11586 3.49E-06 
GO:0022407 regulation of cell-cell adhesion 29/395 231/11586 4.38E-06 
GO:0001655 urogenital system development 30/395 248/11586 5.53E-06 
GO:0001667 ameboidal-type cell migration 33/395 294/11586 5.72E-06 
GO:0032964 collagen biosynthetic process 11/395 30/11586 7.21E-06 
GO:0060389 pathway-restricted SMAD protein 
phosphorylation 
13/395 46/11586 9.50E-06 
GO:0001704 formation of primary germ layer 17/395 84/11586 9.54E-06 
GO:0002683 negative regulation of immune 
system process 
30/395 254/11586 9.82E-06 
GO:0001816 cytokine production 40/395 417/11586 1.08E-05 
GO:0048762 mesenchymal cell differentiation 23/395 158/11586 1.38E-05 
GO:0090288 negative regulation of cellular 
response to growth factor stimulus 
19/395 109/11586 1.54E-05 
GO:0060351 cartilage development involved in 
endochondral bone morphogenesis 
11/395 32/11586 1.60E-05 
GO:0050673 epithelial cell proliferation 30/395 261/11586 1.87E-05 
GO:0050727 regulation of inflammatory 
response 
24/395 174/11586 1.89E-05 
GO:0010712 regulation of collagen metabolic 
process 
10/395 26/11586 2.32E-05 
GO:0033627 cell adhesion mediated by integrin 12/395 41/11586 2.53E-05 
GO:1904888 cranial skeletal system 
development 
13/395 50/11586 2.93E-05 




GO:0030855 epithelial cell differentiation 37/395 382/11586 3.38E-05 
GO:0042476 odontogenesis 16/395 80/11586 3.39E-05 
GO:0010718 positive regulation of epithelial to 
mesenchymal transition 
12/395 42/11586 3.44E-05 
GO:0010717 regulation of epithelial to 
mesenchymal transition 
15/395 70/11586 3.67E-05 
GO:0072001 renal system development 27/395 223/11586 3.68E-05 
GO:0001837 epithelial to mesenchymal 
transition 
18/395 104/11586 4.46E-05 
GO:0060393 regulation of pathway-restricted 
SMAD protein phosphorylation 
12/395 43/11586 4.62E-05 
GO:0002063 chondrocyte development 11/395 35/11586 4.72E-05 
GO:0010469 regulation of signaling receptor 
activity 
27/395 230/11586 7.18E-05 
GO:0048701 embryonic cranial skeleton 
morphogenesis 
11/395 37/11586 9.10E-05 
GO:2000027 regulation of animal organ 
morphogenesis 
21/395 147/11586 9.35E-05 
GO:0045596 negative regulation of cell 
differentiation 
42/395 489/11586 0.00011 
GO:0010810 regulation of cell-substrate 
adhesion 
22/395 162/11586 0.0001112 
GO:0070482 response to oxygen levels 29/395 266/11586 0.0001124 
GO:0003418 growth plate cartilage chondrocyte 
differentiation 
8/395 17/11586 0.0001186 
GO:0003433 chondrocyte development 
involved in endochondral bone 
morphogenesis 
8/395 17/11586 0.0001186 
GO:0022408 negative regulation of cell-cell 
adhesion 
17/395 101/11586 0.0001755 
GO:0050678 regulation of epithelial cell 
proliferation 
26/395 226/11586 0.0002006 
GO:0030512 negative regulation of 
transforming growth factor beta 
receptor signaling pathway 
13/395 58/11586 0.0002031 
GO:0001822 kidney development 25/395 211/11586 0.0002032 
GO:0097529 myeloid leukocyte migration 16/395 91/11586 0.000232 
GO:0003417 growth plate cartilage 
development 
9/395 25/11586 0.0002687 
GO:0050865 regulation of cell activation 30/395 294/11586 0.0002896 
GO:1903845 negative regulation of cellular 
response to transforming growth 
factor beta stimulus 
13/395 60/11586 0.0003125 
GO:0050866 negative regulation of cell 
activation 
17/395 105/11586 0.0003175 
GO:0007369 gastrulation 19/395 131/11586 0.0003413 
GO:0060536 cartilage morphogenesis 8/395 19/11586 0.0003474 
GO:0010631 epithelial cell migration 25/395 219/11586 0.0004239 
GO:0090132 epithelium migration 25/395 219/11586 0.0004239 
GO:0043065 positive regulation of apoptotic 
process 
40/395 476/11586 0.0004348 
GO:0043068 positive regulation of programmed 
cell death 




GO:0001818 negative regulation of cytokine 
production 
20/395 150/11586 0.0006488 
GO:0001817 regulation of cytokine production 34/395 376/11586 0.0007403 
GO:0090101 negative regulation of 
transmembrane receptor protein 
serine/threonine kinase signaling 
pathway 
15/395 87/11586 0.0007875 
GO:0003413 chondrocyte differentiation 
involved in endochondral bone 
morphogenesis 
8/395 21/11586 0.0008806 
GO:0009612 response to mechanical stimulus 19/395 139/11586 0.0008901 
GO:0006935 chemotaxis 35/395 400/11586 0.001078 
GO:0042330 taxis 35/395 402/11586 0.001216 
GO:0032965 regulation of collagen biosynthetic 
process 
8/395 22/11586 0.001343 
GO:0031347 regulation of defense response 34/395 386/11586 0.001376 
GO:0090100 positive regulation of 
transmembrane receptor protein 
serine/threonine kinase signaling 
pathway 
14/395 79/11586 0.001413 
GO:0001666 response to hypoxia 25/395 235/11586 0.001653 
GO:1903034 regulation of response to 
wounding 
15/395 93/11586 0.001939 
GO:0035137 hindlimb morphogenesis 8/395 23/11586 0.001998 
GO:0010862 positive regulation of pathway-
restricted SMAD protein 
phosphorylation 
9/395 31/11586 0.00221 
GO:0042481 regulation of odontogenesis 6/395 11/11586 0.00227 
GO:0070663 regulation of leukocyte 
proliferation 
16/395 107/11586 0.002345 
GO:0042692 muscle cell differentiation 25/395 240/11586 0.002461 
GO:0002526 acute inflammatory response 12/395 60/11586 0.002495 
GO:0048771 tissue remodeling 15/395 95/11586 0.002574 
GO:0001649 osteoblast differentiation 20/395 164/11586 0.002805 
GO:0030574 collagen catabolic process 8/395 24/11586 0.002909 
GO:0002009 morphogenesis of an epithelium 32/395 363/11586 0.003025 
GO:0036293 response to decreased oxygen 
levels 
25/395 246/11586 0.003906 
GO:0061041 regulation of wound healing 13/395 74/11586 0.004104 
GO:0003414 chondrocyte morphogenesis 
involved in endochondral bone 
morphogenesis 
6/395 12/11586 0.00441 
GO:0003429 growth plate cartilage chondrocyte 
morphogenesis 
6/395 12/11586 0.00441 
GO:0090171 chondrocyte morphogenesis 6/395 12/11586 0.00441 
GO:0070661 leukocyte proliferation 18/395 140/11586 0.004638 
GO:0031214 biomineral tissue development 14/395 87/11586 0.004793 
GO:0048562 embryonic organ morphogenesis 21/395 185/11586 0.004892 
GO:0043542 endothelial cell migration 19/395 155/11586 0.004912 
GO:0007507 heart development 34/395 409/11586 0.00522 
GO:0050670 regulation of lymphocyte 
proliferation 




GO:0060317 cardiac epithelial to mesenchymal 
transition 
8/395 26/11586 0.005819 
GO:0010632 regulation of epithelial cell 
migration 
20/395 172/11586 0.006 
GO:0110110 positive regulation of animal 
organ morphogenesis 
11/395 54/11586 0.006045 
GO:0032944 regulation of mononuclear cell 
proliferation 
15/395 102/11586 0.006544 
GO:0072006 nephron development 15/395 102/11586 0.006544 
GO:0051146 striated muscle cell differentiation 20/395 173/11586 0.006575 
GO:0071407 cellular response to organic cyclic 
compound 
33/395 395/11586 0.00673 
GO:0060562 epithelial tube morphogenesis 24/395 237/11586 0.006861 
GO:0046651 lymphocyte proliferation 17/395 130/11586 0.007229 
GO:0060326 cell chemotaxis 18/395 145/11586 0.007774 
GO:0071229 cellular response to acid chemical 18/395 145/11586 0.007774 
GO:0003422 growth plate cartilage 
morphogenesis 
6/395 13/11586 0.007955 
GO:0048589 developmental growth 37/395 474/11586 0.007982 
GO:0032943 mononuclear cell proliferation 17/395 131/11586 0.008052 
GO:0048568 embryonic organ development 27/395 291/11586 0.008549 
GO:0007517 muscle organ development 26/395 274/11586 0.00871 
GO:0050729 positive regulation of 
inflammatory response 
11/395 56/11586 0.008844 
GO:0061333 renal tubule morphogenesis 11/395 56/11586 0.008844 
GO:0010634 positive regulation of epithelial 
cell migration 
16/395 118/11586 0.008938 
GO:1903037 regulation of leukocyte cell-cell 
adhesion 
19/395 163/11586 0.01055 
GO:0072073 kidney epithelium development 15/395 106/11586 0.01074 
GO:0072009 nephron epithelium development 13/395 82/11586 0.01366 
GO:0072132 mesenchyme morphogenesis 9/395 38/11586 0.01446 
GO:0022617 extracellular matrix disassembly 10/395 48/11586 0.01459 
GO:0097530 granulocyte migration 10/395 48/11586 0.01459 
GO:0007596 blood coagulation 21/395 198/11586 0.01468 
GO:0034330 cell junction organization 23/395 231/11586 0.01504 
GO:0006936 muscle contraction 21/395 200/11586 0.01723 
GO:0050817 coagulation 21/395 200/11586 0.01723 
GO:0035265 organ growth 16/395 124/11586 0.0173 
GO:1905207 regulation of cardiocyte 
differentiation 
9/395 39/11586 0.01824 
GO:0061326 renal tubule development 12/395 72/11586 0.01893 
GO:0007423 sensory organ development 31/395 377/11586 0.01939 
GO:0007599 hemostasis 21/395 202/11586 0.02016 
GO:0002685 regulation of leukocyte migration 14/395 98/11586 0.02056 
GO:0003148 outflow tract septum 
morphogenesis 
7/395 22/11586 0.02087 
GO:1905209 positive regulation of cardiocyte 
differentiation 
7/395 22/11586 0.02087 
GO:0071772 response to BMP 15/395 112/11586 0.02158 




GO:0060021 roof of mouth development 12/395 73/11586 0.02197 
GO:0002694 regulation of leukocyte activation 25/395 271/11586 0.02259 
GO:0050707 regulation of cytokine secretion 13/395 86/11586 0.02355 
GO:0035107 appendage morphogenesis 15/395 113/11586 0.02412 
GO:0035108 limb morphogenesis 15/395 113/11586 0.02412 
GO:0050710 negative regulation of cytokine 
secretion 
8/395 31/11586 0.02529 
GO:2000826 regulation of heart morphogenesis 8/395 31/11586 0.02529 
GO:0003007 heart morphogenesis 19/395 173/11586 0.02554 
GO:0034329 cell junction assembly 20/395 189/11586 0.02584 
GO:0061138 morphogenesis of a branching 
epithelium 
16/395 129/11586 0.02904 
GO:0035270 endocrine system development 12/395 75/11586 0.02935 
GO:0030510 regulation of BMP signaling 
pathway 
11/395 63/11586 0.02951 
GO:1901654 response to ketone 16/395 130/11586 0.0321 
GO:0010714 positive regulation of collagen 
metabolic process 
6/395 16/11586 0.03402 
GO:0032967 positive regulation of collagen 
biosynthetic process 
6/395 16/11586 0.03402 
GO:0030282 bone mineralization 11/395 64/11586 0.03457 
GO:0048545 response to steroid hormone 25/395 278/11586 0.03534 
GO:0038065 collagen-activated signaling 
pathway 
5/395 10/11586 0.03691 
GO:0002695 negative regulation of leukocyte 
activation 
13/395 90/11586 0.03931 
GO:0001656 metanephros development 11/395 65/11586 0.04035 
GO:0032102 negative regulation of response to 
external stimulus 
20/395 195/11586 0.04136 
GO:0030509 BMP signaling pathway 14/395 104/11586 0.04161 
GO:0071396 cellular response to lipid 31/395 392/11586 0.04266 
GO:0002040 sprouting angiogenesis 13/395 91/11586 0.04446 
GO:0007159 leukocyte cell-cell adhesion 19/395 180/11586 0.04545 
GO:0030278 regulation of ossification 16/395 134/11586 0.04743 
 









ID Description DERatio BGRatio adjp 
GO:0005201 extracellular matrix structural 
constituent 
39/395 99/11706 2.73E-29 
GO:0030020 extracellular matrix structural 
constituent conferring tensile strength 
17/395 30/11706 2.73E-15 
GO:0019838 growth factor binding 27/395 101/11706 1.01E-14 
GO:0005539 glycosaminoglycan binding 25/395 122/11706 1.24E-10 
GO:0019955 cytokine binding 19/395 66/11706 1.43E-10 
GO:0005178 integrin binding 19/395 88/11706 3.72E-08 
GO:0005126 cytokine receptor binding 21/395 119/11706 2.03E-07 
GO:0038023 signaling receptor activity 45/395 480/11706 2.06E-07 
GO:0005125 cytokine activity 14/395 58/11706 2.59E-06 
GO:0030545 receptor regulator activity 25/395 193/11706 3.63E-06 
GO:0005160 transforming growth factor beta 
receptor binding 
11/395 34/11706 4.01E-06 
GO:0008201 heparin binding 17/395 92/11706 4.70E-06 
GO:0048407 platelet-derived growth factor binding 7/395 11/11706 6.95E-06 
GO:0050840 extracellular matrix binding 12/395 44/11706 7.34E-06 
GO:0048018 receptor ligand activity 22/395 167/11706 2.17E-05 
GO:0005518 collagen binding 12/395 50/11706 3.52E-05 
GO:0004888 transmembrane signaling receptor 
activity 
32/395 348/11706 0.000125 
GO:0050839 cell adhesion molecule binding 35/395 406/11706 0.000162 
GO:0050431 transforming growth factor beta binding 7/395 16/11706 0.000208 
GO:1901681 sulfur compound binding 19/395 160/11706 0.000915 
GO:0000978 RNA polymerase II proximal promoter 
sequence-specific DNA binding 
30/395 367/11706 0.003395 
GO:0000987 proximal promoter sequence-specific 
DNA binding 
30/395 376/11706 0.00547 
GO:0098631 cell adhesion mediator activity 9/395 47/11706 0.01133 
GO:0000982 transcription factor activity, RNA 
polymerase II proximal promoter 
sequence-specific DNA binding 
26/395 315/11706 0.01192 
GO:0001228 DNA-binding transcription activator 
activity, RNA polymerase II-specific 
24/395 286/11706 0.01882 
GO:0002020 protease binding 12/395 89/11706 0.02095 
GO:0004252 serine-type endopeptidase activity 10/395 63/11706 0.0221 
GO:0001077 proximal promoter DNA-binding 
transcription activator activity, RNA 
polymerase II-specific 
19/395 201/11706 0.02483 
GO:0005509 calcium ion binding 31/395 439/11706 0.04125 
GO:0043394 proteoglycan binding 6/395 23/11706 0.04411 
 






ID Description DERatio BGRatio adjp 
GO:0031012 extracellular matrix 71/407 305/12152 6.85E-38 
GO:0062023 collagen-containing extracellular matrix 56/407 215/12152 4.02E-32 
GO:0005581 collagen trimer 22/407 51/12152 4.47E-17 
GO:0005788 endoplasmic reticulum lumen 39/407 214/12152 7.90E-16 
GO:0009986 cell surface 51/407 442/12152 2.09E-12 
GO:0044420 extracellular matrix component 16/407 41/12152 3.10E-11 
GO:0005912 adherens junction 47/407 481/12152 1.09E-08 
GO:0070161 anchoring junction 47/407 491/12152 2.23E-08 
GO:0005925 focal adhesion 37/407 372/12152 9.71E-07 
GO:0005924 cell-substrate adherens junction 37/407 373/12152 1.05E-06 
GO:0030055 cell-substrate junction 37/407 376/12152 1.30E-06 
GO:0005604 basement membrane 15/407 71/12152 3.30E-06 
GO:0005583 fibrillar collagen trimer 7/407 11/12152 4.57E-06 
GO:0098643 banded collagen fibril 7/407 11/12152 4.57E-06 
GO:0098644 complex of collagen trimers 8/407 17/12152 9.54E-06 
GO:0043235 receptor complex 27/407 241/12152 1.26E-05 
GO:0042383 sarcolemma 17/407 102/12152 1.47E-05 
GO:0005901 caveola 11/407 57/12152 0.0008279 
GO:0009897 external side of plasma membrane 16/407 130/12152 0.002382 
GO:0044853 plasma membrane raft 11/407 73/12152 0.009868 
GO:0098797 plasma membrane protein complex 27/407 343/12152 0.0118 
GO:0008305 integrin complex 6/407 20/12152 0.01224 
GO:0098636 protein complex involved in cell adhesion 6/407 20/12152 0.01224 
GO:0005913 cell-cell adherens junction 12/407 91/12152 0.0169 
GO:0045121 membrane raft 20/407 222/12152 0.01962 
GO:0098857 membrane microdomain 20/407 223/12152 0.0209 
GO:0098589 membrane region 20/407 230/12152 0.03215 
 









ID Description DERatio BGRatio adjp 
GO:0099055 integral component of postsynaptic membrane   7/81 81/12598 0.00014 
GO:0098936 intrinsic component of postsynaptic 
membrane 
  7/81 86/12598 0.00021 
GO:0099061 integral component of postsynaptic density 
membrane 
  5/81 38/12598 0.00068 
GO:0099699 integral component of synaptic membrane   7/81 106/12598 0.00085 
GO:0099146 intrinsic component of postsynaptic density 
membrane 
            5/81 41/12598 0.00101 
GO:0099240 intrinsic component of synaptic membrane   7/81 115/12598 0.00145 
GO:0099060 integral component of postsynaptic 
specialization membrane 
  5/81 52/12598 0.0033 
GO:0045211 postsynaptic membrane   1/9  243/12598 0.00412 
GO:0098948 intrinsic component of postsynaptic 
specialization membrane 
  5/81 55/12598 0.00435 
GO:0098839 postsynaptic density membrane   5/81 58/12598 0.00565 
GO:0097060 synaptic membrane  10/81 326/12598 0.00717 
GO:0042734 presynaptic membrane   2/27 115/12598 0.01567 
GO:0099634 postsynaptic specialization membrane   5/81 74/12598 0.01833 
GO:0098978 glutamatergic synapse   1/9  298/12598 0.02 
 












ID Description DERatio BGRatio adjp 
GO:0042330 taxis 209/3770 440/12553 1.97E-11 
GO:0006935 chemotaxis 208/3770 438/12553 2.37E-11 
GO:0097485 neuron projection guidance 122/3770 225/12553 1.22E-10 
GO:0007411 axon guidance 121/3770 224/12553 2.25E-10 
GO:0061564 axon development 200/3770 432/12553 1.83E-09 
GO:0007186 G protein-coupled receptor signaling 
pathway 
223/3770 498/12553 5.43E-09 
GO:0007409 axonogenesis 182/3770 394/12553 2.79E-08 
GO:0007389 pattern specification process 148/3770 310/12553 1.42E-07 
GO:0048667 cell morphogenesis involved in neuron 
differentiation 
215/3770 493/12553 3.00E-07 
GO:0007610 behavior 197/3770 449/12553 1.05E-06 
GO:0007600 sensory perception 148/3770 317/12553 1.09E-06 
GO:0003013 circulatory system process 152/3770 339/12553 2.17E-05 
GO:0007423 sensory organ development 181/3770 419/12553 2.51E-05 
GO:0030198 extracellular matrix organization 126/3770 270/12553 2.53E-05 
GO:0003002 regionalization 113/3770 236/12553 2.60E-05 
GO:0043062 extracellular structure organization 139/3770 306/12553 3.65E-05 
GO:0008015 blood circulation 148/3770 332/12553 5.58E-05 
GO:0043269 regulation of ion transport 194/3770 460/12553 6.86E-05 
GO:0098742 cell-cell adhesion via plasma-
membrane adhesion molecules 
101/3770 210/12553 0.000127 
GO:0001655 urogenital system development 121/3770 263/12553 0.000142 
GO:0010469 regulation of signaling receptor 
activity 
125/3770 275/12553 0.0002 
GO:0001501 skeletal system development 158/3770 366/12553 0.000255 
GO:0090596 sensory organ morphogenesis 94/3770 196/12553 0.000459 
GO:0045165 cell fate commitment 80/3770 161/12553 0.000637 
GO:0072001 renal system development 109/3770 237/12553 0.000706 
GO:0048598 embryonic morphogenesis 185/3770 449/12553 0.001102 
GO:0090066 regulation of anatomical structure size 165/3770 393/12553 0.00121 
GO:0050808 synapse organization 145/3770 339/12553 0.001776 
GO:0055123 digestive system development 56/3770 104/12553 0.001778 
GO:0030900 forebrain development 133/3770 306/12553 0.001851 
GO:0001822 kidney development 103/3770 225/12553 0.002057 
GO:0050890 cognition 106/3770 234/12553 0.002643 
GO:0099177 regulation of trans-synaptic signaling 148/3770 350/12553 0.003066 
GO:0007156 homophilic cell adhesion via plasma 
membrane adhesion molecules 
69/3770 138/12553 0.003451 
GO:0050804 modulation of chemical synaptic 
transmission 
147/3770 349/12553 0.004406 
GO:0048729 tissue morphogenesis 194/3770 483/12553 0.004704 
GO:0043010 camera-type eye development 107/3770 239/12553 0.004717 
GO:0043588 skin development 87/3770 186/12553 0.005332 
GO:0048592 eye morphogenesis 60/3770 117/12553 0.006226 
GO:0048568 embryonic organ development 136/3770 320/12553 0.006285 
GO:0048565 digestive tract development 51/3770 95/12553 0.006666 




GO:0007187 G protein-coupled receptor signaling 
pathway, coupled to cyclic nucleotide 
second messenger 
63/3770 125/12553 0.007381 
GO:0010721 negative regulation of cell 
development 
116/3770 267/12553 0.01055 
GO:0030855 epithelial cell differentiation 178/3770 442/12553 0.01094 
GO:0032970 regulation of actin filament-based 
process 
135/3770 321/12553 0.01357 
GO:0051216 cartilage development 72/3770 150/12553 0.014 
GO:0050673 epithelial cell proliferation 123/3770 288/12553 0.01504 
GO:0048562 embryonic organ morphogenesis 93/3770 206/12553 0.01562 
GO:0048880 sensory system development 121/3770 283/12553 0.01692 
GO:0051961 negative regulation of nervous system 
development 
110/3770 253/12553 0.0185 
GO:0009952 anterior/posterior pattern specification 67/3770 138/12553 0.01881 
GO:0001654 eye development 120/3770 281/12553 0.01993 
GO:0150063 visual system development 120/3770 281/12553 0.01993 
GO:0007611 learning or memory 93/3770 207/12553 0.02009 
GO:0007015 actin filament organization 141/3770 341/12553 0.02465 
GO:0042391 regulation of membrane potential 136/3770 327/12553 0.02526 
GO:0035637 multicellular organismal signaling 63/3770 129/12553 0.02856 
GO:0007416 synapse assembly 68/3770 142/12553 0.02916 
GO:0007626 locomotory behavior 72/3770 153/12553 0.03423 
GO:0032956 regulation of actin cytoskeleton 
organization 
120/3770 284/12553 0.03702 
GO:0032102 negative regulation of response to 
external stimulus 
97/3770 221/12553 0.04261 
GO:0001505 regulation of neurotransmitter levels 114/3770 268/12553 0.04311 
GO:0042063 gliogenesis 95/3770 216/12553 0.04751 
 










ID Description DERatio BGRatio adjp 
GO:0004888 transmembrane signaling receptor 
activity 
213/3776 437/12668 2.20E-14 
GO:0022838 substrate-specific channel activity 151/3776 294/12668 4.45E-12 
GO:0005216 ion channel activity 149/3776 289/12668 4.46E-12 
GO:0015267 channel activity 155/3776 305/12668 6.32E-12 
GO:0022803 passive transmembrane transporter 
activity 
155/3776 305/12668 6.32E-12 
GO:0022839 ion gated channel activity 120/3776 234/12668 3.39E-09 
GO:0046873 metal ion transmembrane transporter 
activity 
148/3776 306/12668 4.01E-09 
GO:0022836 gated channel activity 123/3776 242/12668 4.02E-09 
GO:0005261 cation channel activity 112/3776 220/12668 3.23E-08 
GO:0015276 ligand-gated ion channel activity 57/3776 98/12668 4.64E-06 
GO:0022834 ligand-gated channel activity 57/3776 98/12668 4.64E-06 
GO:0008324 cation transmembrane transporter activity 192/3776 453/12668 4.93E-06 
GO:0022890 inorganic cation transmembrane 
transporter activity 
179/3776 418/12668 6.59E-06 
GO:0022843 voltage-gated cation channel activity 54/3776 97/12668 9.20E-05 
GO:0005267 potassium channel activity 47/3776 82/12668 0.000191 
GO:0048018 receptor ligand activity 94/3776 203/12668 0.000436 
GO:0030545 receptor regulator activity 104/3776 231/12668 0.000593 
GO:0005249 voltage-gated potassium channel activity 36/3776 59/12668 0.000635 
GO:0099094 ligand-gated cation channel activity 43/3776 76/12668 0.00102 
GO:0005244 voltage-gated ion channel activity 66/3776 133/12668 0.001145 
GO:0022832 voltage-gated channel activity 66/3776 133/12668 0.001145 
GO:0015079 potassium ion transmembrane transporter 
activity 
55/3776 107/12668 0.0022 
GO:0008509 anion transmembrane transporter activity 96/3776 217/12668 0.004039 
GO:0004930 G protein-coupled receptor activity 82/3776 180/12668 0.005131 
GO:0015081 sodium ion transmembrane transporter 
activity 
48/3776 92/12668 0.005616 
GO:0015077 monovalent inorganic cation 
transmembrane transporter activity 
111/3776 260/12668 0.005765 
GO:0003779 actin binding 141/3776 346/12668 0.007225 
GO:0005539 glycosaminoglycan binding 64/3776 135/12668 0.0114 
GO:0015370 solute:sodium symporter activity 23/3776 35/12668 0.01189 
GO:0019838 growth factor binding 53/3776 109/12668 0.0262 
GO:0005125 cytokine activity 41/3776 79/12668 0.03123 
GO:0030594 neurotransmitter receptor activity 31/3776 55/12668 0.03594 
GO:0004112 cyclic-nucleotide phosphodiesterase 
activity 
17/3776 24/12668 0.03945 
GO:0098631 cell adhesion mediator activity 30/3776 53/12668 0.04291 
GO:0015108 chloride transmembrane transporter 
activity 


























ID Description DERatio BGRatio adjp 
GO:0031012 extracellular matrix 163/3963 339/13183 9.29E-10 
GO:0043235 receptor complex 140/3963 281/13183 1.34E-09 
GO:0099699 integral component of synaptic 
membrane 
74/3963 123/13183 2.62E-09 
GO:0045177 apical part of cell 128/3963 261/13183 4.66E-08 
GO:0099240 intrinsic component of synaptic 
membrane 
76/3963 133/13183 4.67E-08 
GO:0097060 synaptic membrane 166/3963 362/13183 7.01E-08 
GO:0016324 apical plasma membrane 107/3963 210/13183 1.01E-07 
GO:0045211 postsynaptic membrane 129/3963 271/13183 4.70E-07 
GO:0034702 ion channel complex 109/3963 220/13183 5.70E-07 
GO:1902495 transmembrane transporter complex 115/3963 236/13183 7.02E-07 
GO:1990351 transporter complex 116/3963 244/13183 3.71E-06 
GO:0099055 integral component of postsynaptic 
membrane 
55/3963 96/13183 1.74E-05 
GO:0005911 cell-cell junction 160/3963 369/13183 2.02E-05 
GO:0098797 plasma membrane protein complex 171/3963 403/13183 4.23E-05 
GO:0062023 collagen-containing extracellular matrix 110/3963 238/13183 6.04E-05 
GO:0098936 intrinsic component of postsynaptic 
membrane 
56/3963 101/13183 6.17E-05 
GO:0034703 cation channel complex 82/3963 166/13183 8.15E-05 
GO:0099056 integral component of presynaptic 
membrane 
35/3963 55/13183 0.000181 
GO:0099634 postsynaptic specialization membrane 48/3963 85/13183 0.000242 
GO:0098982 GABA-ergic synapse 36/3963 58/13183 0.000303 
GO:0098793 presynapse 165/3963 399/13183 0.000523 
GO:0043025 neuronal cell body 162/3963 391/13183 0.000573 
GO:0098889 intrinsic component of presynaptic 
membrane 
37/3963 62/13183 0.000847 
GO:0016323 basolateral plasma membrane 76/3963 158/13183 0.000883 
GO:0044297 cell body 180/3963 445/13183 0.000939 
GO:0098839 postsynaptic density membrane 37/3963 65/13183 0.004067 
GO:0031225 anchored component of membrane 51/3963 100/13183 0.00616 
GO:0099572 postsynaptic specialization 130/3963 314/13183 0.007127 
GO:0098984 neuron to neuron synapse 132/3963 320/13183 0.007595 
GO:0099060 integral component of postsynaptic 
specialization membrane 
35/3963 62/13183 0.009285 
GO:0098978 glutamatergic synapse 130/3963 317/13183 0.01238 
GO:0098948 intrinsic component of postsynaptic 
specialization membrane 
36/3963 65/13183 0.01249 
GO:0034705 potassium channel complex 40/3963 75/13183 0.01455 
GO:0031253 cell projection membrane 108/3963 259/13183 0.02718 
GO:0042734 presynaptic membrane 61/3963 132/13183 0.04316 
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